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Welcome to this world of Fools
Of pink champagne and swimming pools
Well, all you have to lose is your virginity
Perhaps we’ll have some fun tonight
So stick around and take a bite of life
We don’t need feebleness in this proximity
-Les Claypool-
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The emergence of a cancer cell
Before a normal somatic cell has evolved
into a malignant cancer cell it has acquired
several traits that contribute to uncontrolled
proliferation. For instance, the programmed cell
death (apoptotic) machinery is inactivated. An
important component of this machinery is the p53
tumor suppressor which can induce apoptosis in
a cell containing severely damaged DNA,
thereby preventing a cell that harbours potential
oncogenic mutations from remaining in a tissue.
Consequently, p53 has been found mutated to
an inactive form in approximately fifty percent
of all cancers (reviewed in (1)). In addition, some
cancer cells contain constitutively activated
signal transduction pathways that transduce anti-
apoptotic signals. The phosphatidylinositol-3-
OH kinase (PI(3)K) pathway, for instance, is
normally controlled by growth factors and can
antagonize apoptosis (2). Hence, mutations or
deletions in the gene encoding a negative
regulator of this pathway, phosphatase and tensin
homologue deleted from chromosome 10 (PTEN,
also known as MMAC1 or TEP1), are found in a
variety of cancers (reviewed in (3)).
Many cancer cells have become
insensitive to anti-growth signals. Certain
extracellular ligands like transforming growth
factor β (TGFβ) inhibit cellular proliferation by
increasing protein expression of cell-cycle
inhibitors such as p15INK4B. One way in which
cancer cells evade this inhibitory signal is by
deleting the p15INK4B locus (reviewed in (4, 5)).
A cancer cell has acquired the potential
for autonomous proliferation. During normal cell
proliferation extracellular growth factors provide
the signal required for the initiation of DNA
synthesis via a cascades of protein modifications
that, amongst others, ultimately inactivate the
retinoblastoma protein (pRb). One of the few
well described pRb-controlling pathways
activated by growth factors is the one controlled
by the Ras GTPase (6). In about fifteen percent
of all cancers, Ras is mutated to an active form,
giving rise to growth factor-independent
proliferation (reviewed in (7)). Besides Ras-
directed signalling, other cascades, including the
previously mentioned PI(3)K cascade, control
cellular proliferation  and certain proteins in these
cascades (e.g. PTEN) are sometimes found
mutated. Last but not least, some tumor cells
produce their own growth factors (8).
A cancer cell has acquired the ability to
undergo more cell doublings than its non-
transformed counterpart. In normal circum-
stances, human cells have limited replicative
capacity due to the shortening of chromosome
ends after each cell division. When these
chromosome ends or telomeres reach a specific
minimal length, the cell activates its apoptotic
program, presumably via p53 (9, 10). One of the
ways in which the length of the telomeres can be
maintained is via the telomerase enzyme that
adds hexanucleotide repeats to the telomeric
DNA. In general, the amount of telomerase
activity present in a cell correlates with its
capacity to proliferate (11). Stem cells, for
instance, have high levels of telomerase activity
and in principle have the ability to divide
indefinitely. Also, when lymphocytes are
presented with antigens a rapid proliferative
response is induced and the amount of telomerase
protein is increased (12). Importantly, cancer
cells have upregulated the expression of
telomerase ensuring that the telomeres never
reach their minimal length (reviewed in (13)).
In addition to all previously mentioned
traits, a malignant cancer cell has acquired the
capacity to metastasize and provide itself with
the required oxygen and nutrients. However, the
minimal amount of properties and the order in
which a cell acquires them in order to become a
cancer cell, malignant or benign, is unclear.
Several of the previously mentioned processes
have a large overlap. Survival induced by PI(3)K
activity, for example, often goes hand in hand
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Figure 1. Simplified scheme of the cell-cycle. When cells
receive a growth factor right after mitosis or during a state
of quiescence (G0), G1 phase progresses and the
initiation of DNA replication is licensed. Beyond the
restriction point (R, or ‘point of no return’), the cell will be
committed to proceed with the cell-cycle and will start
with DNA replication (S-phase) after which a growth
phase (G2) prepares the cell for mitosis and cytokinesis
(M-phase). If the cell is again provided with growth factor
shortly after M-phase, it will proceed with another cell-
division, but if not, it will enter quiescence.
G1
G2
M
S
G0
R
Growth phase I &
initiation of DNA
replication 
Quiescence
DNA replication
Growth phase II
Mitosis & cytokinesis
Cell-Cycle
with the induction of cell-cycle progression (3),
and inactivating mutations in p53 accomplish the
same as overexpression of telomerase: the
inhibition of apoptosis upon telomere shortening.
Nevertheless, one can create a human tumor cell
by ectopic expression of oncogenic Ras, telome-
rase and SV40 large T, which inhibits p53 and
pRb (14). This indicates that, despite some
overlap, most of the characteristics discussed
above contribute a unique feature to the rise of a
cancer cell that the other traits cannot contribute,
but what that unique contribution is and whether
these four elements need to be dysregulated in
all human tumor cells remains to be investigated.
In conclusion, before a cell divides in an
uncontrolled fashion, it has accumulated hits in
multiple crucial genes.
Cancer and the cell-cycle
The division of one cell into two daughter
cells requires several distinct processes that can
be subdivided into four stages (figure 1). In G1
phase a cell is provided with an external growth
signal that initiates cellular growth and permits
the cell to prepare for DNA replication. During
S phase the cell duplicates its entire genome, after
which it prepares for cellular division during G2
phase. Finally, nuclear division (mitosis) and
cytoplasmic division (cytokinesis) is achieved in
M phase. When M phase is done and the cell is
provided with the appropriate external cues, the
whole process can repeat itself. However, when
a cell in G1 does not receive a growth signal, it
can enter the alternative state of cellular
quiescence, also referred to as the G0 phase.
Altogether, this sequence of events is termed the
cell-cycle (figure 1) and is strictly regulated to
ensure that cells do not divide without
permission.
At various stages of the cell-cycle,
checkpoints control its proper progression and
arrest the ongoing cell division whenever a
mishap is sensed. In G2 and M phases, for
instance, the DNA damage checkpoint, which
includes p53, ensures that the cell-cycle does not
continue when DNA is damaged (reviewed in
(15)). Furthermore, in mitosis the spindle
assembly checkpoint halts cell-cycle progression
in case certain chromosomes are misaligned or
not properly attached to the spindle microtubules
(reviewed in (16)). The G1-checkpoint, also
referred to as the restriction point (R in figure
1), is activated in late M phase and cannot be
inactivated unless the cell receives the right
external growth signals. In this checkpoint, the
E2F-1 transcription factor plays a crucial role.
Its activity is required for progression of the cell-
cycle into S phase but is inhibited by pRb
(reviewed in (17)). This pRb protein is one of
the targets of the growth factor signals delivered
in early G1. When cells are provided with such
signals, a cascade of events ensures the activation
of cyclin/cdk complexes that hyperphosphorylate
pRb resulting in its release from E2F-1 and
subsequent S-phase entry (figure 2). The cyclin/
cdk complexes in turn can be inhibited by cdk-
inhibitors (CKI’s) that directly bind and
Cell-cycle control by protein kinase B
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Figure 2. Regulation of G1/S transition. In early G1, pRb
is hypophosphorylated and bound to E2F-1. This complex
actively represses transcription of genes required for G1/
S progression. Activation of cyclin D/cdk4/6 and cyclin
E/cdk2 complexes by growth factors and E2F-1-mediated
transcription causes pRb to be hyperphosphorylated.
E2F-1 is then released from the inhibitory constraints
imposed by pRb and actively transcribes genes required
for G1/S transition. Conversely, G1/S progression can
be inhibited by the p27
kip1
, p16
INK4A
 and p21
waf1/cip1 
families
of cdk inhibitors that directly bind and inhibit the cdk’s
and thus keep pRb in its hypophosphorylated form.
inactivate the cyclin/cdk complex. Growth factor
signalling can interfere with the activity of the
checkpoint at multiple levels ensuring initiation
of DNA synthesis and continuation of the cell-
cycle. For example, growth factors can increase
the activity or expression of the cyclin subunits
of cyclin/cdk complexes, can relocalize cdk
proteins from the cytoplasm to the nucleus and
can decrease the activity or expression of CKI’s
(18, 19, 20, 21). This is one of the reasons why
changes in growth factor-controlled signal
transduction pathways that render them
constitutively active are oncogenic: continuous
activation of such pathways consistently
inactivates the G1 checkpoint.
Growth factor signalling
Transduction of a growth factor signal
across the plasma membrane of a cell normally
requires a transmembrane receptor, one class of
which is the receptor tyrosine kinase (RTK).
Extracellular ligand-binding by the RTK triggers
dimerization and a conformational change in the
intracellular part of the RTK that results in the
activation of its kinase domains. As a result, the
receptor autophosphorylates, creating docking
sites for intracellular signalling proteins that
subsequently bind the receptor. Ultimately, this
leads to activation, through either RTK-mediated
phosphorylation or relocalization, of a variety of
signalling pathways that control processes such
as glucose metabolism, actin dynamics, DNA
synthesis and apoptosis (reviewed in (22)).
Cytoplasmic tyrosine kinases of the Src-family,
for example, associate with the RTKs through a
Src-homology 2 (SH2) domain which leads to
their phosphorylation and thus activation
(reviewed in (23)). Src-like kinases are then
released into the cytoplasm where they tyrosine-
phosphorylate substrates to regulate cytoskeletal
organization, proliferation, and mitosis. Another
important molecule activated by RTKs is
phospholipase C-γ (PLCγ). As Src, PLCγ directly
binds to and is activated by the RTK and
subsequently converts phosphatidylinositol-
(4,5)-diphosphate to diacylglycerol and inositol-
triphosphate, which activates classical protein
kinase C enzymes (PKCs) and mobilizes
intracellular calcium, respectively (reviewed in
(24)). Additional intracellular signalling cascades
activated by RTKs include the JAK/STAT, Ras
and PI(3)K pathways, the latter two of which are
a subject of investigation in this thesis.
Growth factor signalling and the Ras cascade
Ras is a member of the superfamily of
small GTPases that is active when bound to
guanosine triphosphate (GTP) but inactive when
bound to guanosine diphosphate (GDP). Such
GTPases are activated by guanine nucleotide
exchange factors (GEFs) which replace the
bound GDP nucleotide for a GTP nucleotide. Ras
E2F
pRb
E2F
pRb
P
P
P
P
P
cdk4/6
Cyclin D
cdk2
Cyclin E
p16INK4A
p21waf1/cip1 p21waf1/cip1
p27kip1
Repression of genes required 
for G1/S progression
Transcription of genes required 
for G1/S progression
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Figure 3. The Ras signalling cascade. Upon ligand
binding to its receptor, the RTK autophosphorylates,
creating binding sites for SH2 domain-containing proteins.
The Grb2-mSOS complex is recruited to the plasma
membrane which results in an exchange of GDP for GTP
nucleotide on the Ras GTPase. GTP-bound Ras is
capable of binding RBD-containing effector proteins
which results in their activation through relocalization and/
or conformational alteration. In this way, Ras can activate
the serine/threonine kinase Raf, the family of Ral
exchange factors (RalGEF) and PI(3)K.
then undergoes a conformational change
enabling it to interact in a GTP-specific manner
with a variety of Ras binding domain (RBD)-
containing effector molecules that transduce the
signal further downstream. Inactivation of the
GTPase occurs through hydrolysis of GTP to
GDP by its intrinsic GTPase activity which is
stimulated by GTPase-activating proteins
(GAPs) (reviewed in (25)).
Upon activation of a RTK by a growth
factor, the adaptor protein Grb2 is recruited to
the plasma membrane, either directly or via
another adaptor Shc, through interaction of its
SH2 domain with a phospho-tyrosine docking
site on the RTK (26). Grb2 is complexed with
mSOS, a GEF for Ras. Binding of Grb2 to the
RTK thus causes translocation of mSOS to the
plasma membrane where Ras is located and
hence increases the rate of nucleotide exchange
on Ras leading to its activation. (reviewed in
(27)). In this way, Ras can be activated by a wide
variety of growth factors including platelet-
derived growth factor (PDGF), epidermal growth
factor (EGF) and insulin.
As mentioned earlier, activated Ras can
recruit several proteins to the plasma membrane,
but only three effectors have been firmly
established as in vivo targets for Ras-GTP (figure
3). By binding the Raf serine/threonine kinases,
Ras activates the MEK/MAPK pathway that
controls transcription, chromosome separation
and proliferation (28, 29, 30). Through
recruitment of GEFs for the Ras-like GTPase Ral
to the plasma membrane (reviewed in (31)), Ras
activity causes GTP-loading of Ral leading to
activation of phospholipase D, activation of the
c-jun transcription factor, and inhibition of AFX,
a member of the superfamily of Forkhead
transcription factors (32, 33, 34). Finally, in
certain cases, active Ras can bind and activate
PI(3)K, a lipid kinase that will be extensively
discussed furtheron (35). However, to date
involvement of Ras in PI(3)K activation is only
seen in neuronal cells after stimulation with nerve
growth factor (NGF) or upon overexpression of
(oncogenic) Ras in several other cell types (35,
36, 37). Inhibition of endogenous Ras in mouse
fibroblasts, for instance, does not significantly
interfere with PDGF-, EGF- and insulin-induced
PI(3)K activation (38), suggesting that Ras-
mediated activation of PI(3)K might be restricted
to specific cell types and/or growth factors.
Interestingly, artificial membrane targeting
of all mentioned Ras effectors by adding a
carboxy (C)-terminal CAAX localization motif
from Ki-Ras constitutively activates them (39,
40, 41). This indicates that Ras-GTP may
function in general to recruit its effectors to
specific sites in the plasma membrane where
substrates or additional activators are present
(42). Alternatively, the interaction of Ras-GTP
with its effectors may lead to activation via
altering the conformation of the effector, as was
recently shown for the interaction of PI(3)Kγ and
Ras-GTP (43).
PP
PP
RTK
ligand
plasma
membrane
Ras
GTP
PI(3)KRalGEFRaf
mSOS
Grb2
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Growth factor signalling and the PI(3)K
cascade
The classical form of the heterodimeric
lipid kinase PI(3)K consists of a p85 regulatory
subunit and a p110 catalytic subunit. Several
mammalian isoforms of both subunits have been
identified and it is thought that the specific
isoforms function in designated developmental
stages and in certain distinct processes including
vesicular transport and heterotrimeric G-protein
signalling ((44, 45, 46) and reviewed in (47)).
PI(3)K can be activated by cytokines, G-protein-
linked receptors, several kinds of cellular stress
including heat shock and hypoxia, and by growth
factors (reviewed in (48)). Upon RTK
autophosphorylation, two phosphotyrosine
docking sites in a YMXM motif that allow
binding and activation of PI(3)K are created on
the receptor itself, as is the case for the PDGF
receptor, or on a general adaptor protein, such as
IRS-1 in the case for the insulin receptor (InsR)
(49, 50). The p85 protein directly binds the
phosphotyrosines on the receptor through its two
SH2 domains thereby bringing the p110 subunit
in the vicinity of the plasma membrane (reviewed
in (51)). However, the events that follow this
relocalization and that eventually lead to full
activation of PI(3)K are poorly understood. It has
been suggested that RTK-mediated phospho-
rylation of the p85 subunit is required (52), but
additional regulatory mechanisms may include
autophosphorylation, dimerization, p110
conformational stabilization and binding to and
possibly phosphorylation by Src-family kinases
(53, 54, 55, 56). Once activated, PI(3)K
phosphorylates the membrane phospholipid
phosphoinositol (PI) on the 3' position of the
inositol ring producing PI(3)P, PI(3,4)P2 and
PI(3,4,5)P3 (reviewed in (57)). These lipids
function as second messengers to recruit Fab1p/
YOTB/Vac1p/EEA1 (FYVE)- and pleckstrin
homology (PH)-domain containing proteins
(reviewed in (57, 58)). In analogy to Ras
signalling, binding of proteins that harbour a PH-
domain to the 3' phosphorylated phospho-
inositides leads to their activation at least in part
via relocalization to the plasma membrane where
additional activating molecules are present
(reviewed in (59)). Again, as with the Ras
effectors, artificial membrane targeting of the
lipid-binding proteins leads to their constitutive
activation (38, 60). Conversely, direct binding
of effector proteins to the p85 or p110 subunits
has been observed. The microtububle motor
protein dynamin, for instance, can bind the Src-
homolgy 3 (SH3) domain of p85, suggesting an
involvement of PI(3)K in vesicle pinching (61).
Proteins that bind to p110 include Ras and R-
Ras (35, 62). Although most studies concerning
the interaction between p110 and Ras have
focussed on PI(3)K as being downstream of Ras,
the vice versa situation has been reported as well:
PI(3)K as an activator of Ras has been suggested
by several groups although some studies find that
this does not require growth factor-stimulated
PI(3)K but rather basal PI(3)K activity (compare
(63) with (64)). Also, a proline-rich region in the
p85 subunit of PI(3)K can bind Grb2, which
might suggest that p110 binds Ras and p85
recruits mSOS to activate Ras (65). Nevertheless,
it remains to be investigated in what
circumstances one activates the other.
Signalling through 3' phosphorylated
phosphoinositides
In general, FYVE-domain containing
proteins bind PI(3)P lipids and proteins that
harbour a PH domain bind with high affinity to
PI(3,4)P2 and PI(3,4,5)P3 lipids (reviewed in (57,
58)). The use of specific inhibitors of PI(3)K
activity, the fungal metabolite wortmannin and
the structurally unrelated compound LY294002,
greatly helped the identification of proteins that
in vivo are downstream of PI(3)K activity (figure
4) (66, 67). Using these compounds it was shown
that PI(3)K contributes to Rab5-mediated
Chapter 1; General introduction
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Figure 4. Effectors of PI(3)K-generated lipidproducts.
Active PI(3)K converts PI, PI(4)P and PI(4,5)P
2
 to PI(3)P,
PI(3,4)P
2
 and PI(3,4,5)P
3
, respectively. These lipids act
as second messengers to recruit a variety of effector
proteins to the plasma membrane where these are
activated. FYVE domain-containing proteins bind to
PI(3)P but not to PI(3,4)P
2
 and PI(3,4,5)P
3
, and include
EE1A, Hrs and the yeast Vps27p protein. Proteins that
bind all three lipids but display preferential binding to
PI(3,4)P
2 
and PI(3,4,5)P
3
 include several kinases, GEFs,
actin-binding proteins and PLCγ. The PI(3)K-generated
lipidproducts can be dephosphorylated by the 3'
phosphatase and tumor suppressor PTEN that thereby
terminates all PI(3)K-dependent signalling events.
endosome fusion via early endosome antigen 1
(EEA1) that binds PI(3)P via its FYVE-domain
(68). In addition, some other FYVE-domain-
containing proteins that bind PI(3)P, such as the
tyrosine kinase substrate Hrs and the yeast
protein Vps27p, have been identified, but to date
no role for these proteins in PI(3)K signal
transduction has been demonstrated (figure 4)
(69, 70). Through the PI(3,4)P2 and PI(3,4,5)P3
lipids, PI(3)K has been implicated in the
activation of a variety of proteins. First, via PH
domain-containing GEFs, PI(3)K can activate the
GTPases Rac1 (GEF: Tiam-1), involved in
cytoskeletal rearrangements; Arf (GEFs: ARNO,
GRP1), involved in vesicular trafficking; and
possibly even Ras (GEF: mSOS) (71, 72, 73).
Second, PI(3)K activity has been shown to be
required for growth factor induced activation of
PLCγ, either directly or via bruton’s tyrosine
kinase (Btk) (74, 75). Third, some cytoskeleton
binding proteins including profilin and spectrin
have been shown to bind the PI(3,4)P2 and
PI(3,4,5)P3 lipids (71, 76), and finally, several
serine/threonine kinases are activated by PI(3)K
lipid products (figure 4). The PKC family
members PKCδ, PKCε, PKCη and PKCζ, for
instance, are activated by direct binding to the
lipids, and PKCδ and PKCζ can also be activated
indirectly via PI(3)K-mediated activation of an
upstream kinase (77, 78, 79). Besides PKCs,
other kinases that are indirectly activated by
PI(3)K include focal adhesion kinase (FAK),
involved in cellular adhesion (80), and p70S6k,
involved in protein translation (81, 82).
Importantly, two lipid phosphatases have
been identified that can terminate PI(3)K
signalling by dephosphorylating the PI(3)K lipid
products. The heamatopoietic-specific 5'
phosphatases SHIP and SHIP-2 can inactivate
some PI(3)K-dependent signalling pathways by
converting PI(3,4,5)P3 to PI(3,4)P2 (83, 84).
Especially interesting is the gene product of the
PTEN gene. This gene was originally identified
as being mutated in cells from patients with
Cowden’s disease, an inherited disorder
characterized by hamartomas in a variety of
tissues, and was subsequently found mutated or
deleted in quite a number of cancers ((85) and
reviewed in (3, 86, 87)). Recently, PTEN was
found to have phosphatase activity towards the
3' phosphate of the inositol ring of the PI(3)K
lipid products (88, 89, 90). The fact that PTEN
is a tumor suppressor that presumably works via
dephosphorylating phosphatidylinositol lipids at
the very site that PI(3)K phosphorylates them
implies that PI(3)K signalling pathways might
contribute to tumor formation. Indeed, the p3k
protein expressed by the ASV-16 virus encodes
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Figure 5. Schematic
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a constitutively active p110 subunit of PI(3)K
and is responsible for the transformation of
chicken fibroblasts that are infected with this
virus (91, 92). The importance of PI(3)K
signalling in tumor formation will bemore
extensively discussed in chapter 2.
Protein kinase B in PI(3)K signal transduction
Several years ago, two research groups
simultaneously cloned a gene of which the
product displayed high sequence homology to
both the PKC and protein kinase A (PKA) family
of serine/threonine kinases. Based on this
characteristic, it was named protein kinase B
(PKB) and RAC-PK (related to A and C protein
kinases), respectively (93, 94). A third group
isolated the same gene in a screen for cDNAs
that show similarity to the v-Akt gene of the
transforming AKT8 virus. Closer sequence
comparisons revealed that v-Akt cDNA was
identical to this new gene fused to the viral gag
sequence and it was named c-Akt (95, 96). Since
then, PKB-like genes have been found in many
types of species, including Drosophila melano-
gaster, Caenorhabditis elegans and homo
sapiens (93, 97, 98). Three PKB isoforms exist
in mammalian cells: PKBα (AKT) PKBβ
(AKT2) and PKBγ (AKT3) (figure 5) ((93, 95,
99, 100, 101, 102), references are for human
sequences) and it has been suggested that the
three PKB species play roles in distinct cellular
processes. PKBγ is most prominent in neuronal
and renal tissues whereas PKBα and PKBβ are
more widely expressed. However, PKBβ-
expression is relatively high in insulin-
responsive tissues such as liver and muscle,
suggesting that of the three isoforms PKBβ is
particularly important for PI(3)K-mediated
insulin responses in those tissues. This is in
agreement with the recent observations that
PKBβ but not PKBα functions in metabolic
responses of 3T3-L1 adipocytes to insulin
treatment despite the fact that both PKBα and
PKBβ are activated by insulin in these cells (103,
104). Interestingly, all three genes encoding the
PKB isozymes have been found amplified or
upregulated in a number of human ovarian,
mammary, gastric and pancreatic carcinomas
with especially frequent amplifications in
undifferentiated tumors (95, 105, 106, 107, 108,
109). This suggests that PKB has transforming
capabilities and may contribute to tumor
aggressiveness.
The real boost in PKB research interest
came after the discovery in 1995 that PKB is a
mediator of PI(3)K signal transduction, thereby
putatively positioning PKB in all PI(3)K-
mediated cellular responses (38, 110). In
subsequent years the mechanism by which
PI(3)K activates PKB has been largely resolved
and appears to be similar for all three PKB
isoforms (100). Upon formation of PI(3,4)P2 and
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Figure 6. Simplified scheme of PKB activation. PI(3)K
generates 3' phosphorylated phosphoinositides (PI-3-Ps)
that recruit PKB and PDK1 to the plasma membrane by
virtue of their PH domains. PKB is then phosphorylated
by PDK1 and the still unidentified PDK2, resulting in its
full activation. In addition to this catalytic activation of
PKB, the non-catalytic TCL protein is likely to be involved
in activating PKB but details of its function are largely
unknown. Active PKB is released into the cytosol where
it affects diverse cellular processes such as metabolism,
protein translation, survival and cell-cycle progression.
PI(3,4,5)P3, PKB is recruited to the plasma
membrane through its amino (N)-terminal PH
domain (figure 6) ((111) and reviewed in (57)).
Of these two lipid-products, PI(3,4)P2 seems to
be the in vivo activator of PKB, since PKB can
bind this lipid with higher affinity than it binds
to PI(3,4,5)P3 and as a result is activated more
efficiently by PI(3,4)P2 (111, 112, 113). Once
properly localized, PKB is phosphorylated on
T308 and S473 (figures 5 and 6) (T309/S474 in
PKBβ and T305/S472 in PKBγ) after which the
kinase is fully active (38, 110, 114, 115). T308
is phosphorylated by the PI(3,4,5)P3-dependent
kinase 1 (PDK1) that itself binds the
lipidproducts of PI(3)K activity (116, 117).
Besides activating PKB, this PDK1 kinase
appears to be a more general mediator of PI(3)K
signalling, since it was shown that it is involved
in PI(3)K-mediated activation of several PKCs,
PKA, p90rsk and p70S6k (79, 118, 119, 120).
The kinase that phosphorylates S473 of
PKB, conveniently termed PDK2, has yet to be
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Introduction
The notion that PI(3)K-dependent
signalling might be involved in cellular
transformation originates from several
independent findings. First, a p65-form of the
p85 regulatory subunit of PI(3)K was recently
identified in a thymic lymphoma and shown to
contribute to tumor formation in transgenic mice
expressing p65 in T-lymphocytes (1, 2). Second,
a viral oncogene (p3k) in the ASV-16 virus
represents a constitutively active version of the
catalytic subunit of PI(3)K and is a potent
transforming gene in cultured chicken embryo
fibroblasts (CEFs) (3). Third, the gene for the
p110α subunit of PI(3)K (PIK3CA) is found
amplified in cervical cancer cell lines and the
transformed phenotype of these cells is
significantly affected by treatment with the two
specific PI(3)K inhibitors wortmannin and
LY294002 (4). Fourth, these same specific
inhibitors of PI(3)K activity are able to revert
the transformed phenotype of a variety of cancer
cell lines (see for example (5)), and fifth, the
tumor suppressor PTEN is a phosphatase for 3'
phosphorylated phosphoinositides and it was
recently shown that re-expression of PTEN in
PTEN-negative tumor cells decreases PI(3)K
signalling and reverts the transformed phenotype
of the tumor cells (6, 7).
The scale of PI(3)K involvement in human
tumor formation is demonstrated by studies that
have examined mutations and deletions of the
PTEN locus in a variety of tumors and tumor
cell-lines (see (8) and references therein).
Mutations and deletions occurred in 30% of all
primary glioblastomas, >50% of all melanoma
cell-lines, 30-50% of all advanced prostate
cancers and of all endometrial carcinomas.
Despite the observations that PTEN mutations
are found predominantly in advanced glial and
prostate tumors, mutations also occur in a
significant percentage (10%) of breast cancer cell
lines. Finally, occasional mutations in the PTEN
gene are reported in head and neck and thyroid
cancers. Overall, PTEN appears a quite common
target for mutation in human cancer, with a
mutation frequency which approaches that of
p53.
One of the critical mediators of PI(3)K
signalling with respect to cellular transformation
is PKB, as suggested by a number of
observations. Besides amplifications of the gene
encoding PKB found in some cancers and the
fact that PKB was originally identified as the
transforming gene of the AKT8 oncovirus (see
chapter 1), kinase-deficient PKB inhibits BCR/
ABL-dependent transformation of murine bone
marrow cells in vitro and suppresses leukemia
development in severe combined immuno-
deficiency (SCID) mice, presumably by
somehow negatively affecting endogenous PKB
function (5). In another study it was found that
several constitutively active versions of PKB can
induce transformation of CEFs and moreover that
a dominant-negative mutant of PKB inhibits
transformation of CEFs induced by p3k (9).
Finally, a conditionally active version of PKB is
able to transform Rat1 fibroblasts (10), and
overexpression of active forms of PKB can
override the reversal of transformation
accomplished by PTEN re-expression in PTEN-
negative cell-lines or mouse embryo fibroblasts
(MEFs) from mPTEN -/- mice (7, 11). Altogether,
these studies point to PKB as a major mediator
of PI(3)K-induced cellular transformation and
suggest that identifying its substrates and cellular
functions might aid in understanding the
tumorigenic effect of the PI(3)K/PKB pathway.
Control of metabolism and protein translation
by PKB
Insulin stimulates the cellular uptake of
glucose by recruiting glucose transporters of the
GLUT family to the plasma membrane, and
insulin can stimulate the conversion of glucose
to pyruvate during the process of glycolysis. PKB
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Table 1. Putative substrates of PKB
Substrate  Sequence in vitro/in vivo# Reference
Consensus   RXRXXS/T    (127)
GSK3β   RARTSS9 both    (14, 15)
BAD   RGRSRS
112
in vitro**    (42)
Caspase-9   RRRFSS
196
in vitro*    (46)
eNOS   RIRTQS
1177
in vitro*    (55)
IKKα   RERLGT23 in vitro**    (52)
AFX   RRRAAS
193
both    (106)
  RPRSSS
258
both    (106)
FKHR   RPRSCT
24
in vitro*    (105)
  RRRAAS
256
in vitro*    (105)
  RPRTSS
319
in vitro*    (105)
FKHR-L1   RPRSCT
32
in vitro*    (103)
  RRRAVS
253
in vitro*    (103)
  RSRTNS
315
in vitro    (103)
hTERT
a
  RIRGKS
824
in vitro    (128)
Rac   RIRPLS
71
in vitro    (129)
BRCA1
b
  RKRRPT
509
in vitro**    (130)
PFK2   RMRRNS
466
in vitro    (16)
  RPRNYS
483
in vitro    (16)
PDE-3B   RPRRRS
273
both    (18)
Raf   RQRSTS
259
in vitro**    (83)
IRS-1   RPRSKS
265
in vitro**^    (131)
  RSRTES
302
   (131)
  RVRASS
325
   (131)
  RHRGSS
358
   (131)
ASK1   RGRGSS
83
in vitro**    (62)
mTOR   RTRTDS
2448
neither    (33)
#) in vivo is specified as analyzing PKB-dependent substrate phosphorylation in a tissue culture system
using dominant-negative PKB (PKBcaax, PKB-AA or PKB-AAA)
*) in vitro and in cell-culture using catalytically active PKB
**) in vitro and in cell-culture using catalytically active PKB and kinase-dead PKB
^) Not measured for separate residues but for all four serines simultaneously
a) human telomerase reverse transcriptase subunit
b) breast cancer susceptibility gene 1
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is capable of regulating the uptake of glucose by
recruiting (muscle/fat-tissue specific) GLUT4
glucose transporters to the plasma membrane,
and insulin-dependent increase in mRNA and
protein expression of the (erythrocyte-specific)
GLUT1 glucose transporter is dependent on PKB
activity (12, 13). In addition, PKB can directly
phosphorylate and inactivate, both in vitro and
in vivo, glycogen synthase kinase 3 (GSK3), an
enzyme involved in regulating glycogen
synthesis (table 1) (14, 15). Subsequent
observations further emphasized a role for PKB
in controlling aspect of cellular metabolism, and
showed that PKB in vitro directly controls the
activity of an enzyme that takes part in glycolysis,
namely phosphofructo-kinase 2 (PFK2) (table 1)
(16), although a role for PKB in PFK2 function
in vivo was recently questioned (17).
Furthermore, insulin-induced activation of the
cAMP-regulator phosphodiesterase 3B (PDE3B)
in adipocytes was also shown to be mediated
through direct phopshorylation by PKB (table
1) (18).
In addition to these direct forms of
metabolic control, PKB was found to regulate
the transcription of several insulin-responsive
genes. Via an insulin-response element (IRE), the
InsR/PI(3)K/PKB signalling route can inhibit
phosphoenolpyruvaat-carboxykinase (PEPCK)
and insulin-like growth factor-binding protein 1
(IGFBP-1) gene expression, and activate
glucose-6-phosphatase and fatty acid synthase
gene expression (19, 20, 21, 22).
The contribution of PKB-controlled
metabolic processes to cellular transformation is
likely to be of a permissive nature. None of the
above mentioned genes have been implicated in
the onset of tumor formation, but are nonetheless
thought to facilitate growth by increasing the
tumor’s energy supply. With this respect it is
interesting to note that GLUT1 expression,
although normally restricted, is high in most
tumor tissues (23). In addition, besides being
inhibited by insulin, GSK3 negatively regulates
the Wnt/β-catenin/T-cell factor (TCF)/cyclinD1
pathway implicated in the formation of >90% of
all colon carcinomas (reviewed in (24)). GSK3
directly phosphorylates β-catenin which is then
targetted for ubiquitin-mediated degradation via
the Skp1/CulA/F-box (SCF) complex (25).
Inactivation of GSK3 by the Wnt ligand via the
frizzled receptor and the cytoplasmic dishevelled
protein causes stabilization of β-catenin and
activation of the TCF/LEF family of transcription
factors (reviewed in (26)). In this way, GSK3
can regulate the expression of the genes for c-
myc and cyclin D1, involved in proliferation (27,
28). This raises the interesting possibility that
PKB might affect β-catenin stability and thus
cell-cycle progression via the inhibition of GSK3.
Despite the attractiveness of this, solid evidence
is lacking and a recent report suggests that PKB-
regulated GSK3 constitutes a different pool than
the one regulated by Wnt signalling (29). Finally,
GSK3 has been implicated in the regulation of
c-jun transcriptional activity, involved in tumor
formation (30) but no role for PKB in this process
has yet been reported.
A role for PKB in protein translation is
also suggested. PKB is able to phosphorylate and
thereby inactivate the translational repressor 4E-
binding protein 1 (4E-BP1) which in turn
inactivates the translation initiation factor eIF-
4E that facilitates RNA entry into ribosomes (31).
Moreover, hyperactive PKB can activate p70S6k,
the kinase that phosphorylates the S6 ribosomal
subunit to stimulate protein synthesis (32). PKB
may accomplish the latter via direct phospho-
rylation of the p70S6k activator mammalian target
of rapamycin (mTOR) (table 1) (33). Although
it was recently shown that endogenous PKB does
not play an essential role in insulin-stimulated,
PI(3)K-dependent p70S6k activation (34), PKB
might still activate p70S6k in the context of a
transformed cell that contains hyperactive PKB.
In agreement with this, the p70S6k inhibitor
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Figure 1. Survival signalling by PKB. Apoptotic signals
can be antagonized by PKB in a variety of ways. Fas-
mediated apoptosis can be inhibited by PKB via the
inactivation of the Forkhead FKHR-L1 that transcribes
the gene encoding FasL. Mitochondria-mediated
apoptosis is inhibited by PKB via the inactivation of BAD
and via the inhibition of Forkhead-mediated Bim
expression. Additionally, PKB inhibits the catalytic
activities of the pro-apoptotic factors caspase-9 and
ASK1, and activates the survival factors NFκB, CREB,
and eNOS. This figure provides a summary of most
reported PKB targets in survival signalling but does not
intend to imply that all PKB-mediated survival events
happen under the same conditions in every cell-type.
rapamycin inhibits p3k/PKB-mediated
transformation of CEFs, and a catalytically active
PKB that is unable to inactivate 4E-BP1 or
activate p70S6k does not mediate CEF
transformation by p3k (35). Additionally,
overexpression of eIF-4E in rodent fibroblasts
causes cellular transformation, and subsequent
overexpression of 4E-BP1 can revert this (36,
37). Altogether, this suggests that translational
control may play an important role in cellular
transformation induced by the PI(3)K/PKB
pathway.
Survival signalling by PKB
NGF and insulin-like growth factor I (IGF-
I) transduce survival signals to the cell by
activating the PI(3)K/PKB cascade and these
growth factors thereby oppose apoptotic signals
that are elicited by serum starvation or the
addition of toxic stimuli (38, 39, 40). Several
mechanisms as to how PKB transduces the
PI(3)K-mediated survival signal have been
proposed. BAD, a pro-apoptotic member of the
Bcl2 family can induce apoptosis via the release
of cytochrome c from the mitochondrial
membrane, thereby activating certain proteases
termed caspases that are the executioners of cell
death (figure 1) (41). PKB directly phospho-
rylates BAD on serine 136, creating binding sites
for cytoplasmic 14-3-3 proteins (table 1 and
figure 1) (42). Upon PKB-mediated phosphory-
lation, BAD complexes with 14-3-3 proteins and
is thereby kept inactive (42, 43). However
interestingly, BAD inactivation by PKB does not
appear to be the major mechanism for PKB-
mediated survival, since BAD is not ubiquitously
expressed and certain cell-types that do not
express BAD are still protected by PKB activity
((44) and see (45) for a critical review). PKB
has also been reported to directly phosphorylate
and inactivate caspase-9 in cells transformed by
oncogenic Ras (table 1 and figure 1), although
formal proof for involvement of caspase-9
phosphorylation in growth factor-mediated
survival was not provided (46). In fact, the PKB
phosphorylation site in caspase-9 is only present
in the human protein but not in caspase-9 proteins
of lower organisms including mouse and dog,
suggesting that caspase-9 regulation by PKB is
not a general phenomenon conserved throughout
evolution, and that it is unlikely to be involved
in survival signalling during development (47).
Other putative targets for PKB in growth
factor-induced survival signalling include the
cAMP-response element-binding protein
(CREB), IκB kinase (IKK), endothelial nitric
oxide synthase (eNOS) and the apoptosis signal-
regulated kinase 1 (ASK1) (figure 1). Immuno-
precipitated PKB can activate the CREB
transcription factor through phosphorylation of
serine 133, leading to enhanced transcription of
the bcl2 gene that protects cells from apoptosis
BAD
caspase-9 ASK1
FasL
CREBNFκBeNOS
IKK
Bim
Forkhead
Mitochondrion
FasL
Fas
PKB
Fadd
caspase-
cascade
cyt c
apaf-1
APOPTOSIS
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(48, 49). The kinase that is in the PKB immuno-
precipitates and that phosphorylates serine 133
could be either PKB itself or p90Rsk, a protein
kinase previously shown to promote survival via
serine 133 phosphorylation of CREB (50).
Interestingly, as mentioned in the previous
chapter, PDK1 is an activator of p90Rsk and hence
the two proteins might be in the complex with
PKB and precipitate with anti-PKB antibodies.
It therefore remains to be established that PKB
is the kinase that transduces the survival signal
via CREB.
PKB can activate NFκB. This transcription
factor is sequestered in the cytoplasm by proteins
of the IκB family and can be released by the
kinase IKK that phosphorylates IκB and thereby
targets it for ubiquitin-mediated degradation
(reviewed in (51)). Direct phosphorylation of the
α subunit of this IKK on threonine 23 by PKB
results in NFκB activation and a subsequent
survival signal (table 1 and figure 1) (52, 53). In
support of a role for PKB in the transduction of
a survival signal via NFκB is a study that shows
that mice carrying the gagPKB transgene in T-
cells display both enhanced NFκB activity, bcl-
XL expression and protection from apoptosis (54).
In addition to the regulation of the CREB
and NFκB transcription factors, PKB can
increase survival by enhancing the production
of the second messenger nitric oxide (NO)
through direct activation of eNOS (table 1 and
figure 1) (55, 56). eNOS is responsible for the
maintenance of blood vessels by regulating blood
pressure, angiogenesis and vascular remodelling,
and can be activated by shear stress as well as by
the vascular endothelial growth factor (VEGF).
When activated by these two factors PKB
phosphorylates eNOS on threonine 1177 thereby
increasing NO production thus contributing to
endothelial cell-survival (55, 56, 57). Besides
through the regulation of eNOS activity, PKB
seems also more generally involved in
angiogenesis, since VEGF activates PKB which
in turn regulates the expression and activity of
the hypoxia-inducible factor (HIF) that activates
gene expression of the VEGF gene itself (58, 59,
60).
The ASK1 kinase is a mitogen-activated
protein kinase kinase (MKK) that activates the
stress-induced c-jun N-terminal kinase (JNK) as
well as p38 kinases. It thereby participates in the
induction of apoptosis caused by a variety of
toxic agents (61). PKB phosphorylates ASK1 on
serine 83 leading to inhibition of the kinase and
inhibition of JNK/p38-mediated apoptosis (table
1 and figure 1) (62).
This summary of potential PKB targets
and PKB-regulated processes shows that PKB
can act as a survival factor in a large number of
cell types by regulating a variety of proteins that
are somehow involved in the control of apoptosis.
What is, however, the evidence for the
involvement of PKB’s anti-apoptotic function in
cellular transformation? Despite observations
that high PKB activity in tumor cell-lines is often
found associated with increased protection from
apoptotic signals, sufficient formal proof for an
essential function of PKB in survival signalling
in tumor cells is lacking. Most of the studies
concerning PKB and survival have used
constitutively active PKB to overcome an
apoptotic signal (see for example (63, 64)) and/
or a kinase-dead version of PKB (PKB-KD) as a
dominant negative mutant to inhibit a survival
signal (see for example (40)). However, kinase-
dead PKB does not inhibit endogenous PKB
activation by growth factors as shown by van
Weeren et al, whereas a number of other PKB
mutants do (PKBcaax, PKB-AA and PKB-AAA)
(15, 65, 66). Only a few reports to date have
shown, using either of these bonafide dominant-
negative mutants, that PKB can be involved in
anti-apoptotic signalling in certain situations.
Applying calcium at low concentrations to
certain cultured neurons elicits a survival signal
and using PKB-AA it was shown that calcium-
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induced survival in these cells depends on PKB
activity (67). In addition, matrix detachment-
induced apoptosis (anoikis) by overexpression
of ILK is reverted by co-expression of PKB-AAA
(68). Finally, fibroblasts from mice in which the
gene for the PTEN tumor suppressor was
knocked out show increased sensitivity to
apoptotic stimuli and this can be reverted by
expression of PKB-AAA (7).
Because of the apparent implications on
cellular transformation, extensive research on
PKB-mediated survival has been performed in
PTEN-negative tumor cell-lines. Several of such
cell-lines die upon PTEN re-expression and
additional overexpression of an active form of
PKB counteracts this (69, 70, 71). Nevertheless,
the reversal of tumor formation by increasing
apoptosis through expression of a dominant-
negative mutant of PKB in PTEN-negative cell-
lines has never been shown. Moreover, recent
studies suggest that PKB-mediated tumor
formation induced by loss of PTEN function
might actually primarily be due to an effect on
proliferation rather than survival (72, 73). This
is in agreement with other recent findings that
inhibition of interleukin-3 (IL3)-regulated PI(3)K
function by conditional expression of dominant-
negative PI(3)K (∆p85) in Ba/F3 cells mainly
affects proliferation but not apoptosis, despite the
fact that these cells die rapidly upon IL3
withdrawal (74).
PKB and the control of cell proliferation
One of the first studies to describe an
involvement of PI(3)K in mitogenic signalling
showed that micro-injection of neutralizing
antibodies to the p110α catalytic subunit of
PI(3)K blocks the initiation of DNA synthesis
by PDGF- and EGF-receptor signalling in NIH-
3T3 cells (75). Another study showed that
conditional activation of PI(3)K in serum-
deprived cells can induce cell-cycle re-entry and
DNA synthesis (76). Furthermore, the mast cell
c-Kit receptor transduces mitogenic but not anti-
apoptotic signals through the PI(3)K pathway
(77), and reduction of PDK1 protein levels by
an antisense oligonucleotide approach inhibits
p70S6k and PKB activities, which results in a
decrease in cell doublings and an increase in
apoptosis (78). Also, small cell lung cancer cells
have constitutively activated PI(3)K which
mediates anchorage-independent growth of these
cells presumably via PKB and p70S6k (79).
Subsequently, the PI(3)K/PKB pathway was
shown to decrease expression of the p27kip1 cell-
cycle inhibitor and to increase expression of the
D-type G1-phase cyclin, possibly via inhibition
of GSK3 (figure 2) (80, 81, 82). GSK3 was
shown to phosphorylate cyclin D1 on threonine
286 resulting in both decreased stability and a
redistribution of cyclin D1 from the nucleus to
the cytoplasm (81, 82).
Other targets for PKB in the control of
cellular proliferation may include the cell-cycle
inhibitor p21waf1/cip1 via direct inhibition of the Raf
kinase in human breast cancer cells (83), and the
proto-oncogene c-myc (5). Importantly, embryos
of mPTEN knockout mice display regions of
increased proliferation (7), and re-expression of
PTEN in PTEN-negative tumor cells results in
an increase in protein levels of the p27kip1 cell-
cycle inhibitor and a concomitant G1 cell-cycle
arrest (6, 11, 84, 85, 86). In these cells neither
p21waf1/cip1 nor cyclin D1 protein levels were
affected. This suggested that the control of p27kip1
protein levels might play a major role in the
regulation of the G1/S transition by the PI(3)K
pathway in PTEN-negative tumor cells.
Nevertheless, an important question remained
unanswered: What are the targets of PI(3)K
signalling that can mediate cell-cycle progression
through the regulation of the p27kip1 protein?
Recently, those targets were identified and shown
to be three PKB-regulated Forkhead transcription
factors.
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Figure 2. Targets of PKB in the control of cell-cycle
progression. PKB can decrease the expression of the
cell-cycle inhibitors p27
kip1
 and p21
waf1/cip1 
via inactivation
of the Forkhead transcription factors AFX, FKHR and
FKHR-L1, and Raf, respectively. Additional contributions
of PKB to cell-cycle progression include activation of
cdk4 via an increase in cyclin D1 protein levels and
nuclear localization. Finally, PKB can increase protein
levels of c-myc.
Forkhead transcription factors in PKB signal
transduction
The superfamily of Forkhead transcrip-
tion factors consists of approximately ninety
members with orthologues expressed in an array
of species ranging from yeast to man (reviewed
in (87)). All members of the family show high
sequence homology within their DNA-binding
‘winged-helix’ domain to the fork head protein
of Drosophila melanogaster, which is involved
in the formation of terminal structures in the
early fly embryo (88). The prototype of Fork-
heads in mammals are the α, β and γ isoforms
of the hepatic nuclear factor 3 (HNF3). HNF3
is a liver-enriched transcription factor that was
identified as an activator of liver-specific gene
expression in rat (89).
A subset of Forkhead transcription factors
has been associated with tumorigenesis. The
Forkhead gene qin of the ASV-31 virus is
responsible for the transforming activity of the
virus and is closely related to the telencephalon-
specific brain factor-1 (BF-1), a Forkhead
transcription factor of which knockout mice show
severe cerebral hemisphere abnormalities (90,
91). Furthermore, in acute lymphoid leukemias
(ALL), the vast majority of chromosomal
translocations that cause the ALL disrupt the gene
for the mixed-lineage leukemia (MLL)
transcription factor (92). The proteins resulting
from such chromosomal breaks are fusion
proteins consisting of the DNA binding domain
of MLL fused to the transactivation domain of
another transcription factor. Two of those other
transcription factors are the Forkhead genes AFX
and AF6q21 (93, 94). A similar event occurs in
rhabdomyosarcomas. Here, a chromosomal
translocation results in a fusion between the PAX3
DNA-binding domain and the transactivation
domain of the Forkhead protein FKHR (95).
Initial evidence for the control of Forkhead-
mediated transcription by the PI(3)K pathway
came from studies performed on the nematode
Caenorhabditis elegans. Two groups indepen-
dently reported a pathway in the worm that
controls lifespan and dauer formation, a
developmental stage of the animal by which it
ensures survival of adverse conditions by
lowering its metabolism and closing its mouth
and anus. This way, it can live up to ten times
longer than a normal adult. When conditions turn
for the better, the worm goes back into the
development program and lives a normal fifteen
day adult life (reviewed in (96)). Genes that
regulate this dauer formation are called daf genes.
Two studies showed that the pathway
controlling dauer formation is regulated by
pheromones that activate the DAF-16 protein (97,
98). DAF-16 in turn is negatively regulated by
DAF-2 via AGE-1 (also known as DAF-23).
Surprisingly, DAF-2 is an InsR-like protein,
AGE-1 is PI(3)K-like and DAF-16 turned out to
be a transcription factor of the Forkhead family
with highest homology to mammalian AFX,
FKHR and FKHR-L1 (figure 3) (93, 97, 98, 99,
100, 101, 102). Soon thereafter it was shown in
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Figure 3. PI(3)K-mediated inhibition of Forkhead transcription factors is conserved between C. elegans and mammals.
In both nematode and mammalian cells, the insulin receptor (DAF-2) activates PKB (AKT1/AKT2) via PI(3)K (AGE-
1) and PDK1 (PDK1). Conversely, PTEN (DAF-18) inactivates the pathway. Activation of PKB (AKT1/AKT2) leads to
inactivation of Forkhead transcription factors (DAF-16), at least in mammalian systems via direct phosphorylation by
PKB. These Forkheads control dauer formation, lifespan and metabolism in C. elegans, and cell-cycle progression,
apoptosis and metabolism in mammals. See text for further details.
mammalian systems that insulin- and IGF-I-
activated PKB directly phosphorylates the DAF-
16-like Forkheads on two or three residues (T24,
S253 and S316 in FKHR) thereby inactivating
them (103, 104, 105, 106). Subsequently, also a
PKB-like (AKT1, AKT2), a PDK1-like (PDK1)
and a PTEN-like (DAF-18) protein were placed
in the C. elegans dauer formation pathway,
suggesting a signalling route from the InsR to
Forkheads that is fully conserved between worm
and man (107, 108, 109).
In mammalian cells PKB regulates
Forkhead activity by excluding them from the
nucleus (figure 4). For human AFX, FKHR-L1
and FKHR and for mouse FKHR1 it was shown
that phosphorylation by PKB upon insulin-, IGF-
I-, serum- or EGF-treatment of cells relocates
the transcription factors from the nucleus to the
cytoplasm ((103, 110, 111, 112) and chapter 4).
Obviously, this results in the inhibition of gene
transcription of Forkhead target genes, as shown
by reporter assays using either an IGFBP-1
promoter, an IRE from the Fas ligand (FasL)
promoter or a recently identified optimal DAF-
16 binding element (DBE) (103, 104, 106, 113).
The mechanism as to how PKB-mediated
phosphorylation of the Forkheads causes their
relocalization to the cytoplasm is poorly
understood. One report uses progressive C-
terminal truncations to identify a region in mouse
FKHR1 required for nuclear export. In that
region, near a PKB phosphorylation site, lies a
sequence that conforms to a classical nuclear
export signal (NES) and this NES might be
functionally modified by phosphorylation of that
PKB site (figure 4) (110). Alternatively,
Forkheads might be excluded from the nucleus
by cytoplasmic retention due to phosphorylation-
dependent binding of Forkheads to 14-3-3ζ
proteins ((103) and chapter 4). The formation of
a Forkhead/14-3-3 complex as observed for
FKHR-L1 and AFX could, however, have a
function different from cytoplasmic retention.
The 14-3-3 protein Rad24, for instance, binds
the mitotic regulator Cdc25 in the nucleus and
thereby provides Cdc25 with a NES (114). Since
the intrinsic NES-like sequence of AFX does not
seem to function as a NES (see discussion of
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Figure 4. PKB-mediated nuclear exclusion
of Forkhead transcription factors. In
quiescent cells (left), steady-state locali-
zation of Forkheads is nuclear, although
the Forkhead can still shuttle between
nucleus and cytoplasm. Growth factor
treatment of cells activates PKB, which
results in phosphorylation of the
Forkheads. The steady state localization
of phosphorylated Forkheads is then
cytoplamic which is caused by functional
inactivation of a NLS located around the
phosphorylated serine in the DNA binding
domain (serine 193 in AFX, chapter 4) and/
or cytoplasmic retention due to 14-3-3
binding and/or activation of a NES,
although the latter two mechanisms have
yet to be proven.
chapter 4) and since it has not been shown that
Forkheads complex with 14-3-3 in the cytoplasm,
the possibility remains that 14-3-3 proteins, like
Rad24, are required for nuclear export of the
Forkheads. Finally, phosphorylation of the
Forkheads can inactivate a nuclear localization
signal (NLS) (chapter 4). AFX continuously
shuttles between the nucleus and the cytoplasm
and PKB-mediated phosphorylation on serine
193 inactivates a NLS that surrounds that residue
(chapter 4). Subsequently, the steady state
localization of AFX shifts from predominantly
nuclear to predominantly cytoplasmic (figure 4).
The exact mechanism as to how insulin
and IGF-I inhibit the Forkheads might be more
complex than portrayed above. AFX, for
example, is phosphorylated by an as yet
unidentified Ras/Ral-dependent but PI(3)K-
independent kinase and this phosphorylation
contributes to insulin-mediated inhibition of AFX
(106). Furthermore, it was recently argued that
the IGF-I-regulated T24 kinase of FKHR is not
PKB and that S315 in FKHR-L1 is preferentially
phosphorylated by the PI(3)K-dependent serum-
and glucocorticoid-inducible kinase (SGK)
(figure 5) (115, 116). How all these kinases
contribute to the insulin- and IGF-I-induced
inhibition of the Forkheads still remains to be
elucidated, but possibly Forkhead-specific and
growth factor-specific elements are involved as
was suggested for T24 phosphorylation of FKHR
(115).
A role for Forkheads in PKB-mediated
cellular transformation?
Despite the complex regulatory
mechanism of insulin- and IGF-I-mediated
control of the Forkheads, one thing is clear: All
three transcription factors are efficiently inhibited
by PKB-dependent phosphorylation. In this way,
PKB decreases expression of the genes encoding
FasL, Bim and p27kip1 that cause apoptosis,
especially in haematopoietic cells (figure 1) (103,
111, 117, 118, 119). Jurkat T-cells expressing a
triple mutant of FKHR-L1 that cannot be
phosphorylated by PKB and therefore cannot be
inhibited by PKB show a twofold increase in
apoptosis compared to control (103). This
induction of cell death by FKHR-L1 depends on
the presence of a functional receptor for FasL,
the Fas protein, since Jurkat cells expressing a
mutant of Fas that is unable to respond to FasL
do not die upon expression of the active
Forkhead. Besides FasL, FKHR-L1 has been
shown to regulate the expression of Bim, a pro-
apoptotic member of the Bcl2 family which is
expressed in haematopoietic cells (120, 121). The
mouse pre-B cell line Ba/F3 requires IL-3 for its
RTK
PI(3)K
PKB
14-3-3 PPKB
nuclear 
membrane
? ?
P
PP
Forkhead
P
NES P
NESNES
NES
Forkhead
Forkhead
Forkhead
NLS
NLS NLS
NLS
Chapter 2; Cellular transformation by PKB
31
Figure 5. Forkhead-kinases and their effects on
Forkhead function. Insulin-activated PKB phosphorylates
AFX on serines 193 (S193) and 258 (S258), and
phosphorylation of S193 results in the functional
inactivation of a NLS causing nuclear exclusion. Neither
the kinase for the Ral-dependent site nor the site itself is
known, and the effects of the phosphorylation of S258
and the Ral-dependent residue on AFX function are
unknown. Although PKB can phosphorylate FKHR on all
three residues in a PKB consensus site, T24 is possibly
not phosphorylated by PKB upon insulin treatment of cells
and possibly not phosphorylated at all upon IGF-I-
treatment. Phosphorylation of S256 is required for full
inhibition of FKHR, but all three residues seem to
participate in nuclear exclusion. FKHR-L1 is
phosphorylated by at least two kinases: PKB and SGK.
Although both kinases can phosphorylate all three
residues in a PKB consensus site upon IGF-I-treatment
of cells, PKB preferentially phosphorylates S253 whereas
SGK prefers S315. Both kinases can act on T32, but
whether PKB or SGK is the in vivo T32-kinase remains
to be investigated. As for FKHR, all three residues seem
to be required for nuclear exclusion, but only T32 and
S253 bind 14-3-3 proteins. DB; DNA binding domain.
survival and this is mediated by the PI(3)K/PKB
pathway. IL-3 withdrawal causes apoptosis
which coincides with an activation of the
Forkhead FKHR-L1 and a subsequent increase
in the expression of the gene for Bim (118).
Interestingly, in the same system the cell-cycle
inhibitor p27kip1 is upregulated upon Forkhead
activation and this was shown to contribute to
cell death induced by cytokine withdrawal of
mouse bone marrow cells (119). As FKHR-L1,
the other two Forkheads can also induce
apoptosis. FKHR overexpression results in the
death of 293T-cells and AFX overexpression
causes apoptosis in CHO-K1 cells (111, 117).
Nevertheless,  proper proof for the involvement
of any of the three Forkhead transcription factors
in the induction of apoptosis by inactivation of
the PI(3)K/PKB pathway has not been provided,
since no study has yet used an inhibitor of the
Forkheads to reduce apoptosis upon, for instance,
cytokine withdrawal.
In addition to their role in apoptosis, a
surprising new function was recently described
for the Forkheads. Overexpression of AFX,
FKHR and FKHR-L1 in a variety of cell-lines,
including Ras-transformed and PTEN-negative
cells, results in a G1 cell-cycle arrest (116, 122,
123). In two of those studies it was shown that
this is caused by an increase in the expression of
the p27kip1 cell-cycle inhibitor, although other
cell-cycle regulatory targets for the Forkheads
are likely to exist (122, 123). Notably, activation
of PKB can revert the cell-cycle arrest imposed
by Forkhead expression and a putative dominant-
negative Forkhead mutant can partially rescue
the inhibition of cyclin E/cdk2 kinase activity
by an inhibitor of PI(3)K (123). Therefore, PKB
contributes to cell-cycle progression by inhibiting
these Forkheads thus reducing p27kip1 expression.
Altogether, this raises the exciting
possibility that tumors that contain oncogenic
Ras or that carry PTEN mutations have aquired
the capacity of enhanced proliferation and/or
survival, at least in part by inhibiting the DAF-
16-like Forkhead transcription factors (figure 3).
Indeed, PTEN-negative renal and prostate
carcinoma cell-lines show increased Forkhead
phosphorylation and an increased ratio of
cytoplasmic versus nuclear localization
compared to renal and prostate carcinoma cell-
lines that are PTEN-positive (122). Importantly,
overexpression of Forkheads in such PTEN-
negative cells inhibits proliferation by causing
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either apoptosis (PTEN-negative prostate
carcinoma) or cell-cycle arrest (PTEN-negative
renal carcinoma and glioma; Ki-RasL61-
transformed Rat1 fibroblasts)  (122, 123), further
emphasizing the putative importance of Forkhead
inactivation for the enhanced proliferation of
certain types of tumor cells.
Concluding remarks
The PI(3)K/PKB pathway participates in
oncogenesis at multiple levels. Not only does it
influence metabolism and translation, it also
antagonizes apoptotic signals and overcomes
blocks imposed on cell-cycle progression. In this
respect, the recently identified PKB substrates
AFX, FKHR and FKHR-L1 are of particular
interest, for they can regulate the expression of
cell-cycle inhibitory genes but also of pro-
apoptotic and metabolic genes (124). These
Forkhead transcription factors may be key
players in tumor formation caused by
uncontrolled activation of the PI(3)K pathway.
The entire signalling cascade from the
InsR to Forkheads is conserved between humans
and C. elegans, and in the nematode, DAF-16
regulates longevity but not apoptosis. It is of
interest to note that the cell-cycle arrest induced
by Forkhead ativation in mammalian cells does
not precede apoptosis but rather represents an
exit from the cell-cycle (unpublished
observations, chapter 6). With respect to the
contribution of Forkheads to cellular
transformation, this might imply that Forkhead
inactivation is a prerequisite for re-entry into the
cell-cycle of certain types of tumor cells.
The gene targets of DAF-16 that have been
identified to date and that mediate the effect of
DAF-16 on C. elegans lifespan are cytosolic
catalase (ctl-1) and manganese superoxide
dismutase (sod-3) (125, 126). Possibly also in
humans free radical-scavenging enzymes are
targets of AFX, FKHR and FKHR-L1 and might
contribute to the regulation of apoptosis, cell-
cycle progression and tumor formation by
PI(3)K/PKB, and conversely DAF-16 in C.
elegans might regulate the expression of a cell-
cycle inhibitor. Preliminary experiments from our
laboratory in fact suggest that indeed the DAF-
16-like Forkheads cause enhanced protection
form oxidative damage in human cells by
increasing protein levels of manganese
superoxide dismutase (unpublished observations,
chapter 7).
In conclusion, the RTK/PI(3)K/PKB/
Forkhead pathway seems a very good candidate
for providing critical oncogenic signals to cells
and identifying all gene targets of the Forkheads
might prove to be important in understanding the
transformed phenotype of, for instance, PTEN-
negative tumor cells.
Outline of this thesis
Four years ago, a role for PKB in the
regulation of the expression of genes that
contribute to processes like cell-cycle control and
glycogen metabolism was apparent (5, 12).
However, no PKB-controlled transcription
factors that could explain the observed effects
of PKB on gene transcription had been found.
We set out to identify substrates of PKB involved
in transcriptional regulation.
In chapter 3, we describe the identification
of the AFX Forkhead transcription factor as a
bonafide PKB effector in insulin signalling. This
study was inspired by previous observations in
C. elegans that showed control of the DAF-16
Forkhead transcription factor by an InsR/PI(3)K-
like pathway. We confirm and extend those
observations by showing that PKB directly
phosphorylates AFX on two serine residues
causing its inhibition. In addition, we provide
evidence that Ras-mediated activation of Ral
cooperates with PKB in insulin-mediated
inhibition of AFX.
In chapter 4, we illustrate in detail how
AFX is inhibited upon phosphorylation by PKB.
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We show that in the absence of PKB activity, the
steady-state of AFX localization is nuclear but
the protein is actively shuttled between the
cytoplasm and the nucleus. Phosphorylation by
PKB on one of the two designated serines causes
masking of a NLS in AFX leading to cytoplasmic
retention and thus inhibition of the Forkhead.
In chapter 5, we identify a transcriptional
target for the AFX-like Forkheads. Transcription
of the gene for the p27kip1 cell-cycle inhibitor is
shown to be increased upon Forkhead expression,
leading to inhibition of cell proliferation of many
cell-types including tumor-derived cell lines
lacking PTEN activity. Activation of PKB and
Ras might thus contribute to cellular proliferation
via the inhibition of Forkheads.
Chapter 6 deals with the different
responses of distinct cell-types to Forkhead
activity. We show that non-haematopoietic cell-
types do not undergo FKHR-L1-induced
apoptosis as haematopoietic cells do, but rather
enter G0 and remain quiescent. In addition, we
identify a second putative gene target for the
Forkheads, namely the p130 pocket protein, a
pRb-like protein known to be involved in the
maintenance of quiescence.
Finally, in chapter 7 we show that
induction of quiescence by Forkheads is coupled
to enhanced protection from oxidative damage
via direct promoter control of the gene for
manganese superoxide dismutase (MnSOD). In
this chapter we pose that this coupling is required
for survival of the quiescent cells. In conclusion,
we have uncovered the Forkhead transcription
factor AFX as part of the PI(3)K/PKB and Ras/
Ral signalling cascades both proposed to be
involved in cellular transformation. Moreover,
we show that AFX can regulate the expression
of the genes for p27kip1, p130 and MnSOD,
providing new insights into why these pathways
contribute to tumor formation. The possible
consequences of these findings are discussed in
chapter 8.
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To test for potential regulation of the daf-
16 orthologue AFX (5, 6, 9) in mammalian cells,
we labelled A14 cells transiently expressing
haemagglutinin-epitope-tagged AFX (HA-AFX)
with 32P-orthophosphate and treated them with
insulin. HA-AFX underwent a rapid and
sustained increase in phosphorylation following
insulin treatment (figure 1a). Treatment of A14
cells with epidermal growth factor and of Rat1
cells with platelet-derived growth factor also
increased phosphorylation of HA-AFX (data not
shown). Phospho-amino-acid analysis of
immunoprecipitated AFX revealed that AFX was
phosphorylated on serine and threonine residues
(figure 1b). To investigate whether PI(3)K and
protein kinase B (PKB) were involved in insulin-
induced phosphorylation of AFX, we co-
expressed HA-AFX with active forms of PI(3)K
or PKB. Constitutively active, but not inactive,
forms of PI(3)K or PKB induced a strong
increase in HA-AFX phosphorylation (figure 1c).
AFX contains three putative PKB
phosphorylation sites (10) (T28, S193 and S258;
figure 2a) that are conserved between AFX and
daf-16. As PKB activation in vivo was sufficient
to increase HA-AFX phosphorylation, we
investigated whether AFX could be
phosphorylated by PKB in vitro. As shown in
figure 2b, both immunoprecipitated HA-AFX
(right panel) and a bacterially expressed fusion
with glutathione-S-transferase (GST-AFX; left
panel) were phosphorylated by purified active
baculo-PKB (11). Mutating any one of the three
putative PKB phosphorylation sites did not
produce a marked decrease in phosphorylation
by PKB, suggesting that at least two sites were
Direct control of the Forkhead transcription factor AFX by
protein kinase B
Geert J. P. L. Kops, Nancy D. de Ruiter, Alida M. M. De Vries-Smits, David R. Powell*,
Johannes L. Bos and Boudewijn M. Th. Burgering
Laboratory for Physiological Chemistry and Centre for Biomedical Genetics, University of
Utrecht, *Department of Pediatrics, Baylor College of Medicine, Houston, Texas, 77030
The phosphatidylinositol-3-OH-kinase (PI(3)K) effector protein kinase
B (1, 2) regulates certain insulin-responsive genes (3, 4), but the transcription
factors regulated by protein kinase B have yet to be identified. Genetic analysis
in Caenorhabditis elegans has shown that the Forkhead transcription factor
daf-16 is regulated by a pathway consisting of insulin-receptor-like daf-2;
and PI(3)K-like age-1 (5, 6, 7, 8). Here we show that protein kinase B
phosphorylates AFX, a human orthologue of daf-16 (5, 6, 9), both in vitro and
in vivo. Inhibition of endogenous PI(3)K and protein kinase B activity prevents
protein kinase B-dependent phosphorylation of AFX and reveals residual
protein kinase B-independent phosphorylation that requires Ras signalling
towards the Ral GTPase. In addition, phosphorylation of AFX by protein
kinase B inhibits its transcriptional activity. Together, these results delineate
a pathway for PI(3)K-dependent signalling to the nucleus.
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Figure 1. Insulin treatment and active forms of PI(3)K and PKB increase phosphorylation
of HA-AFX in vivo. A. HA-AFX was immunoprecipitated from 32P-orthophosphate labelled
A14 cells left untreated (-) or treated with insulin for 7, 30 or 60 minutes. Following
exposure to film, the blot was probed with 12CA5 monoclonal to ensure equal expression
of HA-AFX in each lane (WB: 12CA5). Fold stim; fold increase in phosphorylation over
control. B. 32P-labelled HA-AFX (30 minute insulin time-point) was subjected to two-
dimensional analysis (28) (nh; non-hydrolysed protein). Positions of phospho-amino-
acids are as indicated. C. A14 cells were transfected with HA-AFX combined with the
indicated cDNAs. Phosphorylation of HA-AFX was analysed as in A.
A
B
C
phosphorylated by PKB (figure 2b). Tryptic
peptide mapping of in vitro phosphorylated wild-
type HA-AFX revealed three reproducibly
radiolabelled peptides designated 1, 2 and 3
(figure 2c). Peptides 1 and 2 contained S258 and
S193, respectively, because peptide maps of the
in vitro phosphorylated S258A and S193A
mutants no longer displayed 32P-incorporation
into the corresponding peptides (figure 2c).
Susceptibility of peptide 1, but not 2, to
secondary thermolysin digestion,  manual Edman
degradation (release of 32P in the third cycle) and
phospho-amino-acid analysis of eluted peptides
1 and 2 (serine phosphorylation only) supported
this conclusion (data not shown). The
phosphorylation of peptide 3 was not due to
phosphorylation of T28, as the T28A mutation
did not abolish phosphorylation of peptide 3.
Therefore, PKB can phosphorylate proteins on
residues not lying within the consensus sequence
for PKB, albeit at a low stoichiometry (figure
2c). Substitution of either S193 or S258 to a
threonine residue (S193T and S258T,
respectively), proved that these two specific
residues are phosphorylated by PKB, because
these mutations conferred phosphorylation of a
threonine residue on HA-AFX whereas only
serines residues were phosphorylated in wild-
type HA-AFX (figure 2d). Peptide mapping of
in vivo phosphorylated HA-AFX showed that the
same 3 peptides are phosphorylated, as well as
one additional peptide designated peptide 4
(figure 2e). Phosphorylation of peptides 1 and 2
was induced when cells were treated with insulin
or when active PKB (gagPKB) was co-expressed
(figure 2e). Peptide map analysis of the S193A
and S258A mutants showed that these two
residues were also phosphorylated in vivo
following insulin treatment (figure 2f). From
these results, we conclude that PKB
predominantly phosphorylates S193 and S258,
both in vitro and in vivo.
Three observations suggest that there is an
insulin-induced, PKB-independent pathway
acting on AFX. First, in vitro, PKB induces only
serine phosphorylation. Second, in vivo, one
PKB-independent peptide is phosphorylated
(peptide 4, figure 2e and 2f). Finally, both
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complete inhibition of PI(3)K (and thus PKB,
data not shown and (1)) by pretreatment of A14
cells with wortmannin (12) (figure 3a) or
LY294002 ((12); data not shown), and inhibition
of endogenous PKB activity by expressing a
dominant-negative PKB (PKBcaax) (11) resulted
in a pronounced but incomplete inhibition of
insulin-induced HA-AFX phosphorylation
(figure 3a). Treatment of A14 cells with insulin
activates many signalling cascades, including
those elicited by activation of Ras (13).
Expression of an active mutant of Ras (RasV12)
(14) induced an insulin-independent
phosphorylation of HA-AFX (figure 3b), in
keeping with the ability of oncogenic Ras to
induce PI(3)K-dependent signalling (15).
Furthermore, inhibiting Ras activation by
expressing a dominant-negative Ras (RasN17)
(14), which does not inhibit PKB activation (data
not shown and (1)), partially inhibited HA-AFX
phosphorylation induced by insulin (figure 3b).
Simultaneous blocking of Ras and PI(3)K using
RasN17 and wortmannin completely blocked
insulin-induced phosphorylation of HA-AFX
A
B
C D
E
F
Figure 2. PKB phosphorylates HA-AFX in vitro and in
vivo. A. Comparison of putative PKB phosphorylation
sites in HA-AFX (T28, S193 and S258) and daf-16 with
known PKB sites (BAD, GSK3β and PFK2) and PKB
consensus as determined by Allessi et al. (10). B.
Immunoprecipitated wild-type HA-AFX and PKB-site
mutants of HA-AFX (T28A, S193A and S258A) or purified
bacterially expressed GST-AFX were incubated in the
presence (+) or absence (-) of 2 ml of purified active
baculo-PKB (bacPKB). C. HA-AFX phosphorylated in
vitro by PKB as in B was processed for two-dimensional
phospho-peptide mapping as described (29). Positions
of the three resolved peptides are indicated by numbers.
D. HA-AFX, S193T and S258T phosphorylated in vitro
by PKB as in B were processed for two-dimensional
phospho-amino-acid analysis as in figure 1b. nh; non-
hydrolysed protein. E. HA-AFX phosphorylated in vivo
following insulin treament of A14 cells or by co-expression
with gagPKB were isolated as in figure 1a, and analysed
as described in C. F. S193A and S258A phosphorylated
in vivo following insulin treament of A14 were isolated
as in figure 1a, and analysed as described in C.
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(figure 3c). As well as PI(3)K, Ras activates the
RalGEF/Ral and the Raf/MEK/MAPK pathways
(16, 17). Expression of active Rlf (Rlfcaax), a
guanylyl-exchange factor for Ral (18), resulted
in phosphorylation of HA-AFX, whereas active
Raf (19) or a catalytically inactive form of Rlf
had no effect (figure 3d). Dominant-negative
RalN28 (20) completely abolished the Rlfcaax-
induced phosphorylation of HA-AFX, whereas
continuous inhibition of PI(3)K using
wortmannin had no effect (figure 3e). Combined
inhibition of both Ral and PI(3)K using RalN28
and wortmannin completely blocked insulin-
induced phosphorylation of HA-AFX (figure 3f).
Figure 3. PKB cooperates with
Ras in the phosphorylation of HA-
AFX by insulin. A-D, F. A14 cells
were left untreated (-) or treated
with insulin for 30 minutes (+).
Precipitates were analysed as in
figure 1a. 32P-labelled HA-AFX
was isolated from transfected A14
cells co-expressing either
PKBcaax or pretreated for 10
minutes with wortmannin (A),
RasV12 or RasN17 (B), RasN17,
pretreated for 10 minutes with
wortmannin, or both (C), RasV12,
Rafcaax, Rlfcaax or Rlf∆catcaax
(D), RalN28, pretreated for 10
minutes with wortmannin, or both
(F). E. 32P-labelled HA-AFX was
isolated from transfected A14 cells
co-expressing either Rlfcaax or
Rlfcaax and RalN28 or co-
expressing Rlfcaax and treated
with wortmannin for 24 h. G. 32P-
labelled HA-AFX was isolated from
transfected A14 cells co-
expressing either PKBcaax,
RasV12 or RasN17 and analysed
as described in figure 2c.
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These findings were corroborated by phospho-
peptide analysis. Dominant-negative PKBcaax
abolished insulin-induced phosphorylation of
peptides 1 and 2, but not 4. In contrast, RasV12
increased the phosphorylation of peptide 4, but
RasN17 abolished insulin-induced
phosphorylation of peptide 4, but not of 1 and 2
(figure 3g). Hence, Ras signalling through Ral
is a strong candidate for mediating PKB-
independent phosphorylation of AFX by insulin.
Members of the Forkhead family, to which
AFX belongs, have been reported to bind to T(G/
A)TTT motif-containing insulin-response
elements (IRE), which inhibit the transcription
of certain genes by insulin (21). To investigate
whether AFX can also bind such IREs, we fused
the AFX DNA-binding domain (DB) carboxy
terminal to GST, creating GST-AFX-DB.
Purified GST-AFX-DB and GST-AFX could
bind specifically to a radiolabelled
oligonucleotide containing the IRE of the insulin-
like growth factor-binding protein-1 (IGFBP-1)
promoter, but not to an oligonucleotide
containing a mutated IRE (Am2Bm2) (22)
defective in insulin responsiveness (figure 4a).
To examine whether AFX can regulate
transcription of the IGFBP-1 gene, we analysed
the activity of a CAT reporter gene under the
control of the IGFBP-1 promoter (1205-CAT)
(22). HA-AFX induced a pronounced increase
in CAT activity (figure 4b). The effect of HA-
AFX depended on an intact IRE, since the
Am2Bm2 mutant blocked the effects of HA-AFX
(figure 4b). Insulin treatment or co-expression
of either gagPKB, RasV12 or Rlfcaax inhibited
the activity of the IGFBP-1 promoter (figure 4c).
Transcriptional repression by insulin was
regulated by the same pathways which induced
AFX phosphorylation. Thus, only simultaneous
blocking of Ras-mediated signalling to Ral
(RasN17, RalN28) and PI(3)K-dependent
signalling to PKB (wortmannin) could fully
inhibit the insulin-induced repression of
transcription (figure 4c). To determine whether
phosphorylation of AFX by PKB was involved
in the ability of AFX to regulate IGFBP-1
promoter activity, we examined the effect of a
double mutant of HA-AFX lacking both PKB
sites (HA-SASA). gagPKB had no effect on
IGFBP-1 promoter activity when HA-SASA was
expressed. In contrast, insulin was  only slightly
less able to inhibit expression of the CAT gene
(figure 4c). This effect was probably due to
insulin-induced Ras/Ral signalling, as RasV12
still inhibited transcription induced by HA-SASA
and blocking only Ras (Ras N17) or Ral
(RalN28), but not PI(3)K (wortmannin),
prevented insulin from inhibiting AFX activity
(figure 4c).
To investigate the underlying mechanism
of insulin-induced inhibition of AFX, we
constructed a fusion protein of full length AFX
with the Gal4 DNA-binding domain (Gal4-FL).
Expression of Gal4-FL with a Gal4-luciferase
reporter construct (23) increased luciferase gene
expression. Again, this transactivation was
inhibited by insulin and involved both PKB and
Ral (figure 4d). To determine which region of
AFX was involved in the insulin-induced
repression, we created Gal4 fusion proteins
containing either the amino terminal or the C-
terminal part of AFX (Gal4-N and Gal4-C,
respectively). We found that the C-terminal part
of AFX acted as a strong transcriptional
transactivating domain. Transcription by Gal4-
C, however, was not repressed by insulin (figure
4d). This, and the observation that insulin could
repress activity of Gal4-FL, may indicate that
the full-length AFX protein is required for
inhibition by insulin.
Insulin induces the phosphorylation of
AFX by way of both PI(3)K/PKB and a Ras/Ral
signalling pathway, PKB phosphorylates AFX
predominantly on two residues, S193 and S258,
and this phosphorylation by PKB can regulate
the transcriptional activity of AFX (figure 4e).
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Figure 4. Phosphorylation of HA-AFX by PKB regulates transcriptional activity. A. GST protein alone (-), GST-AFX-
DB (DB) or GST-AFX (FL) were incubated with 32P-labelled oligonucleotides encompassing the IRE or a mutated IRE
(Am2Bm2) of the IGFBP-1 promoter. Faster migrating complexes in the GST-AFX lane represent GST-AFX break-
down products. FP; free probe. B. A14 cells were transfected with the 1205-CAT reporter construct or the Am2Bm2-
CAT reporter and co-transfected with (AFX) or without (-) wild-type HA-AFX. C. A14 cells were transiently transfected
with the 1205-CAT reporter together with HA-AFX or HA-SASA either in the absence or presence of gagPKB, RasV12,
Rlfcaax, RasN17 or RalN28. Treatment with insulin was for 16 h. Pretreatment with wortmannin was for 10 min. D.
A14 cells were transiently transfected with the Gal4-luc reporter construct together with either Gal4-N, Gal4-C or
Gal4-FL in combination with either gagPKB, Rlfcaax, PKBcaax or RalN28. Treatment with insulin was for 7 h. B-D.
Controls are set at 100%. Data are obtained from three independent experiments. E. A model for insulin-mediated
inhibition of AFX-dependent transcription. Left, the insulin-induced pathways leading to phosphorylation and inactivation
of AFX as described in the text. Inhibitors are indicated by blunted arrows. Right, pathways similar to those depicted
in the left panel have been identified in C. elegans. DB; DNA-binding domain, TA; transactivation domain.
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Although it is unlikely, we cannot formally
exclude that, in vivo, a kinase with PKB-like
specificity activated by PKB acts between PKB
and AFX. Currently, no kinase acting
downstream of Ral is known. Identification of
the non-PKB target site on AFX will probably
facilitate the isolation of such a kinase. Based
on the use of a range of inhibitors and activators,
MAP-kinase kinase (MEK), p90Rsk, p70S6k,
protein-kinase A, protein-kinase C enzymes
sensitive to 12-D-tetradecanoyl phorbol-13-
acetate (TPA), p38/HOG1, glycogen synthase
kinase 3 and calmodulin kinase II do not seem
to be involved in the phosphorylation of this
PKB-independent target site (unpublished
observations). Although activated PKB
translocates to the nucleus, the physiological
consequences of this translocation were unknown
(24). Our data indicate that phosphorylation of
the AFX transcription factor is one of the
consequences of PKB relocalization. Our results
confirm and extend the genetic data obtained in
C. elegans. Complementation studies in C.
elegans have suggested that a PI(3)K (age-1)-
independent route from the insulin receptor (daf-
2) may lead to inactivation of AFX (daf-16), but
the components of this route have yet to be
identified (figure 4e and (25)). To our knowledge,
a role for Ras in the regulation of daf-16 in C.
elegans has not been proposed. Our data identify
the AFX transcription factor as an integration
point for Ras and PI(3)K signalling, and as the
first nuclear target of PI(3)K/PKB-dependent
signalling.
Note added in proof. Recently, Brunet et al.
reported that the AFX-related transcription factor
FKHR-L1 is also a substrate for PKB (Brunet,
A. et al. Akt promotes cell survival by
phosphorylating and inhibiting a Forkhead
transcription factor. (Cell 96, 857-868; 1999))
Methods
Cells and transfections. Insulin receptor overexpressing
mouse NIH3T3 cells (A14) were grown as described (1).
Insulin was added at 1 µg/ml and wortmannin (100 nM; Sigma)
or LY294002 (10 µM; Sigma) was added 10 minutes before
insulin. Transfections were carried out using the CaPO4
method. Generally, 1 µg of the designated plasmid was added
to 7 X 105 cells. Amount of transfected DNA were equalized
using pBluescipt KSII+.
Cloning and plasmids. The 5’ region of the AFX gene was
obtained by PCR of cDNA obtained from human leukaemic
THP-1 cells. The 3’ oligonucleotide (5’-AGCAGCTTGCTGC
TGCTATCCATGGAG-3’) contained the NcoI site located at
position +578 of the AFX gene. The 5’ oligonucleotide (5’-
CACAGAAGGCCGTCGCGATCATAGAC-3’) created a
NruI site at position +26 of the AFX gene. Restriction sites are
underlined. The 3’ region of AFX was obtained from pUC-
AFX1#3 (26). The NruI/NcoI fragment of the PCR product
was ligated to the blunted NcoI/HindIII fragment of pUC-
AFX1#3 and the resulting NruI/HindIII fragment was blunted
and inserted into SmaI-cut pMT2HA. pMT2HA-AFXT28A,
S193A, S258A, S193A/S258A, S193T and S258T were
generated by site-directed mutagenesis of the pMT2HA-AFX
cDNA using the following forward primers and subsequent
complementary reverse primers: T28A (5’-CGCTCCT
GCGCCTGGCCCC-3’), S193A (5’-GCCGGGCCGCCGCCA
TGGATA-3’), S258A (5’-CACGAAGCAGTGCAAATGCCA
-3’), S193T (5’-CCGCCGCCGGGCCGCCACCATGGATAG
CAGCAGC-3’), and S258T (5’-CCGTCCACGAAGCAGTA
CAAATGCCAGCAGTGTC-3’). Basepair changes are
underlined. The double mutant was created by mutating the
S193A cDNA using the S258A primers. pRP261-AFX-DBD
(GST-AFX-DB) was generated by site-directed mutagenesis
of pMT2HA-AFX to create a KpnI site at position +249 and a
XbaI site combined with an in-frame stop codon at position
+623 of the AFX gene, using the following forward primers
and subsequent complementary reverse primers: KpnI (5’-
C G G A A T C C T G G G G G C G G T A C C A G
GTCCTCGGAAGGG-3’) and XbaI (5’-GCCGCAGTAAAG
CCCTCTAGAAGAAACCATCTG TGC-3’). Restriction sites
are underlined and stop codon is in italic. Next, the KpnI/XbaI
fragment was ligated into KpnI/XbaI cut pRP261. GST-AFX
was created by ligating a SalI/XhoI fragment from pMT2HA-
AFX into SalI cut dephosphorylated pRP261. Gal4-N was
created by ligating a blunted SalI/NdeI fragment of pMT2HA-
AFX into XmaI cut and blunted pSG424. Gal4-C was created
by ligating a blunted NcoI/EcoRI fragment of pMT2HA-AFX
into SmaI cut pSG424. Gal4-FL was created by ligating a
blunted SalI/EcoRI fragment of pMT2HA-AFX into XmaI cut
and blunted pSG424. All generated constructs were verified
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by automated sequencing.
The following plasmids have been described: pSG5-gag and
pSG5-gagPKB (1), p110caax and p110-KDcaax (27).
pcDNA3-myrPKB and pcDNA3-myrPKB-KD were obtained
from D. Stokoe.
32P-orthophosphate labelling. In vivo labelling of A14 cells
was performed as described (1).
Immunoprecipitations and western blotting. Immuno-
precipitations using the mouse monoclonal 12CA5 antibody
and western blot analysis were performed under standard
conditions and as described (1).
In vitro kinase assay. In vitro kinase assay using active baculo-
PKB was performed as described (11). The relative activity of
1 µl purified active PKB was calculated to be 1 pmol PO4 per
min, using a peptide containing S258 of AFX as a substrate.
Phospho-amino-acid analysis and tryptic peptide mapping.
32P-orthophosphate labelled HA-AFX was immunoprecipitated
from A14 cells, electroforesed and immobilized on PVDF
membrane (Immobilon). Protein was cut from the membrane
and treated as described previously for phospho-amino-acid
analysis (28) or peptide mapping (29). Sequence-grade trypsin
was obtained from Boehringer-Mannheim.
Electrophoretic mobility shift assay (EMSA). GST-AFX-
DB and GST-AFX were purified using standard GST-fusion-
protein-purification protocol (22). Bandshift assay was
performed using a standard protocol (22) and using the
following oligonucleotides and subsequent complementary
oligonucleotides: IGFBP-1 (5’-CACTAGCAAAACAAACTT
ATTTTGAACAC-3’), Am2Bm2 (5’-CACTAGCAACCATGA
CCATGGTTGAACAC-3’).
Chloramphenicol-acetyl transferase assay. CAT assays were
done as described (30).
Luciferase assay. Luciferase assays were done as described
(23).
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Inhibition of nuclear import by protein kinase B/Akt regulates the
subcellular distribution and activity of the Forkhead transcription factor
AFX
Amy M. Brownawell, Geert J.P.L. Kops*, Ian G. Macara and Boudewijn M.Th. Burgering*
Center for Cell Signaling, University of Virginia, Charlottesville, VA USA 22908 and
*Department of Physiological Chemistry and Centre for Biomedical Genetics, University Medical
Center, 3584 CG Utrecht, The Netherlands
AFX belongs to a subfamily of Forkhead transcription factors that are
phosphorylated by protein kinase B/Akt (PKB). Phosphorylation inhibits the
transcriptional activity of AFX and changes the steady-state localization of the
protein from the nucleus to the cytoplasm. Our goal was threefold: to identify
the cellular compartment in which PKB phosphorylates AFX, to determine
whether the nuclear localization of AFX plays a role in regulating its
transcriptional activity, and to elucidate the mechanism by which
phosphorylation alters the localization of AFX. We now show that
phosphorylation of AFX by PKB occurs in the nucleus. In addition, nuclear
export mediated by the export receptor Crm1 is required for the inhibition of
AFX transcriptional activity. Both phosphorylated and unphosphorylated AFX,
however, bind Crm1 and can be exported from the nucleus. These results suggest
that export is unregulated and that phosphorylation by PKB is not required for
the nuclear export of AFX. We show that AFX enters the nucleus by an active,
Ran-dependent mechanism. Amino acids 180-221 of AFX comprise a non-
classical NLS. Serine 193, contained within this atypical NLS, is a PKB-
dependent phosphorylation site on AFX. Addition of a negative charge at serine
193 by mutating the residue to glutamate reduces nuclear accumulation. PKB-
mediated phosphorylation of AFX, therefore, attenuates the import of the
transcription factor, which shifts the localization of the protein from the nucleus
to the cytoplasm and results in the inhibition of AFX transcriptional activity.
Introduction
PKB promotes cell survival in many
different cell types (1, 2, 3, 4). Following its
initial cloning (5, 6), PKB was isolated as the
transforming gene of v-Akt, hence the name c-
Akt and its classification as a proto-oncogene (7,
8). Activation of PKB requires the lipid
PI(3,4,5)P3 (9) and phosphorylation by an
upstream kinase, PDK1 (10, 11, 12). PIP3 is
produced by PI(3)K in response to signals from
extracellular growth factors (for a review see
(13)). PKB has been shown to phosphorylate and
regulate the activity of transcription factors in
response to survival factors. Genetic studies of
C. elegans have demonstrated that the PKB
signal transduction pathway inhibits the activity
of the daf-16 geneproduct, a Forkhead
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transcription factor that regulates longevity (14).
There are three human orthologues of daf-16,
AFX (15), FKHR (16), and FKHR-L1 (17), that
were first identified as chromosomal breakpoints
in human tumors.
AFX is phosphorylated by PKB in
response to insulin and serum at two sites: serine
193 (S193) and serine 258 (S258) (18).
Phosphorylation of these residues by PKB leads
to both inhibition of the transcriptional activity
of AFX and cytoplasmic retention/nuclear
exclusion of the protein. Withdrawal of serum
or insulin results in AFX dephosphorylation,
nuclear localization, and target gene activation.
In the absence of survival factors, Forkhead
family members have been shown to induce the
transcription of pro-apoptotic genes such as FasL
(19) and Bim (20), thus triggering a cascade of
events that lead to apoptosis. In addition,
overexpression of AFX blocks cell-cycle
progression at G1 by a mechanism that is
independent of functional retinoblastoma protein,
but dependent on the cell-cycle inhibitor p27kip1
(21). Dysregulation of Forkhead proteins may
therefore comprise an important step in
oncogenic transformation by both inhibiting
apoptosis and promoting progression through the
cell-cycle.
Efficient regulated nuclear localization of
transcription factors in response to extracellular
signals is essential for their function (22). For
example, in unstressed cells, p53 continuously
shuttles into and out of the nucleus and its
subcellular distribution varies throughout the
cell-cycle. In response to certain stresses,
however, p53 relocalizes to the nucleus to
promote gene transcription. In some p53-related
tumors there is a defect in p53 localization (23,
24). In these cells, p53 is constitutively
cytoplasmic due to an increase in the export rate
of the protein. As a result, p53 cannot accumulate
in the nucleus to carry out its normal activities.
This defect leads to unregulated cellular
proliferation. Likewise, the transcriptional
activity of Forkhead family members may be
regulated not only by phosphorylation, but also
by changes in their subcellular localization.
Many proteins are transported
constitutively into and out of the nucleus by
members of the β-importin family of nuclear
transport receptors (25, 26). These receptors
recognize specific localization signals within
their cargoes and their association with these
signal sequences is controlled by the small
GTPase Ran. The regulators of Ran are
distributed asymmetrically within the cell: the
RanGTPase activating protein (RanGAP) is
cytoplasmic (27), whereas the Ran exchange
factor (RanGEF) is nuclear (28). Therefore, most
of the Ran present in the nucleus is predicted to
be GTP-bound while cytoplasmic Ran is
predicted to be GDP-bound. The directionality
of transport depends on this RanGTP gradient.
Unloading of cargo from an import receptor in
the nucleus is triggered by the binding of
RanGTP to the receptor (29, 30, 31). Conversely,
an export receptor can only load its cargo in the
presence of RanGTP. Release of export cargo into
the cytoplasm occurs by the hydrolysis of
RanGTP to RanGDP, stimulated by RanGAP and
other required cofactors (32).
In contrast to constitutive transport,
regulated transport occurs only in response to
specific cellular signals, such as phosphorylation
(33). For example, MAPKAP kinase-2 is a
nuclear protein in unstimulated cells. In response
to specific extracellular signals, it is
phosphorylated, binds p38 stress-activated
protein kinase, and is only then exported from
the nucleus (34). Regulated transport
mechanisms play critical roles in augmenting or
attenuating signalling information, by controlling
the cellular localization of proteins. Many
proteins that have regulated transport
mechanisms are shuttling proteins that move
continuously between the cytoplasm and nucleus.
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Thus, their steady-state localization is determined
by the relative rate constants for import and
export. Shuttling coordinates nuclear and
cytoplasmic events by providing a rapid and
reversible method to regulate a nuclear and/or
cytoplasmic activity. Nuclear transport often
works in tandem with other mechanisms to
regulate the function of proteins. Some
transcription factors require phosphorylation in
addition to changes in nuclear localization to
completely regulate their activity. This
redundancy increases the strength of cellular
switches and provides additional ways to
integrate environmental cues with cellular
signals. Finally, proteins that alter their cellular
localization in response to extracellular signals
need a mechanism for turning that signal off
when it is no longer required. Protein
degradation, dephosphorylation, and nuclear
transport are all mechanisms used to terminate
activity.  Although the regulated transport
mechanisms for several yeast proteins have been
identified, including those for Pho4 (35, 36) and
Mig1 (37, 38), few regulated transport
mechanisms have been described for mammalian
proteins.
Our goal, therefore, was to elucidate how
PKB-dependent phosphorylation and the
resulting cellular relocalization of AFX alter its
transcriptional activity. In this study, we show
that PKB phosphorylation of AFX in the nucleus
followed by Crm1-dependent nuclear export is
required to inhibit the transcriptional activity of
the Forkhead family member. Although
phosphorylation by PKB does not significantly
alter AFX export from the nucleus, it appears
that nuclear import of phosphorylated AFX is
regulated. Amino acids 180-221 of AFX are
necessary and sufficient for nuclear import, but
encode a non-classical NLS. Addition of a
negative charge at S193 by mutating the residue
to a glutamate inhibits nuclear import.  Therefore,
phosphorylation of AFX by PKB likely reduces
the nuclear import rate of AFX. This results in a
shift in the steady-state localization of AFX from
the nucleus to the cytoplasm, thereby inhibiting
its transcriptional activity.
Methods
Plasmids and recombinant proteins. pMT2HA-AFX,
pMT2HA-SASA, pMT2HA-A3, pSG5-gagPKB, p1205-luc,
and pCMV-lacZ have been described (18, 21). pMT2HA-AFX
(∆198-216) was constructed using PCR-based mutagenesis.
To construct the vectors encoding the fusions of GFP3 to the
C-termini of various AFX sequences, pKGFP3 was used. To
create pKGFP3, GFP-GFP was PCR-amplified and inserted
as a BglII-BglII fragment into pKGFP. For pKGFP3-AFX(180-
197), pKGFP3-AFX(198-221), and pKGFP3-AFX(180-221),
the indicated residues of AFX were PCR-amplified and ligated
into pKGFP3 as XbaI-XbaI fragments. Site-directed
mutagenesis of residues within pKGFP3-AFX(180-221) to
produce pKGFP3-AFX(180-221)I-V, pKGFP3-AFX(180-
221)S193A, and pKGFP3-AFX(180-221)S193E was carried
out using the Quikchange mutagenesis kit (Stratagene)
according to the manufacturer’s recommendations. All
mutations were verified by sequencing. pQE60-Crm1 was a
gift from Iain Mattaj (EMBL, Heidelberg) (39). Crm-His6 was
purified using Talon beads (Clontech) as described (32). The
addition of 14 mM β-mercaptoethanol was required to retain
the stability of the protein. pQE32-RanQ69L was a gift from
Dirk Görlich (University of Heidelberg). His6-RanQ69L was
prepared as described (31).
Cell Culture. Insulin-receptor overexpressing NIH3T3 cells
(A14) were grown as described (9). All other cells were
passaged in Dulbecco’s modified eagle medium (supplemented
with 5% fetal calf serum (v/v) and penicillin/streptomycin).
Baby hamster kidney cells (BHK21), human embryonic kidney
cells (HEK293), and HeLa cells were cultured in a humidified,
37°C/5% CO2 incubator. tsBN2 cells were grown at 33.5°C.
Where indicated, the tsBN2 cells were temperature-shifted to
39.5°C for 3 h after the addition of 50 µM cycloheximide.
Leptomycin B (LMB) used in some cell-based assays was a
gift from Barbara Wolff (Novartis).
Transfections. HA-tagged AFX constructs were transfected
into A14, BHK21, HEK293, HeLa, and tsBN2 cells by the
calcium phosphate method. At 24 h posttransfection, the
transfection medium was replaced with fresh medium and the
cells were incubated at 37°C for an additional 24 h. Transfected
HEK293 cells were harvested for immunoprecipitations at 48
h posttransfection. Transfected A14 cells were serum-starved
overnight where indicated. For immunofluorescence, A14 cells
53
Chapter 4; PKB inhibits nuclear import of AFX
were either untreated, treated with 10 µM LY294002
(Calbiochem) for 10 min, or treated with 2 ng/ml LMB for 30
min prior to the addition of 1 µg/ml insulin. The cells were
then incubated with insulin for an additional 30 min before
fixation. Transfected tsBN2, HeLa, and BHK21 cells were
plated on poly-L-lysine-coated coverslips. Transfected tsBN2
and HeLa cells, where indicated, were serum-starved for 1.5 h
prior to fixation. BHK21 cells were transfected with all
pKGFP3 constructs using Effectene transfection reagent
(Qiagen), according to the manufacturer’s instructions. These
cells were processed 20 h after transfection. After the indicated
treatments, the transfected cells were fixed and permeabilized
with 4% paraformaldehyde/ 2% sucrose in phosphate-buffered
saline (PBS; 137 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2
mM KH2PO4 (pH 7.4)) and ice-cold methanol as described
previously (40, 41, 42). Fixed cells were then prepared for
analysis by fluorescence microscopy.
Fluorescence microscopy. After fixation and permeabilization,
cells expressing GFP fusions were incubated with 4',6-
diamidino-2-phenylindole (DAPI; 10 ng/ml) to stain the nuclei,
then the coverslips were mounted on glass slides using
GelMount (Biomeda). Images of the cells were captured using
a 60x water-immersion objective lens on a Nikon inverted
microscope equipped with a Hamamatsu CCD camera. All
immunofluorescence data were obtained and processed using
Openlab (Improvision) and Adobe Photoshop software. Images
for each set of experiments were obtained using the same
camera settings. The relative nuclear and cytoplasmic
fluorescence levels of the GFP3 constructs were measured
using Openlab (Improvision). Nuclear fluorescence was
calculated as a percentage of the total cellular fluorescence
(N/(N+C)). All fluorescence measurements were corrected for
background fluorescence levels. Each data point represents the
mean fluorescence obtained from 12 randomly chosen cells.
Error is expressed as the standard deviation of the mean. All
cells expressing HA-tagged AFX constructs were blocked in
10% BSA-PBS at RT; incubated with 12CA5 Mab (2 µg/ml)
and Texas Red-conjugated donkey anti-mouse immunoglobulin
G (Jackson ImmunoResearch Laboratories, 1:1500 dilution)
both in 3% BSA; stained with DAPI; and mounted and viewed
as described above. Cells expressing gag-PKB were detected
using anti-gag and anti-PKB antisera (9).
Immunodetection. BHK21 cells expressing GFP3 constructs
were lysed with an equal volume of boiling Laemmli sample
buffer. Equal volumes of lysate (10 µl) were then analyzed by
SDS-PAGE and immunoblotting for GFP3 with polyclonal
anti-GFP (Molecular Probes, 1:1000) and HRP-conjugated
anti-rabbit secondary antibody (Jackson Laboratories,
1:20,000). Proteins were revealed by chemiluminescence
(Kirkegaard & Perry Laboratories). Subcellular fractionation
of insulin-treated (1 µg/ml) A14 cells was carried out according
to published protocols (43, 44). Anti-phosphoT32 FKHR-L1,
anti-c-cbl, and anti-RNA pol II were gifts from Anne Brunet
(Harvard University), Kris Reedquist (UMC, Utrecht), and
Marc Timmers (UMC,Utrecht), respectively. Anti-
phosphoS193 AFX and anti-phosphoS473 PKB were obtained
from New England Biolabs.
Luciferase assays. A14 cells were co-transfected with the
p1205-luc reporter, pMT2HA-AFX, and pCMV-lacZ. Cells
were also transfected where indicated with pSG5-gagPKB.
Cells were preincubated with LMB where noted for 30 min
prior to the addition of insulin. Cells were then treated with
insulin for 16 hr in the absence or presence of LMB.
Transcriptional activity was measured 48 hr after transfection.
Luciferase and β-galactosidase measurements were performed
as described (18).
Crm1-binding assays. HEK293 cells were either mock
transfected or transfected with pMT2HA-AFX or pMT2HA-
A3. Where indicated, cells were treated with LY294002 (10
µM) for 2 hr prior to lysis. All cells were then washed 2x with
ice-cold PBS, placed on ice, and lysed by the addition of 400
µl lysis buffer (25 mM HEPES, pH 7.4, 300 mM NaCl, 1.5
mM MgCl2, 20 mM β-glycerophosphate, 1 mM sodium
orthovanadate, 0.1% Triton-X100, 1 mM okadaic acid, 1mM
phenylmethylsulfonyl fluoride (PMSF), 10 µg/ml leupeptin,
and 20 µg/ml aprotinin). Lysates were cleared by centrifugation
(5 min at 14,000g, 4°C). The lysate was used for
immunoprecipitation with 12CA5 at 4°C for 1 h. Protein A-
Sepharose beads were added to the samples for 1h at 4°C.
Immunoprecipitates were washed 3x with buffer A (PBS, 1%
NP-40, 20 mM β-glycerophosphate, 2mM sodium
orthovanadate, 1 mM okadaic acid) and once with buffer B
(50 mM MOPS, pH 7.5, 500 mM lithium chloride, 20 mM β-
glycerophosphate, 1 mM sodium orthovanadate, 1 mM okadaic
acid). To release endogenous 14-3-3 protein bound to HA-AFX,
immunoprecipitates were washed 3x with PBS containing 1
M MgCl2 where indicated. Controls were washed 3x with PBS
without added MgCl2.
The immunoprecipitates were resuspended in binding
buffer (20 mM HEPES, pH 7.3, 150 mM potassium acetate, 2
mM magnesium acetate, 0.1% Tween-20, 28 mM β-
mercaptoethanol, 0.05% ovalbumin, 1 mM sodium
orthovanadate, 20 mM β-glycerophosphate, 1 mM okadaic
acid, and 1 mM PMSF). Crm1-His6 was added to each assay
to yield a final concentration of 500 nM. His6-RanQ69L was
added as indicated to a final concentration of 3 µM. Samples
were incubated for 2 h at 4°C and then were washed 3 times
with binding buffer. Beads were resuspended in Laemmli
sample buffer and the proteins were separated by SDS-PAGE,
and immunoblotted with horseradish peroxidase (HRP)-
conjugated 12CA5 (1:5000), monoclonal anti-His6 (BabCo,
1:2000), or polyclonal anti-14-3-3β (Santa Cruz Biotechnology,
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1:100), and with HRP-conjugated goat anti-mouse or anti-
rabbit secondary antibody (Jackson Laboratories, 1:20,000).
Proteins were revealed by chemiluminescence (Kirkegaard &
Perry Laboratories).
Heterokaryon fusion assays. BHK21 cells were transfected
with pMT2HA-A3. An acceptor cell line, GSN2, was a gift
from Bryce Paschal (University of Virginia) (45). This stably
transfected HeLa cell line expresses the nondiffusible nuclear
protein, GFP-streptavidin-SV40NLS. BHK21 and GSN2 cells
were co-plated onto poly-L-lysine coated coverslips overnight.
Cells were treated with 50 µM cycloheximide for 30 min. The
plasma membranes were then fused for 2 min with 50%
polyethylene glycol (MW 8000) prewarmed to 37°C. Cells
were washed 4 times with medium and were incubated at 37°C
for an additional 1 h in the presence of cycloheximide. Cells
were then fixed and processed for immunocytochemistry as
described above.
Results
Phosphorylation of AFX by PKB triggers
relocalization of AFX from the nucleus to the
cytoplasm.
The subcellular distribution of Forkhead
family members is altered on addition of insulin
or serum to cells (19, 46, 47).  This relocalization
is dependent on the phosphorylation of the
Forkhead protein by PKB. As a basis for
subsequent experiments, we confirmed that the
addition of insulin results in a change in the
steady-state distribution of HA-AFX in serum-
starved cells from the nucleus to the cytoplasm
within 30 min (figure 1a). Mutation of PKB
phosphorylation sites S193 and S258 to alanine
(HA-SASA) inhibited this relocalization as did
treatment with the PI(3)K inhibitor LY294002
prior to the addition of insulin (figure 1a).
Additionally, the co-expression of constitutively
active PKB (gagPKB) resulted in the
redistribution of HA-AFX, but not HA-SASA,
to the cytoplasm (figure 1b). A significant
fraction of gagPKB, however, is localized to the
nucleus (figure 1b). This result is consistent with
previous studies that have shown gagPKB
localization at the plasma membrane (40%), in
the cytoplasm (30%), and within the nucleus
(30%) (48, 49). These results confirm that
phosphorylation of AFX by PKB results in a
rapid redistribution of AFX from the nucleus to
the cytoplasm.
Nuclear export subsequent to phosphorylation
by PKB in the nucleus is required for the
inhibition of AFX transcriptional activity.
We wanted to test the hypothesis that PKB-
dependent redistribution of AFX to the cytoplasm
is required to regulate the transcriptional activity
of the protein. The best-characterized nuclear
export pathway uses a leucine-rich NES, which
is bound by the export receptor Crm1 in the
presence of RanGTP in the nucleus (50, 51, 52,
53, 54). The trimeric complex is then exported
to the cytoplasm and is disassembled. Crm1-
dependent export can be inhibited by leptomycin
B (LMB) (55), which specifically inactivates
Crm1 by covalent modification of a key cysteine
residue in the NES-binding region of the protein
(56). We tested, therefore, whether LMB could
inhibit the cytoplasmic relocalization of HA-
AFX in response to insulin (figure 2a) and serum
(data not shown).  As shown in figure 2a, LMB
completely blocked the nuclear export of AFX.
Thus, nuclear export of AFX in response to
insulin or serum proceeds via a Crm1-dependent
pathway.
Activated PKB may enter the nucleus to
phosphorylate its target proteins (57, 58),
however, this view is controversial. In support
of the idea that PKB translocates into the nucleus,
we have observed by subcellular fractionation
that A14 cells show an increase in endogenous
activated PKB within the nucleus 10 minutes
after the addition of insulin (figure 2b; PKB
S473-P). To examine this issue within the context
of Forkhead transcription factors, we used the
inhibition of AFX export by LMB to establish
the cellular compartment in which this protein is
phosphorylated by PKB. The addition of insulin
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HA-AFX
HA-SASA
HA-AFX
+LY294002
- Insulin + Insulin
PKBAFX
HA-AFX+
gagPKB
HA-SASA+
gagPKB
Figure 1. PKB-dependent phosphorylation of AFX
triggers relocalization of AFX from the nucleus to the
cytoplasm. A. A14 cells were transfected with pMT2HA-
AFX or pMT2HA-SASA. At 24 hr post-transfection, serum
was withdrawn for 18-24 hr. Insulin (1 µg/ml) was then
added as indicated and these cells were incubated for
30 min. Cells treated with LY294002 (10 µM) to inhibit
PI(3)K were pre-incubated for 10 min prior to the addition
of insulin. Cells were fixed and then HA-AFX and HA-
SASA were stained with 12CA5 and Texas red-
conjugated secondary antibody. B. A14 cells were
transfected with pMT2HA-AFX or pMT2HA-SASA and
with constitutively active PKB (pSG5-gagPKB). At 48 hr
post-transfection, the cells were fixed and HA-AFX and
HA-SASA were stained as described in A. gagPKB was
stained with anti-PKB antiserum and FITC-conjugated
secondary antibody. Bar, 10 µm.
A
B
to serum-starved cells expressing HA-AFX
resulted in phosphorylation of S193 (figure 2c).
Importantly, an equivalent level of S193
phosphorylation was observed when cells were
treated with LMB prior to the addition of insulin.
This result suggests that PKB can translocate into
the nucleus in order to phosphorylate target
proteins and that PKB-dependent phospho-
rylation of AFX occurs in the nucleus. This
conclusion is supported by our results obtained
for the PKB-mediated phosphorylation of
endogenous FKHR-L1 in the presence of LMB
(figure 2c). FKHR-L1 is another Forkhead family
member that also has a steady-state nuclear
localization in serum-starved cells (19).
Threonine 28 (T28) is a reported PKB-dependent
phosphorylation site on FKHR-L1 (19). This site
was phosphorylated by PKB to similar levels
upon the addition of insulin in either the absence
or presence of LMB pretreatment (figure 2c). We
conclude, therefore, that Forkhead family
members can be phosphorylated by PKB in the
nucleus.
To test whether nuclear export is essential
for the inhibitory effect of PKB on Forkhead
transcriptional activity, we performed a luciferase
reporter gene assay. Forkhead transcription
factors can bind to and regulate the activity of
the IGFBP-1 promoter in vitro. In co-transfection
assays using a CAT-reporter under the control of
the IGFBP-1 promoter, we have shown
previously that Forkhead binding results in
increased transcriptional activity and that insulin
represses this activity (18). HA-AFX activity in
serum-starved cells was normalized to 0%
inhibition of transcriptional activity (i.e., the
relative promoter activity is 100%). PKB-
dependent phosphorylation of HA-AFX resulting
from the addition of insulin or co-expression of
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Figure 2.  Nuclear export subsequent to phosphorylation by PKB in the nucleus is required for the inhibition of AFX
transcriptional activity. A. A14 cells were transfected with pMT2HA-AFX. At 24 hr post-transfection, serum was withdrawn
for 18-24 hr. The cells were treated with LMB (2 ng/ml) for 30 min to inhibit Crm1-dependent export. Then insulin (1
µg/ml) was added as indicated and the cells were incubated for an additional 30 min. Cells were fixed and then HA-
AFX was stained as described previously. Bar, 10 µm. B. Serum-starved A14 cells were treated with insulin (1 µg/ml)
and then fractionated at the indicated times. Equal amounts of nuclear and cytoplasmic lysates (20 µg) were analyzed
by SDS-PAGE and Western blotting. An anti-PKB antibody was used to detect endogenous PKB protein levels. An
anti-PKB S473-P antibody was used to detect activated PKB. c-cbl and RNA pol II represent cytoplasmic and nuclear
protein markers, respectively. C. A14 cells were transfected and treated as described in A. prior to cell lysis. Equal
amounts of cellular lysate (20 µg) were analyzed by SDS-PAGE and Western blotting. An anti-pT32 specific antibody
was used to detect endogenous FKHR-L1 phosphorylated by PKB (19). Since A14 cells do not express endogenous
AFX, an anti-pS193 specific antibody was used to detect HA-AFX phosphorylated by PKB. 12CA5 was used to
visualize HA-AFX expression. D. A14 cells were co-transfected with the p1205-luc reporter, pCMV-LacZ, pMT2HA-
AFX, and, where indicated, pSG5-gagPKB. Cells were preincubated with LMB where noted for 30 min prior to the
addition of insulin. Cells were then treated with insulin for 16 hr in the absence or presence of LMB. Luciferase
activity was measured 48 hr after transfection and luciferase levels were corrected for β-galactosidase expression.
pMT2HA-AFX transfected control cells were serum-starved and the inhibition of AFX activity was normalized to 0%
(i.e., 100% relative promoter activity). Data were obtained from 5 separate experiments.
gagPKB inhibited the reporter gene activity by
~50% (figure 2d). Pretreatment with LMB to
inhibit HA-AFX export, however, attenuated the
effect of insulin to approximately 20% and
abolished the effect of gagPKB on AFX activity.
Since LMB does not affect the ability of PKB to
phosphorylate AFX (figure 2c), the effect of
LMB cannot be explained by a lack of PKB-
dependent phosphorylation. Nor can it be
explained by a global effect on the cellular
transcription machinery, since LMB has no effect
on the transcriptional activity of AFX mutants,
such as HA-SASA and HA-A3 (see below), that
do not relocalize to the cytoplasm on insulin
treatment or on cotransfection of gagPKB (data
not shown). The reduced effect of LMB observed
in insulin–treated cells most likely is due to the
activation of other identified signalling pathways
that regulate AFX activity independent of cellular
localization (18). The complete inhibition
-
+- +-
+- +Insulin:
LMB:
FKHR-L1 T32-P
AFX-S193-P
HA-AFX
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observed in gagPKB cotransfected cells suggests
that PKB-dependent regulation of AFX activity
requires the relocalization of the protein to the
cytoplasm. We therefore conclude that both PKB-
mediated phosphorylation in the nucleus and
nuclear export mediated by Crm1 are essential
for the full inhibition of AFX transcriptional
activity. These data strongly suggest that a major
component of the transcriptional regulation of
AFX occurs at the level of nuclear transport.
Regulation of the localization of AFX by PKB
does not occur at the level of export.
There are several distinct mechanisms by
which PKB-dependent phosphorylation of AFX
could trigger cytoplasmic accumulation of the
protein. First, PKB-dependent phosphorylation
could facilitate nuclear export by promoting the
binding of Crm1 to AFX. In a second model,
AFX may be exported from the nucleus
constitutively, but be reimported rapidly when it
is unphosphorylated so that its steady-state
distribution is predominantly nuclear. PKB-
dependent phosphorylation would then inhibit or
decrease the rate of import, leading to a
redistribution to the cytoplasm. Third, both
nuclear import and export of AFX could be
constitutive and phosphorylation would permit
cytoplasmic retention by increasing the affinity
of AFX for a cytoplasmic anchor protein. Finally,
phosphorylation by PKB could release AFX from
a nuclear anchor.
To distinguish between these possibilities,
we performed Crm1-binding assays. AFX cannot
be expressed in appreciable amounts as a
recombinant protein in E.coli. Therefore, HA-
AFX and HA-A3 (HA-AFX with the following
mutations: T28A, S193A, and S258A) were
immunoprecipitated from mammalian cell
lysates and incubated with recombinant Crm1
in the absence or presence of RanQ69L, a mutant
of Ran locked in its GTP-bound conformation.
RanQ69L increases the affinity of Crm1 for its
export cargoes. Interestingly, both PKB-
phosphorylated (HA-AFX) and unphosphory-
lated (HA-AFX + LY294002, and HA-A3) AFX
bound to Crm1 in the presence of RanQ69L
(figure 3a). These data demonstrate that binding
of Crm1 to AFX is independent of phospho-
rylation by PKB.
To confirm that HA-AFX was phospho-
rylated in this experiment, we examined its
interaction with 14-3-3. The 14-3-3 proteins are
a family of proteins reported to bind Forkhead
transcription factors in a phosphorylation-
dependent manner (19). As shown in figure 3a,
endogenous 14-3-3 co-immunoprecipitated with
HA-AFX from cells grown in the presence of
serum, thereby confirming that phosphorylation
of HA-AFX by PKB had occurred. These data
raised the possibility that Crm1-binding to
phosphorylated AFX is indirect and is mediated
by 14-3-3. It has been reported previously that
14-3-3 contains a leucine-rich NES-like motif
(59). It is not clear, however, that this sequence
can function as a NES, especially when binding
proteins are associated with 14-3-3. To test this
hypothesis, we stripped 14-3-3 proteins from
AFX using 1 M MgCl2. This treatment
substantially decreased the amount of 14-3-3
associated with AFX, but did not reduce the
amount of Crm1/RanQ69L that was bound
(figure 3b). It should be noted that although 14-
3-3 proteins have been reported to bind Crm1 in
the presence of mammalian cell lysates (59), we
have been unable to detect a direct interaction
between recombinant 14-3-3ζ, Crm1, and
RanQ69L (data not shown).
The observation that Crm1-binding to
AFX is independent of PKB-mediated phospho-
rylation is supported by the results of
heterokaryon fusion assays. HA-A3 has a steady-
state nuclear localization, but nonetheless may
actively shuttle into and out of the nucleus.
Nucleocytoplasmic shuttling can be observed by
the use of cell-fusion assays, in which the donor
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Figure 3. Both phosphorylated and unphosphorylated
AFX bind Crm1 and are exported from the nucleus. A.
HEK293 cells were transfected with either pMT2HA-AFX
or pMT2HA-A3, incubated in the presence of serum for
48 hr, and where indicated, incubated with LY294002
(10 µM) for 2 hr prior to cell lysis. The HA-tagged proteins
were immunoprecipitated with 12CA5 and immobilized
on Protein A Sepharose. The beads were then incubated
with recombinant Crm1 (500 nM) in the absence or
presence of RanQ69L (3 µM). Proteins that bound to AFX
were analyzed by SDS-PAGE and Western blotting. An
anti-His
6
 antibody was used to visualize Crm1, which
possesses a C-terminal His
6
 tag. Directly-conjugated
HRP-12CA5 was used to assess HA-AFX and HA-A3
immunoprecipitation. An anti-14-3-3β antibody was used
to detect 14-3-3 binding. B. HEK293 cells were
transfected with pMT2HA-AFX and treated as described
in A. Prior to incubation with Crm1 and RanQ69L,
immobilized HA-AFX was washed with 1 M MgCl
2
 where
indicated to remove bound 14-3-3 proteins.  Proteins that
bound AFX were analyzed as described in A. C.
Heterotypic cell fusions were performed between BHK21
cells transiently transfected with pMT2HA-A3 and a
stably-transfected HeLa cell line expressing GFP-
streptavidin-NLS (GSN2). Cell cultures were trypsinized
24 hr after transfection, mixed, allowed to adhere to
coverslips overnight, and then fused using polyethylene
glycol. After incubation for 1 hr with cycloheximide (50
µM), cells were fixed and stained for HA-A3 with 12CA5
and a Texas-red conjugated secondary antibody. Nuclei
were visualized by staining the DNA with DAPI. Arrows
indicate acceptor nuclei containing HA-A3; asterix
indicates donor nucleus. Bar, 10 µm.
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C
DAPIGSN2HA-A3
*
and acceptor nuclei of the fused cells can be
distinguished. Redistribution of a tagged protein
from one nucleus to another can only occur if
the protein exits the donor nucleus and is
reimported into the acceptor nucleus. To perform
heterokaryon fusion assays, we used BHK21
cells expressing HA-A3 as the donor and a
reporter cell line, GSN2, that expresses green
flourescent protein (GFP)-streptavidin-NLS as
the acceptor. The GFP-streptavidin-NLS fusion
protein which is constitutively nuclear and does
not shuttle, acts as a marker for the acceptor
nuclei. HA-A3 shuttling would lead to its
equilibration into the nucleus of a fused GSN2
cell. On the other hand, if HA-A3 does not
shuttle, no HA-A3 would be detected in the
nuclei of the GSN2 cells. Figure 3c shows an
AFX donor nucleus surrounded by 3 GSN2
acceptor nuclei that also stained positive for HA-
A3. Therefore, even though unphosphorylated
AFX is predominantly nuclear in its steady-state
distribution, it is constitutively shuttling into and
out of the cytoplasm. AFX phosphorylation by
PKB, however, results in a shift in the steady-
state distribution of AFX to the cytoplasm. Taken
together these results suggest that the regulation
of AFX localization in response to PKB
phosphorylation occurs not at the level of nuclear
export or nuclear retention, but instead at the level
of nuclear import or through cytoplasmic
retention of phosphorylated AFX.
AFX import into the nucleus proceeds via an
active, Ran-dependent mechanism.
On account of the results described above,
RanQ69L
LY294002
- + - +-+ ++ +
- + - +- +- - -
Crm1
HA-AFX
14-3-3
mock HA-AFX HA-A3
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mock HA-AFX HA-AFX
- --+ + +
- +-- +
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HA-AFX
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it was important to identify the mechanism by
which AFX is imported into the nucleus. In
principle, AFX could accumulate in the nucleus
either by an active mechanism or by diffusion
followed by nuclear retention. Most active
nuclear transport pathways studied to date require
energy and an intact Ran gradient across the
nuclear envelope. To determine whether the
nuclear accumulation of AFX observed in serum-
starved cells proceeds via an active, Ran-
dependent mechanism, we used tsBN2 cells.
These cells have a temperature-sensitive
RanGEF (RCC1) allele (60). When grown at the
permissive temperature (33.5°C), tsBN2 cells
have an intact Ran-gradient. However, incubation
at the non-permissive temperature (39.5°C)
causes collapse of the Ran-gradient and prevents
Ran-dependent nuclear transport. As we have
shown previously, incubation for 3 hr at 39.5°C
in the presence of cycloheximide (to prevent new
RanGEF synthesis) completely inhibits the
import of other substrates known to utilize a
classical import pathway, such as the
glucocorticoid receptor (61).
To test the Ran-dependence of AFX
import, we transfected tsBN2 cells with a plasmid
encoding HA-AFX. In the presence of
cycloheximide, cells were grown at either 33.5°C
or were shifted to 39.5°C for 3 hr. The cells were
then serum-starved. Immunofluorescence
revealed that at the permissive temperature HA-
AFX entered the nucleus on serum starvation
(figure 4a; 33.5°C). In cells incubated at 39.5°C,
however, HA-AFX did not accumulate in the
nucleus (figure 4a; 39.5°C). We conclude,
therefore, that import of AFX into the nucleus
proceeds via an active, Ran-dependent
mechanism.
Basic residues on both sides of S193 are
necessary and sufficient for nuclear import of
AFX.
HA-AFX DAPI HA-AFX DAPI
+ serum
- serum
33.5oC 39.5oC
∆198-216
+ serum
- serum
HA-AFX DAPI DAPI
Figure 4. AFX import into the
nucleus requires a Ran-gradient
and basic residues downstream
from S193. A. tsBN2 cells were
transfected with pMT2HA-AFX
and were incubated at 33.5∞C in
the presence of serum for 48 hr.
Cycloheximide (50 µM) was then
added to the medium to prevent
new protein synthesis and the cells
were incubated at either 33.5ºC
(left) or 39.5ºC (right) for 3 hr.
Where indicated, the serum was
then withdrawn and the cells were
returned to 33.5ºC or 39.5ºC for
1.5 hr. Cells were fixed and HA-
A3 was stained as described
previously. B. HeLa cells were
transfected with pMT2HA-AFX or
pMT2HA-AFX(∆198-216) and
were incubated in the presence of
serum for 48 hr. Serum was then
withdrawn for 1.5 hr. Cells were
fixed and HA-AFX and HA-
AFX(∆198-216) were stained as
before.  Nuclei were visualized by
staining the DNA with DAPI. Bar,
10 µm.
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To determine whether PKB-dependent
phosphorylation regulates the nuclear import of
AFX, we needed to identify the NLS within the
AFX sequence. Clusters of basic residues are
often predictive that a region of a protein may
act as a NLS. AFX contains two clusters of basic
residues flanking the PKB phosphorylation site
S193. Therefore, deletion of these clusters would
test whether they are required for AFX nuclear
import. Deletion of residues 198-216 from HA-
AFX that are C-terminal to S193 results in a
protein that is unable to enter the nucleus under
the same conditions of serum starvation that
result in HA-AFX accumulation in the nucleus
(figure 4b). Thus, this region is necessary for
nuclear import of AFX. To test whether this
region is sufficient to mediate import, we
expressed residues 198-221 as a N-terminal
fusion to GFP-GFP-GFP (AFX(198-221)-GFP3)
in mammalian cells. The triple GFP construct
(~80 kDa) was used to prevent passive diffusion
through the nuclear pore complex (NPC), which
has a diffusion limit of ~60 kDa. (These fusion
proteins could not be expressed in E. coli because
the NLS is cleaved stoichiometrically during the
induction of expression, under all conditions
tested.) As shown in figure 5a, AFX(198-221)-
GFP3 did not accumulate in the nucleus. The
basic region upstream of S193 was also not able
to act as a NLS in isolation (figure 5; AFX(180-
197)-GFP3). However, a construct containing
both basic regions accumulated efficiently in the
nucleus (AFX(180-221)-GFP3). Expression of
these constructs as C-terminal fusions to GFP-
GFP-GFP resulted in the same localization (data
not shown). We conclude, therefore, that residues
180-221 of AFX constitute a NLS and that basic
residues on both sides of S193 are required for
the nuclear import of AFX.
Although the 180-221 region contains 12
lysine and arginine residues, it does not encode
a classical monopartite or bipartite NLS. In
addition, binding of the classical import receptors
importin α1, importin α3, or importin β to this
region of the protein could not be detected (data
not shown). Therefore, we produced a series of
mutations in AFX(180-221)-GFP3 to identify
residues required for import (figure 6).
Quantification of relative nuclear and
cytoplasmic fluorescence levels demonstrated
that mutation of arginines 188-190 to alanine had
the most deleterious effect on import (figure 6,
mutant II), followed by the mutation of lysines
209-211 (figure 6, mutant V). This result
reinforces the requirement for basic residues both
upstream and downstream of S193 for nuclear
import and confirms that the sequence is an
atypical NLS.
Phosphorylation of S193 reduces the rate of
nuclear import.
Phosphorylation of S193 adds a negative
charge to a positively charged region of AFX.
This may affect the binding of AFX to its nuclear
import receptor and reduce its rate of import. To
test this hypothesis, we created two AFX(180-
221)-GFP3 mutants; S193A, which cannot be
phosphorylated, and S193E, which may mimic
phosphorylation at this site. Nuclear import of
S193A was comparable to wt AFX(180-221)-
GFP3 (figure 7a and c). This demonstrates that
mutation of S193 results in a stable fusion protein
that is able to enter the nucleus. The S193E
mutation, however, substantially reduced nuclear
accumulation (figure 7a and c). This result
suggests that PKB-dependent phosphorylation of
S193 reduces the rate of nuclear import of AFX.
It is important to note that these GFP3 constructs
do not contain a NES. Therefore, over a 20 h
transfection period even with a greatly reduced
rate of import, some nuclear accumulation would
be expected since the construct cannot be re-
exported. Hence, a phosphorylation-dependent
reduction in the import rate of AFX, combined
with constitutive nuclear export would shift the
steady-state distribution of the protein from the
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Figure 5. Basic residues on both sides of S193 are sufficient for nuclear import.  Basic residues on either side of
PKB-dependent phosphorylation site S193 were expressed as N-terminal fusions to GFP-GFP-GFP (GFP3). pKGFP3,
pKGFP3-AFX(180-197), pKGFP3-AFX(198-221), and pKGFP3-AFX(180-221) were transfected into BHK21 cells. At
18 hr post-transfection, A. the cells were fixed and the DNA was stained with DAPI, or B. the cells were lysed and
analyzed by SDS-PAGE (10 µl lysate/lane) and immunoblotting using an anti-GFP antibody. C. The relative nuclear
and cytoplasmic fluorescence levels of the constructs were obtained using Openlab (Improvision). Nuclear fluorescence
was calculated as a percentage of the total cellular fluorescence corrected for the background fluorescence. Each
data point represents the mean fluorescence obtained from 12 randomly chosen cells. Error is expressed as the
standard deviation of the mean. Bar, 10 µm.
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nucleus to the cytoplasm. This mechanism is
consistent with the known redistribution of AFX
to the cytoplasm on addition of insulin or serum.
Discussion
Nuclear transport of the Forkhead
transcription factor AFX plays a critical role in
the regulation of its transcriptional activity.
Phosphorylation of AFX by PKB results in a
rapid change in the steady-state distribution of
the protein from the nucleus to the cytoplasm.
However, the mechanism by which this
relocalization occurs has not been determined,
although it has been proposed by others that
export may be regulated by PKB, and that 14-3-
3 may function as a chaperone for export, as has
also been suggested for the regulation of cdc25
export (62). Based on the data presented in this
paper, we propose a different model, in which
nuclear import, not export, of AFX is the
principal target of regulation by PKB (figure 8).
Unphosphorylated AFX is predominantly
nuclear at steady-state. However, heterokaryon
fusion assays (figure 3c) demonstrated that the
protein is, in fact, continually shuttling between
the nucleus and the cytoplasm. The rate constant
for unphosphorylated AFX import, therefore,
must exceed the rate constant for its export
(figure 8a). Importantly, the nuclear export of
AFX appears to be unaltered by PKB
phosphorylation. Nuclear export of both
phosphorylated and unphosphorylated AFX is
likely mediated by the export receptor Crm1.
Both wild-type HA-AFX and the triple-mutant
HA-A3, the latter of which cannot be
62
Cell-cycle control by protein kinase B
G180GKSGKAPRRRAAS193MDSSSKLLRGRSKAPKKKPSVLPAPPEG221
Mutant: I II III IV V
A AAAAAAAAA AA
GFP DAPI
GFP3
wt
I
II
III
IV
V
0
20
40
60
80
100
GFP3
N
uc
le
ar
 fl
uo
re
sc
en
ce
 (%
 of
 to
tal
)
120
I II III IV Vwt
Figure 6. Basic residues on both sides of S193 are required for nuclear
import and the sequence is not a classical NLS motif. A. There are 12
lysine and arginine residues that surround S193. Five constructs with
mutations of basic residues within AFX(180-221)-GFP were made (I-
V). pKGFP3, pKGFP-AFX(180-221), pKGFP3-AFX(180-221)-I,
pKGFP3(180-221)-II, pKGFP3-AFX(180-221)-III, pKGFP3-AFX(180-
221)-IV, and pKGFP-AFX(180-221)-V were transfected into BHK21
cells. At 18 hr post-transfection, the cells were either B. fixed or C.
lysed and D. analyzed as described for figure 5. Bar, 10 µm.
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phosphorylated by PKB, bind Crm1 in the
presence of RanGTP (figure 3a). In support of
the identification of Crm1 as the export receptor,
we show that AFX export from the nucleus in
response to insulin is blocked by the addition of
LMB (figure 2a), a potent and specific inhibitor
of Crm1 function.
The addition of insulin to cells results in
the activation of PKB and its translocation into
the nucleus where it phosphorylates Forkhead
family members (figure 8b). Treatment of cells
with LMB traps AFX and FKHR-L1 in the
nucleus. However, both are phosphorylated in
response to insulin to the same extent and at the
same residues as in cells not treated with LMB
(figure 2b). This result, therefore, strongly
indicates that PKB enters the nucleus when
activated by insulin to phosphorylate Forkhead
transcription factors and other target proteins.
Phosphorylation alone, however, is not sufficient
to inhibit the transcriptional activity of AFX. We
have shown, using transcriptional activation
assays, that blockade of AFX nuclear export by
the addition of LMB results in a loss of insulin-
induced transcriptional control (figure 2b).
Therefore, both phosphorylation by PKB and
GFP3 wt I II III IV V
α-GFP
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Figure 7. Phosphorylation of S193 reduces the rate of nuclear import. Two
AFX(180-221)-GFP3 mutants were created, S193A and S193E. pKGFP3,
pKGFP3-AFX(180-221), pKGFP3-AFX(180-221)S193A, and pKGFP3-
AFX(180-221)S193E were transfected into BHK21 cells. At 18 hr post-
transfection, the cells were either A. fixed or B. lysed and C. analyzed as
described for figure 5. Bar, 10 µm.
A B C
nuclear export mediated by Crm1 are essential
for complete inhibition of AFX transcriptional
activity.
We have found that AFX enters the nucleus
by an active, Ran-dependent mechanism (figure
4a) and that import requires a basic region in AFX
encompassing PKB-phosphorylation site S193
(figure 5). Importantly, the addition of a negative
charge at S193 substantially attenuates nuclear
import (figure 7), most likely by reducing the
affinity of AFX for its nuclear import receptor.
We propose, therefore, that phosphorylation by
PKB at S193 reduces the rate of AFX import.
Since the steady-state localization of a protein is
determined by its relative rate constants for
import and export, the localization of AFX would
shift from the nucleus to the cytoplasm (figure
8b). This alteration in the transport rate constants
in response to phosphorylation by PKB, in
conjunction with proposed cytoplasmic retention
by binding 14-3-3 proteins (19), would result in
both the efficient nuclear exclusion of AFX and
the inhibition of its transcriptional activity. In
conclusion, we propose that this nuclear
exclusion mechanism is required to regulate the
activity of AFX.
These data are consistent with the results
of transcriptional activation assays reported
previously for FKHR (63). The PKB
phosphorylation site S256 in FKHR is analogous
to S193 in AFX. Mutation of S256 to an alanine
in the context of full-length FKHR abolished the
ability of insulin and PKB to inhibit FKHR
activity. In contrast, mutation of S256 to an
aspartate resulted in a substantial inhibition of
its transcriptional activity. These effects were not
observed when the other two PKB sites were
mutated independently. Although the localization
of the S256D mutant was not assayed, our data
suggest that the inhibition of FKHR activity may
be due, in part, to a deficit in nuclear import.
“Classical” nuclear localization sequences
are characterized by short amino acid stretches
that are enriched in basic amino acids. The NLS
of the large T antigen of the SV40 virus was
identified by deletion analysis that resulted in
mislocalization of the protein to the cytoplasm
(64). It was later defined as a seven amino acid
sequence (PKKKRKV) sufficient to confer
nuclear localization when conjugated to a carrier
protein (65). Some proteins contain similar
sequences that are referred to as monopartite
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Figure 8. Nuclear import, not export, of AFX
is regulated by PKB. A. Unphosphorylated
AFX appears nuclear at steady-state, but is
actually shuttling rapidly between the nucleus
and the cytoplasm. Therefore, the rate of
import of unphosphorylated AFX exceeds its
rate of export. Nuclear export of both
phosphorylated and unphosphorylated AFX
are likely mediated by the exportin Crm1,
since both HA-AFX and HA-A3 bind Crm1
in the presence of RanGTP. NPC, nuclear
pore complex. B. The addition of insulin to
cells activates PKB and causes it to
translocate into the nucleus where it
phosphorylates Forkhead family members.
Phosphorylated AFX exits the nucleus by
binding Crm1. Phosphorylation of AFX at
S193 attenuates nuclear import, perhaps by
reducing the affinity of AFX for its nuclear
import receptor. Therefore, phosphorylation
by PKB decreases the import rate constant
without altering the export rate constant.
Since the steady-state localization of a
protein is determined by its relative rates of
import and export, the localization of AFX
would shift from the nucleus to the cytoplasm
as observed. This alteration in transport rates
in conjunction with proposed cytoplasmic
retention by binding 14-3-3 proteins would
result in exclusion of AFX from the nucleus.
Since AFX requires nuclear localization to
carry out transcription, this mechanism of
regulated transport would inhibit the activity
of AFX in response to phosphorylation by
PKB.
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NLSs. Other proteins, such as nucleoplasmin,
contain bipartite NLSs that consist of two patches
of basic residues separated by a ten amino acid
spacer (66). Generally, proteins carrying classical
or bipartite NLSs bind a cytoplasmic receptor,
importin α (25, 26). Importin α associates with
importin β, a protein that docks import
complexes at the NPC and translocates import
cargo into the nucleus. There are, however, many
exceptions to this type of import and there is a
large family of importins and exportins that can
recognize distinct NLSs and mediate transport
of different subsets of cargo. For example,
ribosomal proteins (67) and histones (68) have
been shown to bind directly to several different
importin β family members and dock at the NPC
independently of importin α. In addition, other
proteins, such as hnRNP K (69) and β-catenin
(70) can translocate through the NPC in the
absence of any soluble factors.
We have delineated residues 180-221 of
AFX as a novel type of nuclear import signal.
This region contains a small portion of the DNA
binding domain. Therefore, like other Forkhead
family members, the DNA binding domain of
AFX contributes to DNA binding and nuclear
localization (71). This region of AFX contains
12 lysine and arginine residues. Although several
groups of these basic residues could act as
monopartite or bipartite NLSs, the information
provided by mutational analysis suggests that
AFX contains a non-classical NLS.  Mutation of
arginines 188-190 in the NLS of AFX has the
greatest inhibitory effect on nuclear import
followed by the mutation of lysines 209-211.
These groups of basic residues are separated by
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18 amino acids and both are contained within
similar sequence repeats (KAPRRR or
KAPKKK). These repeats may be important for
import receptor binding.
The identity of the nuclear import receptor
of AFX remains to be established. Since we do
not observe binding of AFX to several classical
import receptors including importins α1, α3, and
β, it may bind to a novel member of the importin
family (which comprises >20 members in
mammalian cells). Alternatively, AFX may enter
the nucleus in other ways, for instance by “piggy-
backing” on another protein that contains a
classical NLS. The role of PKB-mediated
phosphorylation and 14-3-3 binding in altering
AFX import can be more thoroughly studied once
the receptor is identified.
Binding of Forkhead family members to
14-3-3 proteins has been proposed to play a role
in the retention of phosphorylated Forkheads in
the cytoplasm (19). Phosphorylated FKHR-L1
(19) and AFX (figure 3a) both bind 14-3-3
proteins.  However, we have never observed any
specificity of AFX binding to a particular 14-3-
3 isoform.  In fact, we have observed binding to
14-3-3β, 14-3-3ε, and14-3-3ζ (data not shown).
Recently, it has been proposed that 14-3-3 protein
binding may impart no specific information about
subcellular targeting (72). Instead, a 14-3-3
protein may obscure the NLS or NES of the
protein to which it binds. In this way, 14-3-3
proteins would affect the subcellular localization
of their target proteins by interfering with the
binding of transport receptors. 14-3-3 binding to
Forkhead family members may sterically inhibit
import receptor binding and, thereby, act to
prevent import.
The proposal has also been made that 14-
3-3 possesses a NES that is recognized by Crm1
and participates directly in the export of binding
partners through a Crm1 interaction (59). In our
hands, however, 14-3-3 does not bind Crm1
directly, nor is its association with AFX necessary
for the interaction of AFX with Crm1. Therefore,
in this case at least, 14-3-3 isoforms appear to
play no part in regulating AFX nuclear export.
What is the AFX NES? Leucine-rich
regions found in several Forkhead family
members conform to the consensus sequence for
Crm1-dependent NES (46). This region in AFX
corresponds to residues 300-308 (LELLD
GLNL). Deletion of residues 298-308 results in
a protein that is not properly relocalized from
the nucleus to the cytoplasm on stimulation with
insulin, but still binds Crm1 (unpublished data).
This region, therefore, is unlikely to represents
the Crm1-dependent NES, but might still
contribute to the nuclear export of AFX.
Distinct chromosomal translocations in
pediatric alveolar rhabdomyosarcoma and ALL
involve two human forkhead genes. Alveolar
rhabdomyosarcomas are associated with unique
chromosomal translocations that arise from
fusion of PAX3 or PAX7 to the FKHR gene (16).
The PAX3-FKHR fusion protein is a more potent
transcriptional activator than PAX3 alone (73)
and transforms primary cells (74). Several
chromosomal translocations in ALL occur at the
11q23 locus and all convey a poor prognosis that
is usually associated with a high rate of treatment
failure and relapse. These breakpoints affect the
MLL gene (also called HRX, ALL, Htrx1) that
is disrupted midway through the coding region
(75, 76). A well-documented translocation arises
from the fusion of MLL to the AFX gene on
chromosome X (15).
Importantly, the fusions of AFX and
FKHR to their breakpoint partners occur at
identical amino acid positions within the
Forkhead proteins. The resulting fusion proteins
contain the N-terminal DNA-binding region of
the fusion partner and the C-terminal
transactivation domain of the forkhead protein.
The MLL-AFX fusion protein expresses residues
148-501 of AFX (77).  This preserves the NLS
of AFX identified in this study (residues 180-
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221).  We have shown that deletion of residues
N-terminal to S193 causes a loss of
transcriptional regulation by insulin (18). In
addition, potential loss of S193 phosphorylation
in the context of the fusion protein would allow
constitutive import into the nucleus. Therefore,
both the deregulation of Forkhead activity and a
constitutive nuclear localization likely contribute
to the oncogenic properties of these fusion
proteins.
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In C. elegans, DAF-16 is inhibited by a
pathway consisting of proteins that are
orthologues of the insulin receptor, phosphatidyl-
inositol-3-OH kinase (PI(3)K) and protein kinase
B (PKB)/c-Akt (2, 3, 4). The same pathway exists
in vertebrates, where AFX, FKHR and FKHR-
L1 are directly phosphorylated and inhibited by
PKB (5, 6, 7, 8, 9). Additionally, AFX-mediated
transcription is negatively regulated through Ras/
Ral-signalling (5). As PI(3)K/PKB and Ras
signalling are both important in cell-cycle
progression through G1
 
phase (10, 11, 12, 13),
we hypothesized that the members of the AFX-
family of Forkhead transcription factors might
regulate aspects of G1 progression. Therefore,
we have examined the effect of ectopic
expression of these AFX-like proteins on cell
proliferation in mammalian cells.
Transfection of A14 cells (5) with AFX,
FKHR or FHKR-L1 resulted in efficient growth
suppression (figure 1a). When mutants of these
AFX-like proteins which lack PKB
phosphorylation sites (AFX.A3, FKHR.A3 or
FKHR-L1.A3) were introduced, they inhibited
colony formation even more efficiently, to levels
observed with the cyclin-dependent kinase (cdk)-
inhibitor p16ink4a (figure 1a). However, a mutant
of AFX lacking the DNA-binding domain
(AFX.∆DB) had no effect (figure 1a). Ectopic
AFX and AFX.A3 were expressed at similar
levels at 48 hr after transfection, but very little
ectopic AFX or AFX.A3 could be detected in
colonies that grew after 2 weeks of selection
(figure 1a). AFX is regulated by PKB and Ras
signalling, so we examined the consequences of
expression of AFX or AFX.A3 in the PTEN-
AFX-like Forkhead transcription factors mediate cell-cycle regulation by
Ras and PKB through p27kip1
René H. Medema*‡, Geert J.P.L. Kops†‡, Johannes L. Bos† and Boudewijn M.Th. Burgering†
*Jordan Laboratory G03-647, Department of Hematology and †Department of Physiological
Chemistry and Centre for Biomedical Genetics, University Medical Center Utrecht, The
Netherlands.
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The Forkhead transcription factors AFX, FKHR and FKHR-L1 are
orthologues of DAF-16, a Forkhead factor that regulates longevity in
Caenorhabditis elegans (1, 2, 3). Here we show that overexpression of these
transcription factors causes growth suppression in a variety of cell lines
including a Ras-transformed cell line and a cell line lacking the
tumoursuppressor PTEN. Expression of AFX blocks cell-cycle progression at
phase G1, independent of functional retinoblastoma protein (pRb) but
dependent on the cell-cycle inhibitor p27kip1. Indeed, AFX transcriptionally
activates p27kip1, resulting in increased protein levels. We conclude that AFX-
like proteins are involved in cell-cycle regulation and that inactivation of these
proteins is an important step in oncogenic transformation.
71
Chapter 5; AFX causes cell-cycle arrest via p27kip1
Co
nt
ro
l+i
ns
AF
X.
DB
Co
nt
ro
l In
cr
ea
se
 in
 %
 G
1 
ce
lls
0
-5
0
150
50
100
AF
X.
DB
R
el
. n
um
be
r o
f c
ol
on
ie
s 
(%
)
RR2
Co
nt
ro
l
AF
X
Co
nt
ro
l
AF
X
R
el
. n
um
be
r o
f c
ol
on
ie
s 
(%
)
A3 A3
U87MG
100
80
60
40
20
0
p2
7
kip
1
p2
7
kip
1R
el
. n
um
be
r o
f c
ol
on
ie
s 
(%
)
Co
nt
ro
l
AF
X
AF
X.
A3
FK
HR
FK
HR
.A
3
FK
HR
-L
1
FK
HR
-L
1.
A3 p1
6
AF
X.
∆D
B
100
80
60
40
20
0
HA-AFX
48 hrs 2 wks
A3 A A3 A
C
deficient glioblastoma cell line U87MG, which
contains high levels of PKB activity (14), and in
RasV12-transformed Rat-1 cell line, RR2 (15).
Expression of wild-type AFX caused a marked
inhibition of colony formation in these
transformed cell lines (figure 1b). Growth
inhibition was even more pronounced when using
AFX.A3 (figure  1b). We obtained similar data
with another RasV12-transformed Rat-1 cell line,
RR7 (15) (not shown).
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Figure 1. Expression of AFX causes arrest at the G1 phase of the cell-cycle.  Colony formation assays in A14 cells
(A), U87MG cells and RR2 (B). Cells were transfected with an expression plasmid for wild-type or mutant AFX, FKHR
or FKHR-L1 in combination with pBabe-puro. Puromycin-resistant colonies were scored after two weeks of selection.
Levels of ectopically expressed AFX (A) and AFX.A3 (A3) in total lysates at 48 h and 2 weeks after transfection were
detected by western blot (inset). C. Cell-cycle profiles of transfected A14, U2OS or Jurkat cells expressing the
indicated AFX/FKHR-L1 proteins or respective mutants. D. Absolute increase in percentage of A14 cells in the G0/
G1-phase upon expression of the indicated proteins. E. Increase in colony formation and a decrease in G1 content in
cells expressing the AFX.DB mutant. The data in D and E are the averages of three independent experiments. Where
indicated cells were treated with nocodazole (noco) or insulin (ins) during the last 16 h before collection.
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Introduction of AFX into A14 cells
resulted in accumulation of cells in the G0/G1-
phase of the cell-cycle (figure 1c), indicating that
these cells are arrested in G1. This change in cell-
cycle distribution was even more clear when cells
were treated with nocodazole after transfection
so that cycling cells would accumulate in the G2/
M phase, unless they had been arrested in G1
(figure 1c). Expression of AFX.∆DB had no
effect on the cell-cycle distribution (figure 1d),
indicating that transcriptional activity is required
for G1 arrest. Insulin treatment overcame the G1
arrest induced by AFX, but had very little effect
on mock-transfected cells in the presence of 10%
fetal calf serum (FCS) (figure 1d). However,
insulin did not overcome the AFX.A3-induced
cell-cycle arrest (figure 1d). This is consistent
with the finding that insulin efficiently inhibits
AFX-mediated transcription (5), but transcrip-
tional activation by AFX.A3 is only marginally
affected (data not shown). Fluorescence-
activated cell sorting (FACS) analysis of other
cell lines, in particular tumor-derived cell lines,
demonstrated that expression of AFX, AFX.A3,
FKHR-L1 or FKHR-L1.A3 in U87MG, RR2,
RR7 or U2OS osteosarcoma cells caused a clear
G1-arrest (figure 1c and data not shown).
Observation of the percentage of cells cells with
less than 2N DNA content indicated only minor
increases in the number of apoptotic cells. For
comparison, we studied Jurkat T cells, which
become apoptotic upon introduction of the
FKHR-L1.A3 mutant (6). However, increased
apoptosis was only seen with this particular
mutant, whereas all other AFX/FKHR-L1
expression plasmids tested caused a G1-arrest
(figure 1c). Thus, although apoptosis may be
affected, the G1-arrest seems to be a more general
response to all AFX-like proteins.
To investigate whether inhibition of
endogenous AFX-like activity would affect the
proliferative capacity of A14 cells, we expressed
a mutant of AFX encoding only the DNA binding
domain (AFX.DB). This mutant is unable to
transactivate (data not shown), but is likely to
compete with endogenous AFX-like proteins for
binding to DNA. Interestingly, expression of
AFX.DB resulted in a significant increase in
colony formation (greater than 40%) and a
decrease in the percentage of cells in G1, similar
to that observed upon addition of insulin (figure
1e). These data show that interference with
endogenous AFX-like activity results in a
proliferative advantage in these cells.
To investigate the mechanism underlying
the AFX-induced G1 arrest in more detail, we
transfected A14 cells with myc-tagged pRb in
combination with AFX or AFX.A3. Expression
of AFX or AFX.A3 caused an inhibition of pRb-
phosphorylation, indicating that AFX can arrest
cell-cycle progression prior to the G1 restriction
point (figure  2a). To analyze the expression and
activity of endogenous cell-cycle regulators, we
separated the transfected and untransfected A14
cells by magnetic-activated cell sorting (MACS).
Exogenous AFX and AFX.A3 were detected in
the transfected cells, but no protein was seen in
the untransfected cells, indicating that separation
was effective (figure 2b). We found that the
kinase activity of cyclin E and cdk2
immunoprecipitates were significantly inhibited
in cells expressing AFX or AFX.A3 (figure 2b),
although cyclin E and cdk2 protein levels were
not decreased (data not shown). Expression of
the cdk-inhibitor p21waf1/cip1 was unchanged upon
introduction of AFX-proteins (not shown). In
contrast, expression of AFX or AFX.A3 caused
an increase in the protein levels of the cdk-
inhibitor p27kip1 (figure 2b), suggesting that AFX-
induced upregulation of p27kip1 is responsible for
the observed inhibition of cyclin E/cdk2
complexes. These effects were not seen with the
AFX.∆DB mutant (figure 2b).
Next we examined the effect of PKB
activation or inactivation on the expression of
p27kip1 and phosphorylation of endogenous AFX
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Figure 2. AFX expression induces upregulation of p27kip1.
A. Myc-tagged pRb was transfected in combination with
the indicated AFX mutants. Exogenous pRb was
immunoprecipitated (IP) using anti-myc monoclonal
antibodies (9E10) and the phosphorylation state was
analysed on western blots (WB) using anti-pRb
(Pharmingen). The first lane represents untransfected
A14 cells. ppRb, hyperphosphorylated pRb. B.
Transfected and untransfected A14 cells were separated
by MACS, lysed and used for analysis of expression of
p27kip1, HA-tagged AFX, AFX.A3 and AFX.∆DB. Actin
expression is the loading control. Cyclin E- and cdk2-
associated kinase activity was analysed by in vitro kinase
reaction (22). C. A14 cells were treated with insulin and
U87MG cells were treated with LY294002 (LY). Treatment
was performed for 16 h, after which cells were lysed and
total lysates were probed for expression of PKB,
phosphorylated PKBpS473, phosphorylated AFXpS193,
phosphorylated FKHR-L1pT32, and expression of p27kip1,
and actin as additional loading control. D. A14 cells were
transfected with the indicated expression plasmids,
treated with nocodazole for the last 16 h after transfection
and analysed by flow cytometry. The data are the
averages of three independent experiments.
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and FKHR-L1. Insulin stimulation of A14 cells
resulted in activation of PKB, and a reduction in
p27kip1 expression (figure 2c). We were unable
to detect endogenous AFX in A14 cells, but saw
induction of FKHR-L1 phosphorylation in
response to insulin (figure 2c). Conversely,
inhibition of PKB in U87MG cells by addition
of the PI(3)K inhibitor LY294002 caused a
reduction in AFX- and FKHR-L1- phosphory-
lation and a concomitant increase in p27kip1
expression (figure 2c). Therefore, PKB-mediated
phospho-rylation of AFX-like Forkhead factors
is coupled with a decrease in p27kip1 levels in both
of these cell lines.
We next reasoned that if induction of
p27kip1 levels is responsible for the AFX-induced
G1 arrest, co-expression of cyclin/cdk complexes
should titrate out the induced p27kip1 and rescue
cells from the cell-cycle arrest. Indeed, combi-
nations of cyclin D/cdk4 or cyclin E/cdk2 could
fully override the AFX.A3-induced cell-cycle
arrest (figure 2d). In addition, we examined the
effect of co-expression of the SV40 large T
oncoprotein, which binds and inactivates pRb
and p53. Co-expression of  SV40 large T did not
rescue the AFX.A3-induced G1 arrest, although
it could override a p16ink4a-induced cell-cycle
arrest (figure 2d).
Cells devoid of functional pRb no longer
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AFX, induction of p27kip1,
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cdk2, inhibition of cyclin E-
associated kinase activity
and association of p27kip1
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infected immortalized mouse embryo fibroblasts
(MEFs) with a retrovirus encoding AFX. In wild-
type MEFs, this resulted in induction of p27kip1
expression (figure 3a), inhibition of cyclin E-as-
sociated kinase activity (figure 3a), strong inhi-
bition of BrdU incorporation (figure 3b) and in-
creased binding of p27kip1 in cyclin E-complexes
(figure 3a). When the same retrovirus was used
to infect immortalized pRb-deficient MEFs, a
similar inhibition of BrdU incorporation was seen
(figure 3b). More importantly, in immortalized
p27kip1-deficient MEFs, inhibition of BrdU in-
corporation (figure 3b) and cyclin E-associated
Areas 1, 2 and 3 represent G0/G1, S, and G2/M respectively. C.
Primary cultures of wild-type and p27kip1-deficient MEFs were
infected with the AFX-encoding retrovirus. Inhibiton of BrdU
incorporation (left) and cyclin E-associated kinase activity (right)
relative to cultures infected with the control retrovirus
(pBabe.puro) were determined at 48 h after infection. Each bar
is an independent experiment. D. Inhibition of cyclin E-associated
kinase activity by ectopic AFX or LY294002 in immortalized wild-
type or p27kip1-/- MEFs. Cells were infected with a control, p16ink4a,
or AFX-encoding retrovirus (left), or treated with LY294002 for
24 h (right), and cyclin E-associated kinase activity was
determined by in vitro kinase assays. Percentages below each
lane indicate the relative activity compared to the control samples.
E. A14 cells were transfected with a control plasmid, or a plasmid
encoding AFX.DB, and treated overnight with LY294002 or left
untreated. Transfected cells were isolated by MACS and cyclin
E-associated kinase activity was determined by in vitro kinase
assay (22). H1, histone H1.
require cyclin D-associated kinase activity, but
do need cyclin E-associated kinase activity to
initiate S phase (16). Thus, if p27kip1 mediates
the AFX-induced cell-cycle block, pRb-deficient
cells should arrest in response to AFX and p27kip1-
deficient cells should not. To examine this, we
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kinase activity (figure 3d) by AFX were greatly
reduced, although inhibition of BrdU incorpora-
tion by p16ink4a occured normally in these cells.
BrdU incorporation and cyclin E-associated ki-
nase activity were also differentially affected in
primary MEFs established from wild-type and
p27kip1 null mice (figure 3c), ruling out the pos-
sibility that genetic variation occurring during
immortalization gave rise to the observed differ-
ences. In addition, inhibition of endogenous
PI(3)K/PKB signalling by addition of LY294002
caused a very efficient inhibition of cyclin E-
associated kinase activity in wild-type MEFs.
This inhibitory activity was severely reduced in
the p27kip1-deficient MEFs, very similar to our
observations after ectopic expression of AFX
(figure 3d). Moreover, LY294002-mediated
inhibition of cyclin E/cdk2 activity requires
endogenous AFX-like activity, as expression of
the AFX.DB interfering mutant reduced
LY294002-induced inhibition of cyclin E/cdk2
complexes in A14 cells (figure 3e). Thus, our
data show that the inhibition of cyclin E/cdk2
complexes by AFX and the endogenous PI(3)K/
PKB signalling pathway both act mainly through
p27kip1. Some residual inhibition of cyclin E-
associated kinase activity still appears in response
to AFX in p27kip1-deficient MEFs, and therefore
other cell-cycle targets of AFX besides p27kip1
may exist. Nevertheless, these data clearly show
that p27kip1 is a major target of the PI(3)K/PKB/
AFX signalling pathway in regulation of cellular
proliferation.
To examine whether the observed increase
in p27kip1 protein levels by AFX is due to a
stabilization of the protein, we analyzed p27kip1
degradation in the absence or presence of AFX
by western blot, using cycloheximide-treated
cells (figure  4a) or a 35S-methionine pulse-chase
experiment (not shown). The kinetics of p27kip1
degradation were similar in both cases (t1/2~45
p27kip1
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Figure 4. AFX regulates p27kip1 transcription. A. Wild-
type MEFs were infected with either the control or the
AFX-expressing (AFX) retrovirus. Forty-eight hours post-
infection, cells were treated with cycloheximide and
p27kip1 levels were followed by western blotting of total
cellular lysates. B. Jurkat cells (left) and A14 cells (right)
were transiently transfected with the p27GL-1609
construct with or without the various AFX plasmids and
luciferase activity was measured. A14 cells were left
untreated or treated with insulin (+ ins) for 16 h. Luciferase
levels were corrected for LacZ expression. C. Total RNA
(20 µg) was isolated from AFX-, or control-infected MEFs,
blotted onto nitrocellulose and probed for the presence
of p27kip1 messenger. Levels were corrected for GAPDH.
D. Total RNA (20 µg) from A14 cells treated with insulin
for the indicated periods was probed for p27kip1
messenger levels. Levels are corrected for GAPDH. In
B-D, results represent the averages of three independent
experiments.
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min), although p27kip1 protein levels were el-
evated in AFX-expressing cells (figure 4a). To
study whether AFX enhances transcription of the
p27kip1 gene, we transiently transfected Jurkat and
A14 cells with a luciferase reporter construct
driven by the p27kip1 promoter, which contains
multiple putative AFX binding sites (5, 17),
together with the various AFX plasmids. AFX
and AFX.A3 increased luciferase activity up to
20-fold (figure 4b). Insulin treatment of A14 cells
expressing AFX inhibited luciferase activity by
50%, similar to the observed inhibition of insulin
on other AFX-regulated promoter constructs (5,
6, 7). These experiments show that AFX can
regulate p27kip1 promoter activity. Next, we
performed northern blots using RNA isolated
from wild-type MEFs infected with  the
pBabe.AFX or pBabe.puro retroviruses. Cells
expressing AFX displayed a moderate, but
consistent, increase in p27kip1 mRNA levels
(figure 4c). In addition, insulin treatment of A14
results in the phosphorylation and inactivation
of endogenous Forkheads (figure 1d), and a
consequent reduction in p27kip1 mRNA levels
within 2 h (fig 4d).
The data presented here demonstrate that
AFX is important in regulating cellular
proliferation. AFX integrates signals from
PI(3)K/PKB signalling as well as Ras/Ral
signalling to regulate transcription of p27kip1.
Indeed, p27kip1-/- cells are significantly less
inhibited by AFX activity than their p27kip1+/+
counterparts, showing that p27kip1 is a major
target of AFX-like Forkhead proteins. Our
finding that these Forkhead transcription factors
are predominantly involved in the regulation of
cell-cycle progression indicates that the
proclaimed role of PI(3)K/PKB signalling in
tumorigenesis may need refinement. The
disruption of the PI(3)K/PKB/Forkhead
transcription factor pathway in tumorigenesis
may override a cell-cycle block rather than
bestow protection from apoptosis. In this respect,
it is interesting to note that the ability to arrest in
G1 is coupled with the ability to undergo
apoptosis in certain cells (18, 19). This indicates
that a G1 arrest may precede apoptosis, similarly
to G1 arrest preceding cell differentiation.
Methods
Cloning, plasmids and cells. pBabe.AFX was created by li-
gating a Klenow-blunted PstI/KpnI fragment from pMT2HA-
AFX (5) into EcoRI-cut and Klenow-blunted dephosphorylated
pBabe.puro plasmid (20). pMT2HA-AFX.A3 was created by
mutating T28, S193 and S258 to alanine using the primers as
described (5). pMT2HA-AFX.∆DB was created by deleting
basepairs +313 to +537 by PCR-based mutagenesis using the
primer ∆DB (5’-GAAATCAGTCATATGCAGAAGGAGGC
AAGAGCGGCAAAGC-3’). pMT2HA-DB was created by
ligating a KpnI/XbaI fragment from pRP261-AFX.DB (5) into
KpnI/XbaI-cut pMT2HA. Myc-tagged pRb and pCMV.p27kip1
were a gift from Dr. R. Bernards. pBabe.p16ink4a, pCMV.CD20,
pCMV.cyclin D1, pCMV.cyclin E, pCMV.cdk4, pCMV.cdk2,
pCMV.largeT and pCMV.p16ink4a have all been described (20).
pECE.FKHR-L1 and pECE.FKHR-L1.A3 were a gift from M.
Greenberg (6). pAlter-MAX-FKHR and pAlter-MAX-
FKHR.A3 were a gift from T. Unterman (7). p27GL-1609 was
a gift from I. Touw (17). Immortalized wild-type, pRb-deficient
and p27kip1-deficient MEFs were a gift from D. Peeper (13).
Early passage primary wild-type and p27kip1-deficient MEFs
were a gift from B. Scheyen.
Cell culture. A14 (NIH3T3 overexpressing human insulin
receptor), U87MG, RR2, U20S, Phoenix and MEF cells were
grown in DMEM with standard supplements. Jurkat cells were
grown on RPMI-1640 medium. Insulin, LY294002, nocodazole
or puromycin were added at a final concentration of 1 µg ml-1,
10 (A14) or 20 µM (U87MG and MEFs), 250 ng ml-1 or 5 µg
ml-1, respectively.
Antibodies. The following antibodies were used: 9E10
(Pharmingen), anti-p27kip1 (Transduction Laboratories), 12CA5
for HA-tagged proteins, anti-actin (Santa Cruz), anti-PKB (21),
anti-phosphoS473 PKB (New England Biolabs), anti-
phosphoT32 FKHR-L1 (gift from A. Brunet) and an anti-
phosphoS193 AFX (a donation from New England Biolabs).
Anti-AFX was generated by immunizing rabbits with a C-
terminal peptide from AFX conjugated to KLH (Isogen).
Colony formation. Cells were transfected with the expression
plasmids in combination with pBabe-puro and pCMV.CD20.
Transfection efficiency of individual plates was determined at
48 hr after transfection by FACS analysis of CD20-positivity
(20). Equal numbers of transfected cells were plated and cells
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were then grown in the presence of 5 µg ml-1 puromycin for
two weeks, after which colonies were scored.
Retroviral infection of MEFs. Recombinant retroviruses were
obtained by transfection of the relevant retroviral construct
into Phoenix cells. Conditioned medium from these cells was
collected 36 hr after transfection, filtered and diluted 1:1 with
fresh medium and 6 µg ml-1 polybreen was added. This mixture
was used to infect exponentially growing MEFs by two
consecutive rounds of infection. We routinely obtained 80-90%
infection efficiency, as determined by puromycin selection.
Cell-cycle distribution. To analyse cell-cycle redistribution
in response to ectopic expression of AFX-like proteins, cells
were transfected with the appropriate expression plasmids in
combination with CMV.CD20. Thirty-six hours after
transfection DNA profiles of CD20-positive cells were obtained
by flow cytometry (20) and analysed using ModFit software
(Becton Dickinson). Retrovirally infected MEFs were pulsed
with 1 µM BrdU for 30 min at 48 h after infection and analysed
by bivariate flow cytometry as described (22).
Magnetic activated cell sorting (MACS). Cells transfected
with pCMV.CD20 and the indicated expression plasmids were
stained with anti-CD20 monoclonal antibody (DAKO)
followed by staining with goat-anti-mouse microbeads
(Miltenyi Biotec). Transfected (CD20-positive) and non-
transfected (CD20-negative) cells were then separated on
miniMACS separation units (Miltenyi Biotec) according to
the supplier’s protocol. Transfected (elution) and non-
transfected (flow-through) fractions were obtained from each
transfection and cells were lysed in the appropriate buffers.
Positively selected cells were >85% CD20-positive, and <10%
CD20-positive cells remained in the negatively selected
fraction.
Kinase assays. MACS-separated or retrovirally infected cells
were used for determination of cdk2- or cyclin E-associated
kinase activity as described (22).
Northern blotting. Total RNA was extracted from wild-type
MEFs infected with the indicated retroviruses using standard
guanidine isothiocyanate extraction method. We
electrophoresed 20 µg of RNA and blotted it onto nitrocellulose
and probed for p27kip1 and GAPDH messenger using
radiolabelled cDNA probes.
p27kip1 protein stability. MEFs infected with the indicated
retroviruses were treated 48 h post-infection with 10 µg ml-1
cycloheximide for 30 minutes. Cells were collected at 0, 30,
65, 125, 240 and 460 min after cycloheximide treatment, and
p27kip1 and actin levels were determined by western blotting
of total cell lysates.
Luciferase assay. Cells were transfected with 1 µg (A14) or 5
µg (Jurkat) p27GL-1609 plasmid along with the various AFX
plasmids and 1 or 5 µg pCMV-lacZ. Luciferase and lacZ
measurements were performed as described (5).
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Introduction
Mammalian cells require an extracellular
proliferative signal directly after mitosis in order
to keep on growing and dividing. When cells are
faced with a lack of such a signal, depending on
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The proto-oncogenes Ras and protein kinase B (PKB or c-akt) can
promote cellular proliferation by inhibiting the Forkhead transcription factors
AFX, FKHR and FKHR-L1. Inducing Forkhead activity causes an arrest in
the G0/G1 phase of the cell-cycle, in part via an increase in p27kip1 gene
transcription. We set out to identify novel targets of the Forkheads that can
regulate G1/S progression. Here, we show that conditional activation of FKHR-
L1 causes upregulation of the p130 pocket protein, a pRb-like protein
associated with quiescence and a previously suggested cdk2 inhibitor. However,
the FKHR-L1-induced increase in p130 levels does not contribute to the
Forkhead-induced, p27kip1-independent cdk2 inhibition. Rather, it reflects a
state of cellular quiescence as indicated by the following observations: i) the
phosphorylation status of p130 shifts to a G0-specific form; ii) an increase in
p130/E2F4 complexes was observed after Forkhead activation, and iii) the
Forkhead-induced G0/G1 arrest is sustained in time without a marked increase
in cell death, and this sustained arrest is reversible. In addition, we show that
protein levels and hyperphosphorylation of p130 upon cell-cycle re-entry are
controlled by the PI(3)K/PKB pathway. Together, these results indicate that
Forkhead transcription factors can induce a state of cellular quiescence, even
in human tumor cells, and they are the first demonstration of a complete
PI(3)K-activated pathway controlling exit and entry from the cell-cycle. We
propose that Forkhead inactivation by Ras and PKB signalling in quiescent
cells is a crucial step in cell-cycle re-entry and contributes to the processes of
transformation and regeneration.
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the cell-type, the cell will either die or growth-
arrest in post-mitotic G1 phase. Two of the
intracellular signalling pathways that transduce
proliferative signals are the Ras and PI(3)K
pathways. Ras and PI(3)K can regulate various
features of cell proliferation, such as cytoskeletal
rearrangements, gene transcription, DNA
synthesis and survival (reviewed in (1, 2)). The
proto-oncogene PKB is a major target of PI(3)K
signalling in the control of cell proliferation
(reviewed in (3)). PKB is involved both in anti-
apoptotic signalling as well as cell-cycle control.
Recently, PKB was found to directly
phosphorylate and inactivate a subfamily of
Forkhead transcription factors, consisting of
AFX, FKHR and FKHR-L1 (4, 5, 6). In addition,
Ras, via the RalGEF/Ral pathway, cooperates
with PKB in inhibiting AFX activity (4).
Importantly, these two pathways are often found
deregulated in tumor cells. Ras itself is mutated
to an active form in 15% of all cancers and the
negative regulator of PI(3)K signalling, the tumor
suppressor PTEN, has been shown to be mutated
or deleted in a wide variety of tumors (reviewed
in (7, 8)).
Inactivation of the Forkhead transcription
factors may play a major role in the control of
cellular proliferation by the PI(3)K/PKB and Ras/
Ral pathways. We and others have recently
shown that all three Forkheads inhibit cell-cycle
progression at the G1/S transition, at least in part
by controlling transcription of the gene for the
p27kip1 cdk inhibitor (9, 10, 11). Nevertheless, a
p27kip1-independent mechanism for Forkhead-
induced cell-cycle arrest is likely to exist, since
AFX was still able to partly reduce activity of
the cyclin E/cdk2 complex in the absence of
p27kip1 (9).
The continuation of cell proliferation at
various stages of the cell-cycle involves the
inactivation of at least one of three members of
the retinoblastoma family of nuclear pocket
proteins. The general mechanism by which this
family exert its effects is by binding different
members of the E2F family of transcription
factors, thereby actively repressing genes
required for cell-cycle progression (reviewed in
(12)). The pRb/p105 protein is an essential
component of the G1/S checkpoint. pRb is
present at relatively constant levels throughout
the cell-cycle but is hyperphosphorylated by
cyclin/cdk complexes and released from E2F-1
at the G1/S transition allowing continuation
through the cell-cycle (reviewed in (13)).
Conversely, the p107 and pRb2/p130 proteins are
regulated at the protein level as well as by
phosphorylation. p107 protein levels are low
during quiescence (commonly reffered to as G0)
and early G1 but high during the other stages of
the cell cycle. p130 protein levels, on the other
hand, are low in cycling cells, but increase once
cells exit the cell cycle (reviewed in (12)). The
rise in p130 protein levels at the G0 stage of the
cell cycle is accompanied by a change in
phosphorylation of p130 from predominantly
hyperphosphorylated form 3 in cycling cells to
the hypophosphorylated forms 1 and 2 in G0 cells
(14, 15). The high amount of hypophos-
phorylated p130 in G0 cells binds to the E2F-4
transcription factor which is thought to repress
genes required for re-entry into early G1 phase
thereby maintaining the quiescent state (16).
In addition to this well documented
function for p130 is the recent observation that
p130 can participate in the direct inhibition of
cyclin E/cdk2 complexes (17). In that report it
was shown that serum-starved MEFs from p27kip1
knockout mice still display efficient inhibition
of cyclin E/cdk2 activity, which could be
accounted for by the presence of p130 in the
cyclin E/cdk2 complexes. Since p130 in addition
has a cyclin-interaction motif (18), it might
therefore in certain cases function as a ‘classical’
cdk-inhibitor. Nevertheless, it remains to be
established that p130 can function as a cdk-
overexpression of exogenous wild-type p130
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does not induce a growth arrest (19).
In an attempt to identify cell-cycle
regulators besides p27kip1 that are regulated by
Forkhead transcription factors, we observed an
upregulation of p130 protein levels by
conditional Forkhead activation. Although p130
has been reported to be able to function as a cdk2-
inhibitor, we find that in our cells the increase in
p130 upon Forkhead activation does not
contribute to p27kip1-independent cdk2 inhibition.
Rather, we show that the increase in p130 protein
represents an entry into quiescence of a number
of cell types, including human tumor cells, as
supported by several additional G0 hallmarks.
Furthermore, PKB signalling can drive quiescent
cells back into G1 as shown by a decrease in
p130 protein levels and a decrease in p130/E2F-
4 complexes. These data suggest that activation
of PKB and/or Ras by growth factors or by
oncogenic mutations in quiescent cells can lead
to a cell-cycle re-entry through the inhibition of
Forkhead transcription factors.
Methods
Plasmids. pBabe-FKHR-L1.A3 was created by ligating a
Klenow-blunted HindIII/BamHI fragment of pcDNA3-HA-
FKHR-L1.A3 into Klenow-blunted BamHI-cut pBabe-puro.
pSG5-mycBimL and pSG5-mycBimS have been described
(25). pcDNA3-HA-FKHR-L1.A3-ER has been described (20).
pBabe-HA-AFX has been described (9). pCMV-HA-p130 was
a gift of D. Cobrinik.
Cell culture. The DL23 cell-line was created as follows:
linearized pcDNA3-HA-FKHR-L1.A3-ER (20) was
transfected into DLD-1 human colon carcinoma cells by
electroporation. Transfectants were selected for two weeks on
300 µg/ml geneticin. Subsequently, clones were isolated and
analyzed for expression of the fusion protein. The DL23
subclone was chosen for further study. Primary MEFs derived
from wild-type, p27kip1 -/-, p130 -/- and p27kip1/p130 -/- mice
were a gift of B. Scheyen. MEFs, A14, U87MG and 3T3-PKB-
ER (29) cells were grown on DMEM with standard
supplements. MCF-7 cells were grown on DF12 medium.
DL23 and DLD-1 were grown on RPMI-1640 supplemented
similarly. 4OHT (Sigma) was diluted in RPMI-1640 and added
to the cells at a final concentration of 500 nM (DL23 and DLD-
1) or 1 µM (3T3-PKB-ER). LY294002 was dissolved in DMSO
and used at a final concentration of 10 µM.
RNA preparation and northern blotting. Total RNA was
isolated from DL23 cells using the RNAZol procedure (TEL-
TEST, INC). polyA+-RNA was purified from 1 mg total RNA
using the polyA-Tract method (Promega). Northern blotting
of 2 µg mRNA was performed as described (9).
Electrophoretic mobility shift assay (EMSA). Bandshift
analyses of DLD-1, DL23 and 3T3-PKB-ER cells was done
as described (26).
Antibodies, immunoprecipitations and immunoblotting.
Anti-p130 (C-20), anti-E2F4 (C-20), anti-ERα (MC-20), anti-
cdk4 (C22), anti-cdk2 (M2), anti-p16 (C-20), anti-p21 (N-20),
anti-cyclin D1 (H11), anti-cyclin E (C-19) and anti-actin (I-
19) were from Sant-Cruz. Anti-pRb was from Pharmingen.
Anti-p27kip1 was from Transduction Laboratories. Anti-Bim
was from Affinity Bioreagents. Anti-phosphoT32-FKHR-L1
was a gift of A. Brunet (6). Anti-TOK1 was a gift of Dr. Ariga
(22). For immunoprecipitations, DL23 cells were lysed in lysis-
buffer (50 mM Tris, pH 7.5, 1% Triton-X-100, 100 mM NaCl
and 5 mM EDTA supplemented with NaF, aprotinin, leupeptin,
benzamidin and NaV04) and the cleared supernatant was
incubated in the cold with 10% protein A-sepharose and 3 µl
anti-cdk2 for 3 hours. Beads were washed three times and
resuspended in 1X Laemmli sample buffer. For
immunoblotting of total lysates, cells were lysed in 1X
Laemmli sample buffer, electrophoresed and blotted onto
nitrocellulose according to standard protocol. Immunoblotting
was performed by blocking the membranes in blotto (2%
protifar, 0.5% BSA in PBS-Tween (PBS plus 0.1% Tween-
20)) for 1 hour at room-temperature. Primary and secondary
antibody incubations were in PBS-Tween overnight and for 2
hours at 4ºC, respectively, and the membrane was washed four
times after each incubation. Proteins were visualized by
standard enhanced chemiluminescence and autoradiography.
35S-methionine pulse labeling. DLD-1 and DL23 cells were
grown to sub-confluency, labeled with 100 µM 35S-Methionine
for 2 hours and lysed in 50 mM Tris pH 7.5/1%TX-100.
Samples were corrected for amount of cells, and 35S-Methionine
incorporation was measured by scintillation counter.
BrdU incorporation, FACS analysis and cyclin E-associated
kinase assay. BrdU incorporation, FACS analysis and cyclin
E/cdk2 kinase assays were performed as described (9).
Retroviral Infections. Retroviral infections using pBabePuro,
pBabe-HA-AFX and pBabePuro-HA-FKHR-L1.A3 were
performed as described (9).
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Results
Forkhead-activation causes upregulation of
the p130 pocket protein
To examine the effect of specific Forkhead
activation on cellular proliferation, we created
the DL23 cell-line, a DLD-1 human colon
carcinoma subclone that stably expresses a fusion
of conditionally active HA-FKHR-L1.A3 with
a modified form of the estrogen receptor
hormone-binding domain (HA-FKHR-L1.A3-
ER) (20). This fusion is inactive untill the cells
are presented with the ligand for the modified
ER, 4-hydroxy-tamoxifen (4OHT) (21). Specific
activation of the Forkhead transcription factor
by 4OHT in the DL23 cell-line resulted in
upregulation of p27kip1 protein, hypophos-
phorylation of pRb, inhibition of cdk2 activity
and subsequent cell-cycle arrest (figure 1),
consistent with data obtained in NIH3T3 cells
(9). These cell-cycle inhibitory events are
specific for Forkhead activity, since the DLD-1
cell-line did not display such effects upon 4OHT
addition (figure 1 and not shown). The DL23 cell-
line enabled us to investigate what cell cycle
parameters besides p27kip1 might be under the
control of the PI(3)K/PKB/Forkhead pathway
specifically. We therefore analyzed the
expression of various proteins involved in cell-
cycle regulation in DL23 cells treated with
4OHT. We did not observe a Forkhead-induced
change in protein levels of cdk2, cdk4, cyclin
D1, cyclin E, p16ink4a, p21waf1/cip1 and TOK-1
(figure 2a, (9, 22)). Interestingly however, we
did observe an effect on the protein amount of
the p130 pocket protein. p130 protein was
drastically upregulated within 16 hours of
Forkhead activation, with similar kinetics as
p27kip1 upregulation (figure 2b). The effect of
FKHR-L1 on p130 expression is not restricted
to FKHR-L1, since infection of primary MEFs
with a HA-AFX-expressing retrovirus also
increases p130 protein levels (figure 2c).
Moreover, p130 upregulation was independent
of Forkhead-mediated regulation of p27kip1, since
a similar infection of HA-AFX in MEFs from
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WB: ER
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Figure 1. Cell-cycle arrest by a conditionally active FKHR-L1. A.
DL23 and DLD-1 cells were left untreated (0) or treated with 500
nM 4OHT for 8, 12, 16 and 24 hours. Total cellular lysates were
electrophoresed and blotted for presence of p27
kip1
, pRb, HA-FKHR-
L1.A3-ER or actin. Cell lysates were analyzed for cdk2 kinase
activity by cdk2 immunoprecipitation and in vitro kinase reaction
using histone H1 as a substrate (58). The cdk2 kinase reactions
were blotted, autoradiographed and probed for p27
kip1
 presence.
WB: western blot. B. BrdU incorporation of DL23 and DLD-1 cells
left untreated (con) or treated with 500 nM 4OHT for 16 hours.
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Cell-cycle control by protein kinase B
84
cycD1
cycE
cdk4
cdk2
p21waf1/cip1
0 8 12 24 hrs. 4OHT
DL23
p16ink4a
TOK1αβ
16
p27kip1 knockout mice still caused an increase of
p130 protein (figure 2c). Northern blotting
revealed that after Forkhead activation p130
mRNA levels are also increased thus indicating
that p130 protein levels are not solely regulated
by means of protein stability (figure 2d, (23)).
However, in transient reporter assays using a
small (300bp) fragment of the human p130
promoter (24) we could not demonstrate
regulation of p130 transcription by Forkheads
(not shown). This could mean either that a
Forkhead responsive element is located outside
the promoter fragment that we have analyzed,
that regulation is not at the level of transcription
initiation, or that the regulation is indirect.
Forkhead-mediated increase in p130 protein
levels does not contribute to inhibition of
cyclin E-associated kinase activity
Forkhead-induced cell-cycle arrest is
mediated by p27kip1 but other cdk2-inhibitors
might be involved, since AFX is still able to
inhibit cylin E-associated kinase activity to some
extent in p27kip1 -/- cells (9). Considering that
p130 was recently reported to inhibit cdk2 kinase
activity in the absence of p27kip1 by direct binding
to the cyclin E/cdk2 complex (17), we
investigated whether p130 upregulation by
12 16 2480 4 hrs 4OHT
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p130
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IP:12CA5
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Figure 2. FKHR-L1 upregulates p130 protein levels. A. DL23 lysates
prepared as mentioned in figure 1a were blotted for the presence of cdk2,
cdk4, cyclin D1, cyclin E, p21
waf1/cip1
, p16
ink4a
, and TOK-1. B. Total cellular
lysates from DLD-1 and DL23 cells treated without (0) or with 500 nM
4OHT for 4, 8, 12, 16 or 24 hours were analyzed by western blotting for
presence of the p130 retinoblastoma-like protein. Anti-HA
immunoprecipitations of A14 cell transiently transfected with empty vector
(con) or pCMV-HA-p130 served as controls. C. MEFs from wildtype (wt)
or p27
kip1
 knockout (p27
kip1
 -/-) mice were infected with a control retrovirus
or a HA-AFX-containing retrovirus. Total cellular lysates were subsequently
analyzed for p130, p27
kip1
 and HA-AFX expression levels. D. 2 µg polyA+-
RNA from DL23 cells left untreated (0) or treated with 500 nM 4OHT for 8,
16 or 24 hours was electrophoresed and blotted onto a nylon membrane.
The Northern blot was hybridized with radiolabelled probes from p130 or
GAPDH cDNA.
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Forkheads could contribute to the Forkhead-
induced cyclin E/cdk2 inhibition and cell-cycle
arrest. We infected a panel of MEFs with a
FKHR-L1.A3-encoding retrovirus and analyzed
cell proliferation and cyclin E-associated kinase
activity. FKHR-L1.A3 induced a strong
inhibition of BrdU-incorporation and cyclin E/
cdk2 activity in wild-type MEFs (figure 3a and
3b, (9)). These effects were greatly reduced but
not eliminated in p27kip1 -/- cells (figure 3a and
3b, (9)). However, when compared to p27kip1 -/-
MEFs, Forkhead expression in p130-/- p27kip1-/-
cells showed no additional attenuation of cell
proliferation arrest or decrease in cyclin E/cdk2
activity (figure 3a and 3b). Similar effects were
seen in similar experiments using AFX instead
of FKHR-L1.A3 (not shown). Finally, no
increase of p130 protein in cyclin E/cdk2
complexes was observed in 4OHT-treated DL23
cells (figure 3c), as was observed for p27kip1
(figure 1a), and as has been observed in
serumstarved p27kip1-deficients MEFs (17).
These data therefore suggest that p130 does not
contribute to p27kip1-independent inhibition of
cyclin E/cdk2 complexes upon Forkhead
activation.
Forkhead transcription factors induce cell-
cycle exit
Since the increase in p130 protein levels
caused by active Forkheads does not seem to
A
B
C
Figure 3. Forkhead-induced upregulation of p130 does
not contribute to G1 arrest. Primary wild-type MEFs and
MEFs from p27
kip1
, p130, or p27
kip1
/p130 knockout mice
were infected with a control or FKHR-L1.A3-encoding
retrovirus. 24 hours post-infection, proliferation was
measured by BrdU-incorporation (A) and cyclin E-
associated kinase activity (B). Relative inhibition of
proliferation by FKHR-L1.A3 compared to control, as
measured by these two assays, is depicted. Data
represent average of at least three independent
experiments. C. DL23 cells, treated with or without 4OHT
for 24 or 48 hours, were lysed and cdk2 was
immunoprecipitated. The cdk2 immunoprecipitates were
subsequently analyzed for the presence of p130 by
western blotting. WCL; whole cell lysate. IP-Ab; immuno-
precipitating antibody.
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contribute to cdk2 inhibition, we questioned
whether it might be indicative of a Forkhead-
induced state of cellular quiescence. Several
markers for the G0 phase of the cell-cycle have
been described. First, p130 protein is upregulated
(16), as observed after Forkhead activation
(figure 2a). Second, p130 phosphorylation status
changes from hyperphosphorylated form 3 to
phosphorylated forms 1 and 2 (14, 15). Third,
p130 associates with E2F-4, resulting in active
repression of genes required for cell-cycle re-
entry (16).
To more closely study the possible role of
the Forkheads in the regulation of cell-cycle exit
and entry, we first chose to determine the effect
of prolonged Forkhead activity on cellular
proliferation. To this end, we added 4OHT to the
DL23 cells for a period up to 9 days, and
measured sub-G1 DNA content and BrdU-
incorporation to determine apoptosis and
proliferative status, respectively. As seen in figure
4a, activation of FKHR-L1.A3 by 4OHT resulted
in rapid, drastic and continued inhibition of
BrdU- incorporation, but no great increase in the
relative amount of cells in apoptosis was
observed, not even after nine days. In agreement
with this, no increase in protein levels of the
Forkhead-regulated pro-apoptotic gene product
Bim was observed (figure 4b), whereas the same
approach (FKHR-L1.A3-ER expression) does
result in Bim expression and apoptosis in the
haematopoietic Ba/F3 mouse pre-B cell-line (25).
Furthermore, protein synthesis was slowed down
in cells treated with 4OHT for 48 hours, as
measured by 35S-methionine pulse-labelling
(figure 4c). These observations suggested to us
that the lack of apoptosis upon Forkhead
activation correlates with an inability of these
cells to upregulate pro-apoptotic genes such as
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Figure 4. Long-term activation of FKHR-L1 causes
continued arrest rather than apoptosis. A. DLD-1 and
DL23 cells were treated with 500 nM 4OHT for 9 days.
Samples were taken at various timepoints to measure
proliferation by BrdU-incorporation (solid lines) and cell
death by FACS analysis of sub-G1 population (dashed
lines). B. DL23 cells were left untreated (0) or treated
with 500 nM 4OHT for 8, 12, 16 and 24 hours. Total
cellular lysates were electrophoresed and blotted for
presence of Bim. As a control, lysates from COS7 cells
transiently transfected with two Bim isoforms, BimS and
BimL, were analyzed similarly. WB: western blot. C. DLD-
1 and DL23 cells were left untreated (-) or treated with
500 nM 4OHT for 48 hours (+) and labelled with 
35
S-
Methionine to measure protein synthesis.
A
B
C
BimS
BimL
0 8 12 16 24 hrs. 4OHT
DL23
CO
S7
 + 
Bim
S
CO
S7
 + 
Bim
L
WB: αBim
Chapter 6; Forkhead transcription factors cause cell-cycle exit
87
Bim, and in addition that the cells are in a
constitutive arrest or had entered a quiescent or
senescent state.
To investigate the phosphorylation status
of the p130 protein, we analyzed the 4OHT-
treated DL23 cells for the different
phosphorylated forms of p130. Normal cycling
DL23 cells show most p130 protein
hyperphosphorylated to form 3, as described for
other cycling cells (figure 5a, (14, 15)). 24 hours
of 4OHT treatment, however, resulted in an
increase in the relative amount of p130 protein
phosphorylated to forms 1 and 2 (figure 5a).
Next, we examined the functional interaction
between p130 and E2F-4. Band-supershift
analysis using an oligonucleotide containing a
consensus E2F family binding sequence and
antibodies against the various E2F and pocket
proteins (26) showed that the interaction of the
p130/E2F-4 complex with E2F binding
sequences was increased in cells containing the
activated Forkhead, whereas p107-containing
complexes were lost (figure 5b). Furthermore,
using an antibody against cyclin A, we observed
a decrease in p107/cyclin A/E2F-4 complexes
previously described to exist in S-phase (27).
Taken together, these data suggest that activation
of Forkhead transcription factors induces cells
to exit the cell cycle and enter G0. Moreover,
the data imply that the effect of the Forkheads
on proliferation is sufficiently strong to cause
human tumor cells to enter quiescence.
The Forkhead-induced cell-cycle exit is
reversible and mediated by the PI(3)K/PKB
pathway
Forkhead transcription factors were
previously shown to be involved in a PI(3)K-
induced senescent-like phenotype in primary
MEFs through the regulation of p27kip1 (28). In
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Figure 5. Sustained arrest by FKHR-L1 represents exit
from the cell-cycle. A. Total cellular lysates from  DLD-1
and DL23 cells left untreated (0) or treated with 500 nM
4OHT for 24 hours were electrophoresed on a 6%
polyacrylamide gel and immunoblotted for the presence
of p130. The three phosphorylated forms of the p130
protein are indicated as 1, 2 and 3. WB: western blot. B.
Total cellular lysates form DL23 cells left untreated (left)
or treated with 500 nM for
48 hours (right) were
analyzed for the presence
of E2F/DP-1/pocket
protein complexes.
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these cells, the induced arrest was accompanied
by p130 upregulation. We therefore wanted to
know whether the FKHR-L1-induced cell-cycle
exit represents quiescence or senescence. To
distinguish between these two possibilities, we
determined whether the Forkhead-induced cell-
cycle exit is reversible. To this end, we treated
DL23 cells up to 5 days with 4OHT after which
the cells were grown for three days in medium
without 4OHT. As seen in figure 6a, BrdU-
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Figure 6. Forkhead-induced G0 is reversible and
mediated by the PI(3)K/PKB pathway. A. Cells were
treated as in figure 4a. After 5 days of 4OHT treatment
(day 6), 4OHT was removed, and then added back at
day 9. Samples were taken at days 0, 1, 2, 3, 4, 6, 9 and
11, and BrdU-incorporation was measured. B. U87MG
cells were treated with 10 µM LY294002 (LY) for 0, 10 or
24 hours. Total cellular lysates were immunoblotted for
the presence of p130 protein and T32-phosphorylated
FKHR-L1. C. MCF-7 cells were serumstarved for 48 or
72 hours, subsequently treated with insulin for 24 or 48
hrs, with or without a 30 minute pre-incubation with
LY294002. p130 protein was subsequently analyzed by
western blotting. pp130; hyperphosphorylated p130. D.
3T3-PKB-ER (PKB-ER) and 3T3-PKB-ERmutant (PKB-
ER
m
) cells were serumstarved for 48 hours, then left
untreated (-) or treated with 1 µM 4OHT for 14 hours.
Total cellular lysates were immunoblotted for the
presence of p130 protein. D. 3T3-PKB-ER (PKB-ER) and
3T3-PKB-ERmutant (PKB-ER
m
) cells were treated as in
C and analyzed for the presence of p130/E2F-4
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incorporation after 5 days of 4OHT treatment was
diminished from 50 to 9 percent, but was almost
completely reverted upon withdrawal of 4OHT
for a subsequent 3 days. All cells had re-entered
the cell-cycle, since more than 95% of the
population stained BrdU-positive when given
BrdU for 40 hours (not shown). The cells that
re-entered the cell-cycle upon removal of 4OHT
were efficiently arrested again upon re-addition
of 4OHT, reflecting true reversibility. (figure 6a).
This latter result demonstrates that we did not
select a non-4OHT-responsive subpopulation
during the initial prolonged arrest. Since one
critical characteristic of senesence is
irreversibility, this result demonstrates that the
Forkhead-mediated cell-cycle exit indeed
represents the quiescent state.
To examine whether the endogenous
PI(3)K/PKB/Forkhead pathway is involved in the
regulation of cell-cycle exit and entry, we
investigated whether inhibition of PI(3)K could
mimic the activation of Forkheads with respect
to increased p130 protein levels. Indeed,
treatment of the PTEN-negative glioblastoma
cell-line U87MG with the PI(3)K-inhibitor
LY294002 for 24 hours resulted in Forkhead
dephosphorylation and a concomitant increase
in p130 protein levels (figure 6b). Similarly,
serum deprivation of MCF-7 cells resulted in an
increase in p130 protein, which could be reverted
by the re-addition of serum. However, pre-
incubation with LY294002 completely blocked
this, showing PI(3)K-dependence of p130
regulation in these cells (figure 6c). Next, to show
that quiescence can be reverted through the
PI(3)K/PKB signalling pathway, we analysed
NIH3T3 cells stably expressing a myrPKB-ER
fusion. In these cells PKB can be activated by
adding 1 µM 4OHT (29). Previously we have
shown that serum deprivation of primary
fibroblasts results in an increase in p130 levels
(28). Serum deprived 3T3-PKB-ER cells
displayed relatively high levels of p130 protein
(figure 6d). Importantly, specific activation of
PKB by 4OHT treatment resulted in decreased
p130 expression, whereas 4OHT had no effect
on NIH3T3 cells containing a mutant fusion
protein (figure 6d). In addition, p130/E2F-4
complexes accumulated as a result of serum-
starvation (data not shown and (30)) and
disappeared upon PKB activation (figure 6e).
This strongly suggests that the PI(3)K/PKB/
Forkhead pathway is involved in the regulation
of cell-cycle exit and entry.
Discussion
In this study we show that signalling-
independent activation of the Forkhead
transcription factor FKHR-L1, which is normally
controlled by the PI(3)K/PKB signalling pathway
(6), results in an increase in mRNA and protein
expression of the retinoblastoma-like protein
p130. Increase in p130 appears not to result in
inhibition of cyclin E-dependent cdk2 activity
but rather reflects an exit from the cell cycle. This
is indicated not only by the upregulation of p130
protein itself, but also by the change in p130
phosphorylation pattern and the increase in E2F4/
p130 complex formation. Induction of cellular
quiescence (G0) by growth factor deprivation
also induces p130 upregulation and importantly
ligand-independent activation of PKB can revert
this. Although the regulation of the amount of
p130 protein is generally considered to be post-
translational, we observe an increase in p130
mRNA upon Forkhead activation. Interestingly,
differentiating myoblasts have elevated p130
mRNA levels (31) and serum-stimulation of
quiescent REF52 cells results in a decrease in
p130 transcript (23), indicating that
transcriptional regulation of p130 may indeed
contribute to increased p130 protein levels.
Forkheads may be indirect, since we have not
been able to show direct control of p130 gene
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transcription by FKHR-L1.
Previously, we and others have shown that
PKB activation results in an inhibition of
Forkhead activity (4, 5, 6). Furthermore, we have
provided evidence that through this pathway the
levels of the cdk-inhibitor p27kip1 can be regulated
(9, 20). Together with the results presented here
this suggests an elegant model in which the
PI(3)K/PKB signalling pathway regulates cell-
cycle arrest/exit and entry through transcriptional
regulation of p27kip1 and p130 (figure 7).
Consistent with this, disruption of p27kip1
expression or specific activation of PI(3)K can
drive quiescent cells into G1/S (32, 33, 34, 35,
36). Nevertheless, it is at present unclear whether
the regulation of p27kip1 and p130 by Forkheads
is sufficient to induce a cell-cycle exit. Possibly,
yet more cell-cycle regulators are affected by
Forkhead activity. This is supported by our
findings that in MEFs deficient for both p130
and p27kip1, Forkheads can still cause a decrease
in cdk2 activity (figure 3b). Although we have
tested a variety of proteins known to be involved
in the regulation of cell-cycle progression in G1
phase (figure 2a), we cannot exclude that yet
unidentified G1/S regulators are targets for
Forkhead activity.
We show that the Forkhead-induced cell-
cycle exit is reversible. This is in agreement with
data obtained in Caenorhabditis elegans. In this
nematode, the AFX/FKHR/FKHR-L1-like DAF-
16 Forkhead transcription factor is regulated by
a PI(3)K/PKB-like pathway and induces
longevity and dauer formation (37, 38, 39). This
latter effect is an exit from development at the
second larval stage in adverse situations such as
lack of nutrients. The dauer phenotype is
reversible, allowing the worm to re-enter the
developmental program when conditions turn for
the better (reviewed in (40)). This suggests that
also in C. elegans, the PI(3)K/PKB/Forkhead
pathway might regulate a process that in many
ways resembles quiescence rather than
senescence or apoptosis.
It has been proposed that the presence of
p130/E2F-4 repressor complexes on DNA has
the significance of conferring reversibility to the
cell-cycle exit program (12). This is potentially
important in the context of oncogenic
transformation and regeneration. Conceivably,
quiescent tissue is forced back into the cell-cycle
by activation of the PI(3)K/PKB pathway.
Indeed, ligand-independent activation of PKB in
quiescent cells reduces the amount of p130
protein, indicating a return to the G1 phase of
the cell-cycle, and PI(3)K activated in a similar
manner drives cells out of quiescence (36). This
cell-cycle re-entry function of PKB might
contribute to the oncogenic effect of mutations
or deletions in the PTEN tumorsupressor (41,
Figure 7. Model for cell-cycle regulation by
the PI(3)K/PKB/Forkhead pathway. When
cells do not receive growth factors in early
G1, PKB is not activated and Forkheads
remain active. This results in the
upregulation of the genes for p27
kip1
 and
p130, leading to cell-cycle exit (in DLD-1 and
NIH3T3 cells, for example) and, with the
additional regulation of the Bim and FasL
gene products, to apoptosis (in Jurkat and
Ba/F3 cells, for example). Subsequent
activation of PKB through RTKs leads to
inactivation of Forkheads by nuclear
exclusion and therefore cell-cycle re-entry
via the downregulation of p27
kip1
 and p130
proteins. See text for further details.
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42), especially in normally quiescent tissue such
as the brain in parts of which PTEN genetic
alterations are quite common (43, 44). Once
inactivated, PTEN no longer inhibits PKB-
dependent inactivation of the Forkheads, leading
to inhibition of p27kip1 and p130 gene expression
and entry into the cell-cycle.
The data presented here show that specific
activation of FKHR-L1 alone is sufficient to
induce human tumor cells to exit the cell-cycle.
Not only can Forkheads inhibit proliferation of
human colon carcinoma cells, they also have the
ability to arrest human leukemia cells, human
glioblastoma cells, human renal carcinoma cells,
and human osteosarcoma cells (9). This potent
capacity of the Forkheads may indicate that
proliferation during the process of oncogenic
transformation cannot occur in the presence of
active Forkheads. Possibly, during this
transformation process, endogenous Forkhead
activities have been diminished to allow the
emerging tumor cell to proliferate. Indeed,
human U87MG glioblastoma cells (this
manuscript) and human Jurkat leukemia cells
(unpublished observations) have high levels of
phosphorylated and thus inactivated FKHR-L1.
Furthermore, exogenous FKHR is located in the
cytoplasm, and thus kept inactive, in human renal
and prostate cancer cells (11). The putative
importance of this pathway in oncogenesis is
further supported by the findings that in many
tumors p27kip1 (reviewed in (45)) or p130 ex-
pression is low (46, 47).
Forced activation of the Forkheads that are
regulated by PKB either causes cells to go into
apoptosis or results in a cell-cycle exit. It is of
interest to note that we only observe clear
induction of apoptosis in cell-systems derived
from haematopoietic cells ((6, 9, 20) and GJPLK,
RHM, BMTB, unpublished observations). The
cell-cycle exit appears more common and is seen
in cells from various origins (fibroblasts,
glioblastomas, ostesarcomas, colon carcinoma
(this manuscript and (9)). In the haematopoietic
cell compartment, most cells have a relatively
high proliferative capacity and a concomitant
limited lifespan (reviewed in (48, 49)). One can
imagine that cell cycle arrest/exit in these cells
in the absence of PI(3)K/PKB signalling would
be deleterious and result in the activation of a
default death pathway. The ability of Forkheads
to induce pro-apoptotic genes such as those
encoding Bim and FasL is likely to constitute
part of this default death pathway. Yet the cell-
types for which we observe cell-cycle arrest/exit
are derived from tissues that normally display a
relatively low proliferative capacity. We do not
yet understand the mechanism by which the
default death pathway is silenced in these cells.
For instance, conditional activation of FKHR-
L1 in the DL23 cell-line does not result in
upregulation of Bim, whereas activation of the
same construct in Ba/F3 cells (pre-B-cells) does
(25). Furthermore, the DLD-1 cell-line which is
the parental cell-line for the DL23 clone is not
sensitive to FasL-induced apoptosis despite high
levels of CD95 (50, 51). To understand more
about these striking differences between the two
cell-types, it will be interesting to examine what
other cellular factors determine why Bim is not
Forkhead-responsive in non-haematopoietic cells
and why CD95 presence does not necessarily
mean FasL responsiveness.
Certain differentiated tissues, such as liver,
smooth and skeletal muscle, pancreas and
auditory sensory epithelial have the ability of
regeneration. During the process of skeletal
muscle differentiation a sub-population of
myoblasts, termed reserve cells, remains
quiescent and confer the capacity to regenerate
onto skeletal muscle (52). Recently, it was
proposed that p130 is involved in defining this
pool of reserve cells (31). Interestingly, that study
showed that not only p130 protein but also p130
mRNA accumulates during muscle differen-
tiation of the reserve cells (31). Since we show
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in this study that p130 mRNA levels are increased
upon Forkhead activation, this might suggest a
role for the PI(3)K/PKB/Forkhead pathway in
muscle reserve cell differentiation and muscle
regeneration. A similar population (i.e.
supporting-cell population) in mouse auditory
sensory epithelium is kept quiescent because of
p27kip1 activity, but to date a role for p130 in this
process has not been studied (34). Nevertheless,
we have shown recently that p27kip1 is under the
control of Forkhead transcription factors (9, 20),
suggesting the possibility that in these cells
quiescence is maintained by Forkhead-dependent
regulation of p27kip1. In addition, high p27kip1
protein levels has been been suggested to be
involved in the maintenance of the quiescent state
of germinal centre/memory (GC/M) B-cells (53).
Finally, p130 or p27kip1 have been implicated in
liver, pancreas, and smooth muscle regeneration
(54, 55, 56, 57). It is tempting to speculate that
in the cells of tissues such as liver, pancreas and
muscle, the PI(3)K/PKB/Forkhead pathway
contributes to cell-cycle re-entry.
In conclusion, we have identified a novel
function for the AFX, FKHR and FKHR-L1
Forkhead transcription factors in cell-cycle
control. We have shown that these Forkheads
induce cells to exit the cell-cycle and enter a state
of quiescence as demonstrated by an upregulation
of protein levels of the p130 retinoblastoma
family member, an increase in p130/E2F-4
complexes and the reversibility of the cell-cycle
arrest. This latter observation further emphasizes
the importance of activation of the PI(3)K/PKB
pathway in processes such as oncogenic
transformation, in that it may relieve the
inhibitory constraints on cell-cycle progression
imposed by Forkhead-mediated regulation of
p27kip1 and p130 levels, resulting in a re-entry
into the cell-cycle.
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The activity of the PI(3)K/PKB signalling
pathway has been widely implicated in survival
signalling (reviewed in (2)). An important
component of anti-apoptotic signalling by active
PKB appears to be the inhibition of the DAF-
16-like Forkhead transcription factors AFX,
FKHR and FKHR-L1 that regulate the pro-
apoptotic genes Bim and FasL (3, 4, 5, 6). Indeed,
in cell systems derived from the haematopoietic
cell compartment, absence of PKB activity
correlates with apoptosis partly via an increase
in Bim and FasL expression (Jurkat, (3); Ba/F3,
(6)). However, in many other mammalian cell
types activation of the Forkheads or absence of
PI(3)K/PKB signalling causes cell-cycle arrest
and quiescence rather than apoptosis, at least in
part through the regulation of p27kip1 gene
expression ((1, 7, 8) and chapter 6). In agreement
with this, in the nematode C. elegans the absence
of AGE-1/AKT signalling and concomitant
activation of DAF-16 results in longevity, not
apoptosis (9, 10, 11, 12). We set out to investigate
how cells that have been driven into quiescence
by the DAF-16-like Forkheads are protected
from cytotoxic stress in the absence of PKB
activity. Since reactive oxygen species (ROS) are
a primary cause of cellular damage (reviewed in
(13)), we focussed on examining the effects of
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In the absence of protein kinase B (PKB or c-Akt) activity the Forkhead
transcription factors AFX, FKHR and FKHR-L1, orthologues of Caenorhabditis
elegans DAF-16, cause a G0/G1 arrest and an entry into quiescence ((1) and
chapter 6). Similar to anti-apoptotic signalling in proliferating cells, which
involves PKB activity, quiescent cells need to be protected from damaging agents.
Here we show that FKHR-L1 protects the arrested cells from oxidative stress.
Cells containing active FKHR-L1 display increased levels of manganese
superoxide dismutase. FKHR-L1 directly activates the gene for manganese
superoxide dismutase (SOD2) via a DAF-16 Binding Element, resulting in an
increase in mRNA levels. Importantly, the increase in manganese superoxide
dismutase is responsible for the Forkhead-induced enhancement of cellular anti-
oxidant capacity. We propose that Forkhead transcription factors increase
cellular lifespan by coupling a state of cellular quiescence with enhanced
protection from oxidative damage.
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Forkhead activity on cellular anti-oxidant
capacity. To this end, we stably transfected a
conditionally active HA-FKHR-L1.A3-ER
fusion (14) into DLD-1 human colon carcinoma
cells. The HA-FKHR-L1.A3-ER fusion protein
is constitutively expressed but remains inhibited
unless presented with a modified ligand for the
estrogen receptor (ER),  4OHT (15). Treatment
of the DL23 subclone with 500 nM 4OHT for
24 hours resulted in the specific activation of
FKHR-L1 as measured by previously described
Forkhead activity assays, including reporter
assays with the promoters for the IGFBP1 and
p27kip1 genes (figure 1a), a strong increase in
p27kip1 protein levels, and a decrease in cell
proliferation (figure 1b, c) (1, 4, 14). Further-
more, protein levels of the p130 pocket protein
were increased and pocket protein/E2F com-
plexes shifted from p107/E2F-4 to p130/E2F-4
(Chapter 6). Importantly, 4OHT had no effect
on the control DLD-1 cells (figure 1). To
determine whether FKHR-L1.A3 activation
affects cellular protection against ROS, we made
use of the lipophilic C11-BODIPY581/591 probe
which is suited for quantifying lipid-oxidation
in single living cells (16). Upon oxidation, the
fluorescence excitation/emission maxima of the
C11-BODIPY581/591 probe shift from 581/591 to
490/510 nm, facilitating the measurement of the
fraction of oxidized probe versus time. DL23
cells left untreated or treated with 4OHT for 16
hours were loaded with the C11-BODIPY581/591
probe and after addition of 200 µM H2O2 as a
radical inducer followed in time with dual-
excitation laser scanning microscopy. It is to be
noted that the C11-BODIPY581/591 probe is not
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Figure 1. Specific activation of FKHR-L1.A3 in DL23 cells by 4OHT.
A. DL23 and DLD-1 cells were transfected with the p1205-luc or
p27GL2 reporter constructs containing the Forkhead-regulated
promoters of the IGFBP1 or p27
kip1
 gene, respectively. The cells were
left untreated or treated with 500 nM 4OHT for 16 hours and luciferase
activity was measured. Data represent the average of three
independent experiments. B. To show that Forkhead activation in the
DL23 cells is homogeneous, DL23 cells were left untreated (-4OHT)
or treated with 500 nM 4OHT (+4OHT) for 16 hours and stained for
p27
kip1
 expression by immunofluorescence or analyzed for cell
proliferation by BrdU-incorporation. Pictures were taken with identical
exposure times. C. Total lysates of DL23 and DLD-1 cells treated
with or without 500 nM 4OHT were subjected to western blotting using
antibodies to p27
kip1
 (anti-p27
kip1
), HA-FKHR-L1.A3-ER (anti-ER), and
actin as a loading control (anti-actin). WB: Western Blot.
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oxidized by H2O2 itself, but by hydroxyl radicals
formed in the Fenton-reaction: H2O2+ O2•¯→
HO•+OH¯+O2 (catalyst: Fe2+). Fifty minutes after
H2O2 addition the total oxidized fraction of the
probe was 2-3 times lower in cells containing
active Forkhead compared to cells containing
inactive Forkhead (figure 2a). Furthermore, the
initial rate of oxidation of the probe in those cells
was 4 times slower (figure 2b). Again, treatment
of the DLD-1 control cell-line with 4OHT had
no effect. These results demonstrate that specific
activation of Forkheads increases the cellular
protection against ROS.
Next we examined whether Forkheads
increase cellular anti-oxidant capacity via the
regulation of anti-oxidant enzymes. The increase
in protection displayed in figure 2 could be due
to upregulation of either catalase or superoxide
dismutase, as shown by the Fenton-reaction.
Superoxide dismutase was recently shown to
prevent apoptosis possibly due to an inhibition
of cytochrome c release, as induced by
superoxide accumulation, from the mitochondria
(17). We therefore investigated whether
Forkhead activity affects protein levels of
superoxide dismutase. 4OHT-treatment of the
DL23 cell-line for up to 24 hours showed a
gradual increase in the amount of manganese
superoxide dismutase (MnSOD) protein but no
change in protein levels of copper/zinc
superoxide dismutase (Cu/ZnSOD) (figure 3a).
The increase in MnSOD expression was not a
secondary event caused by p27kip1-induced cell-
cycle arrest, since wildtype and p27kip1 -/- MEFs
showed a similar increase in MnSOD protein
upon infection with a FKHR-L1.A3-expressing
retrovirus (figure 3b). Similar effects were seen
when we used an HA-AFX-expressing
retrovirus, indicating a general effect of this
Forkhead subfamily (data not shown).
To investigate whether the regulation of
MnSOD protein levels by Forkheads is at the
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Figure 2. Forkhead transcription factors increase cellular protection against ROS. A. DL23 cells left untreated or
treated with 500 nM 4OHT for 16 hours were loaded with the C11-BODIPY
581/591
 probe for 20 minutes and subjected
to 200 µM of the free-radical-inducing agent H
2
O
2
 for 50 minutes. Images of clusters of cells at timepoint 0 and 50
minutes after H
2
O
2
-addition were taken by confocal microscopy, and the fraction oxidized probe in arbitrary units
(a.u.) was calculated as described in the ‘Methods’ section. (For full-color images, please refer to the back of the
thesis: Yellow areas represent 100% oxidation, black areas represent 0% oxidation.) The circular black areas in the
cell-population represent nuclei that fail to be loaded with the probe and have been ommitted from the final analysis.
B. DL23 (solid lines) and DLD-1 (dashed lines) cells were treated as in A. Images were taken at timepoints 0, 8, 16,
24, 32, 40 and 48 minutes after H
2
O
2
-addition. Calculations of the fraction of oxidized probe per timepoint in arbitrary
units (a.u.) were performed as described under ‘Methods’.
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level of transcription, we first examined MnSOD
mRNA expression in the DL23 cell-line. As seen
in figure 4a, MnSOD mRNA levels are elevated
between 8-16 hours of 4OHT-treatment and a
~10-fold increase is seen after 24 hours of
FKHR-L1 activation. Second, we investigated
the effect of specific Forkhead activation on a
3340 basepair promoter fragment of the human
SOD2 gene for MnSOD using a luciferase
reporter plasmid (pSODLUC-3340) (18).
MnSOD
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Cu/ZnSOD
WB: MnSOD
WB: Cu/ZnSOD
WB: actin
8 24
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MnSOD
p27      +/+kip1 p27      -/-kip1
Figure 3. Forkhead activation results in upregulation of MnSOD. A.
Total lysates of DL23 cells left untreated (0), or treated with 500nM
4OHT for 8, 16 or 24 hours were analyzed for expression of MnSOD,
Cu/ZnSOD and actin as a loading control. WB: Western Blot. B.
Wildtype or p27
kip1
 -/- MEFs were infected with a retrovirus containing
a control plasmid (puro) or FKHR-L1.A3 (L1.A3). Total lysates were
collected 24 hours post-infection and subjected to western blotting
using an antibody against MnSOD.
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Figure 4. FKHR-L1 directly regulates the MnSOD promoter
via an inverse DBE. A. 2 µg mRNA isolated from DL23 cells
left untreated (0) or treated with 500 nM 4OHT for 8, 16 or 24
hours were electroforesed, blotted onto a nylon membrane,
and probed for presence of MnSOD and GAPDH using
radiolabelled probes. B. pSODLUC-3340 and pSODLUC-1
were transfected into DL23 or DLD-1 cells that were
subsequently left untreated or treated with 500 nM 4OHT for
16 hours after which luciferase activity was measured. Data
represent the average of three independent experiments. C.
pSODLUC-3340 carrying a point mutation at position -1244 in
the first DBE (DBE1mut) or at position -995 in the second DBE
(DBE2mut) or both (DBE12mut) were transfected into DL23
cells. Luciferase activity was measured after cells were left
untreated or treated with 500 nM 4OHT for 16 hours. Data
represent the average of three independent experiments.
Drawing represents linearized SOD2 promoter fragment
containing the two DBEs.
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Luciferase expression controlled by this fragment
was increased 3-4-fold upon cotransfection with
the various Forkhead transcription factors in
several cell-lines (data not shown) and upon 16
hours of 4OHT-addition to DL23 but not DLD-
1 cells (figure 4b). No effect was seen on a similar
reporter construct lacking the sequences
upstream of the transcription startsite
(pSODLUC-1) (figure 4b). Recently, the optimal
DNA-binding sequence for the DAF-16-like
Forkhead transcription factors has been
determined (19). This DAF-16-binding element
(DBE) contains the core sequence TTGTTTAC.
Point mutations in the TTGTTT sequence
prevent Forkhead-binding to the DBE and
transactivation of a 6XDBE reporter construct.
Within the human SOD2 promoter fragment one
inverse DBE at position -1249 (GTAAACAA,
DBE1) and one sub-optimal DBE at position -
997 (TTGTTTAA, DBE2) are found (figure 4c).
To determine whether Forkhead-mediated
increase in MnSOD gene expression is direct,
we mutated single basepairs in the two DBEs. A
single G to C substitution in the TTGTTT
sequence of DBE2 had no effect on FKHR-L1-
induced luciferase activity of the SOD2 reporter
construct, but a similar substitution in the
AAACAA sequence of DBE1 completely
abolished  FKHR-L1-mediated SOD2 gene
expression (figure 4c). This clearly demonstrates
that Forkhead transcription factors directly
regulate MnSOD gene expression through a
single inverse DBE.
MnSOD is a mitochondrial anti-oxidant
enzyme that converts the free-radical-containing
superoxide anion (O2•¯), generated as a byproduct
of the electron-transport-chain, into
hydrogenperoxide (H2O2). Some of the harmful
effects of the superoxide anion such as lipid-
oxidation and the induction of DNA breaks have
been implicated in various diseases and aging
(reviewed in (20)). By reducing the amount of
superoxide anions, MnSOD can participate in the
cellular protection against free radicals and thus
contribute to the maintenance of cellular
integrity. However, the hydrogenperoxide
formed by MnSOD is still harmful to the cell.
Therefore we investigated whether the hydrogen-
peroxide-metabolizing enzyme catalase is
increased in cells after Forkhead activation.
Indeed, DL23 cells treated with 500 nM 4OHT
displayed an increase in catalase protein with
kinetics similar to MnSOD upregulation (figure
5a). This indicates that the direct regulation of
MnSOD by Forkheads which results in the
production of hydrogenperoxide is coupled to the
regulation of catalase which converts hydrogen-
peroxide to water and oxygen. Next, we inves-
tigated whether the enhancement of cellular anti-
oxidant capactiy by Forkheads as seen in figure
2 is due to a Forkhead-mediated increase in
MnSOD gene expression. To this end we
analyzed the effect of Forkhead expression on
cellular stress in Sod2 -/- MEFs (21, 22) using
the C11-BODIPY581/591 probe assay. Infection of
primary MEFs from wild-type mice (Sod2+/+)
with a retrovirus carrying FHKR-L1.A3 resulted
in a marked two-fold enhancement of cellular
anti-oxidant capacity compared to infection with
a control virus (figure 5b). However, in primary
MEFs from Sod2 knockout mice (Sod2-/-)
FKHR-L1.A3 expression could not protect cells
from H2O2-induced cellular stress (figure 5b).
This last results also indicates that the Forkhead-
induced upregulation of catalase might be an
indirect consequence of MnSOD increase, for the
Sod2-/- cells are no longer protected. Altogether,
these data clearly show that Forkhead
transcription factors can decrease radical-induced
oxidative damage via direct regulation of
MnSOD gene expression.
In proliferating cells the activation of PKB
has been associated with protection from
apoptosis induced by various stimuli. Here we
show that a signal equivalent to the absence of
PKB activity in non-proliferating, quiescent cells
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can accomplish the same result. When challenged
with incriminating stimuli such as H2O2, cells that
contain active FKHR-L1 are protected form
oxidative damage through a Forkhead-mediated
increase in MnSOD gene expression. This
suggests a situation where the outcome of the
activity of the PI(3)K/PKB/Forkhead pathway
with respect to protection from cellular damage
depends on the cell-system and the cell-cycle
phase the cells are in (figure 5c). In C. elegans
the DAF-2/AKT/DAF-16 pathway regulates
metabolism, dauer formation and organismal
lifespan (9, 10, 11). Restoration of DAF-2/AKT/
DAF-16 signalling in different cellular
compartments of DAF-2 mutants has revealed
that reconstitution in neuronal cells results in
rescue of  all three phenotypes (12). To date, the
only gene targets found for DAF-16 are the free-
radical-scavenging enzymes cytosolic catalase
(ctl-1) and MnSOD (sod-3) and they were shown
to be required for DAF-16-induced dauer
formation (23, 24). The observation that C.
elegans organismal lifespan is solely determined
by DAF-16 signalling in the brain has led to the
suggestion that anti-oxidant enzymes contribute
to an increased cellular lifespan of neurons that
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Figure 5. FKHR-L1-induced protection from
oxidative damage depends on MnSOD. A.
Total cellular lysates from DL23 cells left
untreated (0) or treated with 500 nM 4OHT
for 8, 16 or 24 hours were immunoblotted for
the presence of catalase. WB: western blot.
B. Primary MEFs from wild-type (solid lines)
or Sod2 knockout (dashed lines) mice were
infected with control (con) or HA-FKHR-
L1.A3-expressing retrovirus (L1.A3). Three
days post-infection, the cells were analyzed
for cellular anti-oxidant capacity as in figure
2. Images were taken at 6-minute intervals
after H
2
O
2
-addition. Calculations of the
fraction of oxidized probe in arbitrary units
(a.u.) per timepoint were performed as
described under ‘Methods’. C. Model for
Forkhead-mediated cell-fate decision. In
highly proliferative cell such as those from
the haematopoietic system, PKB activity
induces a survival signal by inhibiting
Forkheads, BAD and caspase-9. In quiescent
cell-types, however, the absence of PKB
activity does not automatically lead to
apoptosis. In these cells the maintenance of
quiescence is coupled to survival through
Forkhead-mediated expression of p27
kip1
,
p130 and MnSOD.
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deliver neuro-endocrine signals to the organism.
Our results now start to define a remarkable
conservation of function. Neurons are generally
considered to be post-mitotic or quiescent cells.
The finding that FKHR-L1 expression is
relatively high in the brain (19) allows us to
speculate that the DAF-16 like Forkheads might
be involved in the regulation of neuronal cellular
lifespan through the maintenance of quiescence
and protection from oxidative damage. Possibly,
as in C. elegans, this might contribute to the
control of organismal lifespan. In addition,
quiescent/differentiated cells have upregulated
levels of anti-oxidant enzymes, especially of
MnSOD protein and mRNA (25, 26, 27), a
property that is lacking in various tumor cells
(reviewed in (28)). Our data suggest that the
observations that certain tumors have low levels
of p27kip1 and/or MnSOD (reviewed in (29))
might be a consequence of the inactivation of
the DAF-16-like Forkheads by activation of the
PI(3)K/PKB pathway and furthermore that this
might contribute to the process of oncogenic
transformation. Finally, it is important to note
that Cu/ZnSOD is not regulated. Apparently, Cu/
ZnSOD does not need to be induced for enhanced
protection during quiescence which might relate
to the fact that Cu/Zn SOD is cytosolic whereas
MnSOD is mitochondrial. This points to the
unique function of MnSOD and illustrates the
importance of its regulation by external cues. In
agreement with this, overexpression of Cu/
ZnSOD in MnSOD-deficient mouse fibroblasts
cannot prevent neonatal lethality nor oxidative
aconitase inactivation (30). In conclusion, we
propose that the mammalian DAF-16-like
Forkhead transcription factors AFX, FKHR and
FKHR-L1 increase cellular lifespan by coupling
cell-cycle exit with enhanced protection from
oxidative damage.
Methods
Cell culture, retroviral infections and stable cell-lines. The
DL23 cell-line was created as follows: linearized pcDNA3-
HA-FKHR-L1.A3-ER (14) was transfected into DLD-1 human
colon carcinoma cells by electroporation. Transfectants were
selected for two weeks on 500 µg/ml geneticin. Subsequently,
clones were isolated and analyzed for expression of the fusion
protein. The DL23 subclone was chosen for further study. The
DLD-1 and DL23 cell-lines were maintained in RPMI-1640
with standard supplements and the appropriate selection
antibiotic. Retroviral infections and maintenance of
immortalized wildtype and p27kip1 -/- as well as primary
wildtype and Sod2-/- MEFs has been described (1, 22).
Cloning and plasmids. pBabe-FKHR-L1.A3 was created by
ligating a Klenow-blunted HindIII/BamHI fragment of
pcDNA3-HA-FKHR-L1.A3 into Klenow-blunted BamHI-cut
pBabe-puro. pcDNA3-HA-FKHR-L1.A3-ER has been
described (14). pSODLUC-3340 and pSODLUC-1 were a gift
of M. Yim (18). pSODLUC-3340.DBE1mut and pSODLUC-
3340.DBE2mut were created by site-directed mutagenesis
using the primers 5'- CTGACGTCTGTAAAGAAGCCCAG
CCCTTC-3' and 5'- CATTCAGGATTGTTCTTTAACTGTT
GAG-3', respectively. p1205-luc was a gift of D. Powell (31).
p27GL2 has been described (1). pBabe-puro used for retroviral
infections of MEFs has been described (1). pGEMZ-MnSOD
was a gift of J. Wispe (32).
Western blotting, antibodies and standard
immunofluorescence. Western blotting of total lysates was
performed as described (4). Antibodies to MnSOD and Cu/
ZnSOD were from StressGen. The antibodies to ER (C-20)
and actin (I-19) were from SantaCruz. The p27kip1 antibody
was from Transduction Labs. Anti-catalase has been described
(33). Standard immunofluorescence using the p27kip1 antibody
was performed as follows: cells were fixed in 4%
paraformaldehyde, permeabilized and blocked with PBS
containing 0.1% TX-100, 0.5% BSA and stained with anti-
p27kip1 followed by Cy3-conjugated goat anti-mouse secondary
antibody (Jackson ImmunoResearch Labs).
Northern blotting. 2 µg of polyA+-RNA (polyA-Tract,
Promega) purified from 1 mg total RNA (RNAZol, TEL-TEST,
Inc.) was run on a formaldehyde denaturing gel and blotted
onto GeneScreen-Plus nylon membrane (NEN). The blot was
hybridized using radiolabeled MnSOD (EcoRI fragment of
pGEM3Z-MnSOD) and GAPDH (NotI-linearized pUC19-
GAPDH) probes.
Luciferase assays. Luciferase assays were performed as
described (4).
BrdU incorporation. BrdU incorporation was performed as
described (1).
Microscopy and fluorescence ratio-imaging. Generally,
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microscopy and fluorescence ratio-imaging were performed
as described (16). Shortly, cells cultured on coverslips were
placed in a temperature (37°C)-controlled coverslip holder in
the microscope and incubated for 20 min with C11-BODIPY581/
591
 (Molecular Probes). To this end, C11- BODIPY581/591 was
dissolved in fetal calf serum to a final concentration of 0.1 mg
ml-1. This stock was diluted 1000 times in PBS supplemented
with 5 mM glucose, 0.5 mM MgCl2 and 0.9 mM MgCl2
(PBS+). After washing with fresh PBS+, images were taken
with a Leica TCSNT confocal laser scanning system on an
inverted microscope DMIRBE (Leica Microsystems) with an
argon-krypton laser as excitation source. The green and red
fluorescence of C11-BODIPY581/591 was acquired
simultaneously using double wavelength excitation (laserlines
488 and 568 nm) and detection (emission bandpass filter 530/
30 nm for green and longpass 560 nm followed by a bandpass
600/30 nm for red). Oxidized and non-oxidized C11-
BODIPY581/591 are spectrally well separated and this property
was used to quantify the fraction of oxidized and non-oxidized
C11-BODIPY581/591 simultaneously at any time point. Images
were processed and calculated with Scion Image 1.62 on a
Macintosh PowerPC. Image calculus of figure 2a was
performed as follows: the red and green fluorescence of the
probe was assesed at several timepoints. The fraction oxidized
probe in every timepoint was calculated as the ratio of Igreen to
Igreen+Ired, where Igreen and Ired are the intensities of the green
and the red fluorescent signal respectively. Images were
smoothed before the algorythm was applied. The signal of the
probe was filtered from the rest of the images by tresholding.
The calculated fractions were averaged using the smooth filter.
A false colour look-up table was applied to visualize low and
high oxidation of the probe. All data are normalized, arbitrary
units.
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In the G1 phase of the cell-cycle growth
factors provide a cell with a license to divide. It
has previously been shown that the PI(3)K/PKB
and Ras signal transduction pathways can play
an important role in the process of cell-cycle
progression through G1 into S phase. In this
thesis we have described the identification of a
component shared by the PI(3)K/PKB and Ras
pathways that can be involved in their effects on
G1/S transition. The Forkhead transcription
factors AFX, FKHR and FKHR-L1 inhibit
cellular proliferation at the G1 phase and induce
cellular quiescence via increased transciption of
the genes encoding the p27kip1 cell-cycle inhibitor
and the p130 retinoblastoma-like pocket protein
((1) and chapter 6), with a possible involvement
of superoxide radicals (chapter 7). Activation of
the PI(3)K/PKB cascade directly inactivates
AFX, FKHR and FKHR-L1 (2, 3, 4) leading to
a release of this block on proliferation imposed
by the Forkheads (1). For AFX, we show that in
addition to the PI(3)K/PKB pathway, the Ras/
Ral cascade is involved in inhibition of the
Forkhead, possibly also through phosphorylation
(3).
Regulating Forkhead activity
The AFX, FKHR and FKHR-L1 Forkhead
transcription factors are inactivated by
phosphorylation on multiple sites. Inactivation
may involve several mechanisms. The most
striking one found to date is the PKB-mediated
relocalization from the nucleus to the cytoplasm
((2, 5, 6) and chapter 4). This kind of regulation
of the activity of a transcription factor through
phosphorylation-dependent relocalization is
reminiscent of several factors in yeast. In
phosphate-starved Saccharomyces cerevisiae, for
example, the Pho4 transcription factor is
unphosphorylated and nuclear, and transcribes
phosphate-responsive genes (7). Addition of
phosphate activates the cyclin-cdk complex
Pho80/Pho85 that phosphorylates Pho4 on five
serine residues (7). These multiple phosphory-
lations all contribute to inactivation of Pho4, by
either disturbing an interaction with its transcrip-
tional partner Pho2 or by relocalizing Pho4 to
the cytoplasm. Two of the serine residues interact
with the Msn5 nuclear export factor in a
phosphorylation-dependent manner (8) and one
serine is located within a NLS (figure 1).
Phosphorylation of Pho4 therefore not only
interrupts an interaction with a co-activator, it
also enhances nuclear export and inhibits nuclear
import, all functions carried out separately by
distinct phosphorylated residues (9). Another
yeast regulatory cascade that controls
transcription factor activity via phosphorylation-
dependent relocalization is the Tor/Msn2/Msn4
pathway. Here, the PI(3)K-like kinase Tor
phosphorylates the Msn2 and Msn4 transcription
factors causing them to complex with the 14-3-
3-like protein Bmh2, which results in the
cytoplasmic localization of Msn2 and Msn4 (10).
As with Pho4, full inhibition of AFX
requires that all sites are phosphorylated. Growth
factor-induced activation of either PKB or Ral
only partially inactivates AFX (3) and mutation
of either of the PKB sites only partially attenuates
the inhibition induced by insulin (unpublished
observations). This implies that the
phosphorylations of the Ral-dependent site(s)
and of the PKB-dependent serines 193 and 258
are all functionally relevant, but the contribution
of all sites to growth factor-induced inactivation
of the transcription factors is not completely
understood. Interestingly, we observe similarities
between Pho4/Msn2/Msn4 and Forkhead
regulation. Serum starvation of mammalian cells
causes unphosphorylated AFX to be nuclear and
active. Subsequent addition of insulin causes
phosphorylation on multiple sites (two PKB-
mediated and at least one Ral-mediated, see (3)).
A function for one of the residues in the
inactivation of AFX has been determined and
shown to be the inhibition of nuclear import
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(chapter 4). PKB-mediated phosphorylation of
AFX on serine 193 functionally inactivates a
NLS located around that residue, causing the
continuously shuttling transcription factor to be
detained in the cytoplasm (chapter 4), much like
phosphorylation of serine 152 (SP4) in Pho4
(figure 1) (9).
What role might the other phosphorylated
residues play in the inhibition of AFX, with
respect to nuclear exclusion or otherwise? First,
one or more phosphorylated residues might serve
as a specific binding sequence for cytoplasmic
anchors, such as the Bmh2-binding to the Msn2
and Msn4 transcription factors in budding yeast
(10). Two of the three phosphorylated PKB sites
in FKHR-L1 are responsible for binding the 14-
3-3ζ protein (2), which, as suggested by the
authors, might fulfill the function of cytoplasmic
anchoring (figure 1). However, it remains to be
demonstrated that Forkheads complex with 14-
3-3 proteins upon growth factor treatment of cells
and it is unknown whether this complex is formed
in the cytoplasm or in the nucleus. Besides the
possibility that 14-3-3 proteins bind the Fork-
heads in the cytoplasm where they function as a
cytoplasmic anchor, 14-3-3-Forkhead complex
formation might occur in the nucleus. In this way,
14-3-3 could provide a NES, as was shown for
the phosphorylation-dependent nuclear export of
the cdc25 protein by the 14-3-3 family member
Rad24 (11). Although the Forkheads have a
classical NES themselves, it does not appear to
function as a NES, since deletion, despite having
an effect on  nuclear export of AFX, does not
disturb binding to the Forkhead exportin Crm1
(see discussion of chapter 4). This leaves the
possibility that an additional protein in the
Forkhead/Crm1 complex might provide the
required NES. Conversely, 14-3-3 binding might
have nothing to do with regulating nuclear-
cytoplasmic localization, but rather may affect
lation sites is unclear. Possibly, they
interrupt binding to a co-factor, as was
shown for the yeast Pho4/Pho2
complex (panel B). Alternatively, the
phosphorylated residues could create
a binding site for a cytoplasmic
anchor, such as 14-3-3 proteins, as
was shown for the yeast Msn2 and
Msn4 transcription factors that bind
Bmh2 (see text). How the Forkheads
are relocalized to the nucleus is
unknown. Possibly, a phosphatase
dephosphorylates the residues
leading to unmasking of the NLS, as
was shown for calcineurin (CnA)-
dependent dephosphorylation of NF-
AT (panel C). Additionally,
dephosphorylation could lead to
release from the putative cytoplasmic
anchor, similar to Sit4-mediated re-
activation of the yeast Gln3
transcription factor through release of
the cytoplasmic Ure2 protein (panel
D). See text for further details. N,
nucleus; C, cytoplasm. Panel C was
adapted from (17). Panel D was
adapted from (10).
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Figure 1. Models for the regulation of transcription factors
activity by phosphorylation-dependent relocalization. The
Forkheads AFX, FKHR and FKHR-L1 are inhibited by
phosphorylation on multiple sites. PKB-dependent
phosphorylation of one site is responsible for masking a
NLS, leading to cytoplasmic localization (panel A; see
also chapters 2 and 4). The role of the other phosphory-
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transcriptional activity of the Forkheads more
directly. The association of the C. elegans DAF-
16 Forkhead with 14-3-3 proteins, for instance,
was recently suggested  to inhibit the DNA-
binding capacity of DAF-16 (12).
Second, phosphorylation might disturb an
interaction with a co-factor, like phosphorylation
of serine 223 (SP6) of Pho4 disrupts binding to
the co-activator Pho2 (9). Recently, the p300/
CREB-binding protein (CBP) was reported to be
a co-activator for the C. elegans Forkhead
transcription factor DAF-16 as well as for FKHR,
but no evidence was presented as to whether
phosphorylation of a specific site could inhibit
the interaction between the Forkhead and p300/
CBP (13). Third, phosphorylation of a specific
residue might affect the rate of nuclear export,
although we suggest in chapter 4 that for AFX,
Crm1 binding is not affected by phosphorylation
of the Forkhead. Nevertheless, a LMB-sensitive,
Crm1-independent export pathway may exist,
and phosphorylation of one of the sites could
mediate the association of an exportin with the
Forkheads in a similar manner as the yeast Msn5
exportin associates with Pho4 via phosphorylated
serines 114 and 128 of Pho4 (9). Fourth,
phosphorylation might affect the stability of the
protein, as was shown for phosphorylation-
dependent ubiquitin-mediated targetting of
p27kip1 to the proteasome (14, 15). However, no
change in the amount of AFX protein was
detected even after prolonged treatment of A14
cells with insulin (unpublished observations),
arguing against this mode of regulation. Finally,
phosphorylation in the C-terminus (serine 258
in AFX) might directly affect the affinity of the
transactivating domain for the basal transcription
machinery, and phosphorylation in the DNA-
binding domain (serine 193 in AFX) could alter
its affinity for Forkhead-specific promoter
sequences. Elucidating the way in which the
phosphorylation on all sites affects AFX function
will be important for understanding the exact
mechanism by which a growth factor can regulate
these Forkheads and thereby affect cellular
proliferation.
What causes nuclear relocalization of AFX
when growth factor signalling is terminated?
Depriving cycling HeLa cells of serum for ninety
minutes causes a relocalization of AFX from the
cytoplasm to the nucleus (chapter 4). This is
unlikely to be due to high turnover of AFX and
the nuclear accumulation of newly synthesized
AFX protein, since preliminary experiments
suggest that AFX is highly stable (t1/2 > 10 hours,
unpublished observations). Hence, it seems more
likely that in the absence of PKB activity AFX
relocalization to the nucleus is caused by its
dephosphorylation. Several studies in yeast and
mammalian cells on other transcription factors
have already reported the existence of such a
mechanism of activation. When phosphorylated,
the yeast GATA-like Gln3 transcription factor is
bound to the cytoplasmic Ure2 protein. Nitrogen
starvation, however, activates the type 2A-like
phosphatase Sit4 that dephosphorylates Gln3,
freeing it from Ure2 thereby causing Gln3 to be
imported into the nucleus (10). Addition of
nutrients activates Tor which in turn inactivates
Sit4, leading to cytoplasmic localization and thus
inactivation of Gln3 (figure 1). In mammalian
systems, the localization of the T-cell
transcription factor NF-AT is regulated by the
phosphatase calcineurin. In the absence of
calcium signalling, NF-AT is phosphorylated by
GSK3 which causes masking of a NLS but not
of a NES, resulting in Crm1-mediated export and
cytoplasmic localization (16). In the presence of
calcium, however, calcineurin is activated and
binds to the region in NF-AT containing the NES
but in addition dephosphorylates the NLS-
masking domain, causing nuclear accumulation
of NF-AT (figure 1) (17). All these studies
provide elegant mechanisms for the
phosphorylation-dependent activation of
transcription factors through relocalization.
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Whether or not such mechanisms apply to AFX
re-activation remains to be investigated and this
will await the identification of the functional role
of all growth factor-induced phosphorylation
events on AFX.
Apoptosis versus cell-cycle arrest
As determined thus far, overexpression of
AFX, FKHR and FKHR-L1 can have two short-
term effects: apoptosis and cell-cycle arrest.
Which of these events occurs upon Forkhead
expression seems to largely depend on the
cellular context. All non-transformed haemato-
poietic cells (and some transformed ones) tested
to date die upon Forkhead activation, either by
Forkhead overexpression or withdrawal of a
required survival factor that normally inactivates
the transcription factors. In this way,
programmed cell death of human CTLL2 T
lymphocytes (R. H. Medema, personal
communication), human UT-7/EPO leukemia
cells (18), primary human erythropoid progenitor
cells (19) and mouse Ba/F3 pre-B cells (20) has
been linked to Forkhead activity. Furthermore, a
non-phosphorylatable form of FKHR-L1
(FKHR-L1.A3) can cause apoptosis in human
Jurkat lymphoma cells (1, 2). In cell-types that
are not derived from the haematopoietic
compartment, however, overexpression of
Forkheads causes cell-cycle arrest/quiescence.
Mouse A14 fibroblasts (1), MEFs (1), human
U2OS osteosarcoma cells (1), human U87MG
glioblastoma cells (1), human DLD-1 colon
carcinoma cells (chapter 6 and 7), human 786-0
renal carcinoma cells (21) and human CCL39
fibroblasts (22) arrest in the G1 phase of the cell
cycle in response to Forkhead activation.
Importantly, no non-transformed haematopoietic
cells have yet been reported to arrest and survive
upon Forkhead expression and conversely, few
non-haematopoietic cells have been reported to
die when Forkheads are activated. With respect
to the latter, overexpression of a non-
phosphorylatable constitutively active version of
the Forkheads can cause some apoptosis in
chinese hamster ovary CHO-K1 cells (6), human
LNCaP prostate carcinoma cells (21), human
CCL39 and 293T fibroblasts (2, 23) and post-
mitotic neurons (2), albeit to a much lower extent
than in haematopoietic cells. Altogether, it seems
that in cells that continuously require an anti-
apoptotic signal to survive, such as cells from
the haematopoietic compartment, Forkhead
overexpression results in apoptosis. The anti-
apoptotic signals (for instance IL-3 for the Ba/
F3 cells) will thus likely induce survival at least
in part via the inactivation of the Forkheads, and
subsequent removal of the signal will activate
the Forkheads hence causing apoptosis. On the
other hand, in cells like fibroblasts that do not
need a continuous survival signal and that upon
growth factor withdrawal exit the cell-cycle
rather than undergo apoptosis, Forkhead expres-
sion results in a cell-cycle block. We therefore
propose that in haematopoietic cells PKB
activation causes survival at least in part via
Forkhead inactivation in addition to BAD and
caspase-9 inactivation, but that in non-haemato-
poietic cells PKB-mediated Forkhead inactiva-
tion contributes to cell-cycle progression rather
than survival (see figure 5c of chapter 7).
Why do cells derived from the haemato-
poietic compartment die upon Forkhead
activation whereas other cells enter quiescence?
Several answers might apply to this question. The
target genes of Forkheads in haematopoietic cells
could be different from the ones in other cell-
types. Two Forkhead gene targets associated with
apoptosis are Bim and FasL. Although no FasL
protein levels after Forkhead activation have
been measured in any of the two cell-types, Bim
expression is seemingly restricted to cells from
the haematopoietic lineage ((24, 25) and chapter
6). This is in agreement with observations made
in chapter 6 where DLD-1 cells that exit the cell-
cycle when a conditionally active FKHR-L1.A3
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is turned on do not express detectable levels of
Bim, neither before nor after Forkhead activation.
On the other hand, Forkheads might
regulate anti-apoptotic genes in non-
haematopoietic cells but not in haematopoietic
cells. In this respect, the gene for MnSOD is an
interesting candidate target, since preliminary
experiments suggest that upon Forkhead
activation MnSOD is not upregulated in Ba/F3
cells (unpublished observations). MnSOD
overexpression can elicit a survival signal in
many cell types (26, 27, 28, 29, 30, 31),
presumably by reducing the accumulation of
superoxide radicals in the membrane of the
mitochondria thereby preventing leakage of
cytochrome c from that membrane (32). Possibly,
selective upregulation of MnSOD by Forkhead
transcription factors contributes to the distinct
responses of different cell-types to Forkhead
activity.
Finally, different cell-types might respond
differently to Forkhead-mediated expression of
the same geneproduct. p27kip1, for instance,
potently arrests the cell-cycle upon AFX or
FKHR-L1 expression in A14 cells, MEFs, DLD-
1 and 786-0 cells (1, 21), whereas a similar p27kip1
regulation by FKHR-L1 in Ba/F3 cells causes
apoptosis (20). Elucidating the differences
between cell types in their response to Forkhead
activity will be helpful in understanding
specificity of PKB signalling in particular and
possibly of signal transduction events in general.
Forkheads and cellular transformation
Several studies have provided some
compelling data that Forkhead inactivation is one
of the events that contributes to cellular
transformation upon loss of PTEN expression.
Forkhead overexpression in PTEN-negative
tumor cells has the same effect on cellular
proliferation as overexpression of PTEN in these
cells: cell-cycle arrest in the G1 phase of the cell-
cycle and/or apoptosis (1, 21). In addition,
ectopically expressed FKHR is cytosolic in
PTEN-negative renal and prostate carcinoma
cells, and expression of a FKHR mutant that
cannot be phosphorylated by PKB causes
apoptosis in the prostate carcinoma cells and a
G1 arrest with a concomitant p27kip1 upregulation
in the renal carcinoma cells (21). All this suggests
that PTEN overexpression might mediate its
effects by activating the Forkheads through the
inactivation of PKB. Following from this, one
may also suggest that PTEN-negative cells may
contain inactive Forkhead protein, which may
play a role in the emergence of the transformed
phenotype of those cells.
Might PTEN deletions or mutations alone
be enough to fully inhibit the Forkheads, in
particular AFX? Since we have shown that both
Ras and PI(3)K signalling are required for full
growth factor-induced inhibition of AFX, one
might predict that it is not (3). This would be in
agreement with recent findings that both
oncogenic Ras (RasD12) and constitutively
active PKB (myristoylated PKB) need to be
expressed in astrocytes and neural progenitor
cells in mice to induce glioblastoma formation
(33), indicating that either Ras and PKB have
separate but complementary effectors and/or that
both need to be activated to fully inhibit a shared
target, for instance the Forkheads. On the other
hand, both hyperactive forms of Ras (RasV12)
or PKB (gagPKB) alone can fully inhibit AFX
in a reporter assay (3) and the RasV12 protein in
addition can cause constitutive activation of PKB
in various cell-types (34, 35). Investigating
whether cells that contain genomic PTEN
deletions or mutations have additional mutations
of the Ras gene and vice-versa and whether
Forkheads are fully inactivated in these cells will
contribute to the clarification of the role of
Forkheads in cellular transformation and of the
role of the two pathways in controlling Forkheads
in tumor cells  (figure 2).
How would Forkhead inactivation
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promote cellular transformation? In tumor cells
from haematopoietic origin, Forkhead
inactivation might be part of one of the survival
signals that contribute to transformation. On the
other hand, in cells from tumors that arise from
quiescent tissues, for example brain, Forkheads
might play a role in enhanced and unlicensed
proliferation. Such cells have had to re-enter the
cell-cycle at one point during their evolution into
a cancer cell. Active FKHR-L1 and AFX induce
and maintain a state of cellular quiescence, at
least in non-haematopoietic cells and subsequent
inactivation of these Forkheads reverses this
(chapter 6). Interestingly, the PTEN gene is often
found deleted in glioblastoma tumor cells derived
from originally quiescent neuronal tissue, and
Forkhead inactivation due to loss of PTEN
function in such cells might be an important step
for re-entry into the cell-cycle (36, 37). It will be
of interest to see whether or not in general
Forkheads are inactive in such tumor cells but
are active in the normal quiescent counterparts.
In accordance with a role for inactive Forkheads
in transformation via cell-cycle re-entry are the
observations that the Forkhead target genes
encoding p27kip1, p130 and MnSOD are generally
low in tumor cells (38, 39, 40, 41).
How might Forkhead-mediated regulation
of MnSOD expression participate in cellular
transformation? Of all anti-oxidant enzymes,
MnSOD in particular has been associated with
cell-cycle progression. MnSOD is low during S-
phase and high in G0 in several cell-lines
including fibroblasts (42) and overexpression of
MnSOD in NIH3T3 cells can block cellular
proliferation (43). Concordant with a role for
MnSOD in cell-cycle control is an observation
made twelve years ago that superoxide radicals
enhance proliferation of fibroblasts (44) although
to date no data has been provided to suggest a
mechanism by which this may occur. Impor-
tantly, overexpression of MnSOD can revert the
transformed phenotype of a variety of tumor cell-
lines, including those transformed by the Ras
oncogene ((45, 46, 47) and reviewed in (42)) and
it was suggested that superoxide radicals are
required for cellular transformation, possibly by
acting as second messengers (48). Maintaining
high levels of MnSOD might therefore be one
of the ways in which Forkheads inhibit
proliferation. Interestingly, in a recent study the
MnSOD promoter was found to be mutated in
PTENMUT
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RalGEF
Ral
X
Forkhead
CELLULAR TRANSFORMATION
?
Other
proteins
Other
proteins
p27kip1/Bim/FasL/p130/MnSOD
Figure 2. Model for contributions of PI(3)K
and Ras signalling pathways to cellular
transformation via regulation of the
Forkheads. Under normal circumstances,
activation of both PKB and Ral is required
for full inhibition of AFX and possibly also
of the other two Forkheads. Oncogenic
mutations in PTEN (PTEN
MUT
) and Ras
(Ras
MUT
) might contribute to cellular
transformation by a combined effort to
reduce expression of the genes encoding
p27
kip1
, Bim, FasL, p130 and MnSOD, thus
inducing survival or cell-cycle re-entry and
cell-cycle progression, depending on the
cellular context. Conversely, PTEN
MUT
 or
Ras
MUT
 alone might be sufficient to
accomplish the same effect. Hyperactive
PKB (via PTEN
MUT
) or Ras (Ras
MUT
) alone
can fully inhibit the Forkheads and Ras
MUT
may accomplish this by activating the
PI(3)K pathway in addition to Ral, again
leading to the activation of the two
pathways that are required for Forkhead
inactivation in the normal situation.
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five out of fourteen human cancers examined
(49), suggesting that transcriptional inactivation
of the gene encoding MnSOD may be an
important component of cellular transformation.
However, analyzing cellular proliferation of
Sod2-/- cells upon infection with Forkheads did
not reveal any function of MnSOD in cell-cycle
control by the Forkheads (unpublished
observations). Control of MnSOD expression by
Forkhead transcription factors might thus merely
be required to protect quiescent cells from
oxidative stress (chapter 7), and low levels of
MnSOD protein in tumor cells might therefore
just be a consequence rather than a cause of
Forkhead inactivation and cell-cycle re-entry.
AFX and FKHR were originally identified
as part of t(2;13) and t(X;11) chromosomal
translocations that are associated with ALL and
rhabdomyosarcomas, respectively (50, 51). In
these translocations, the transactivation domains
of AFX and FKHR fuse with the DNA-binding
domains of the MLL and PAX3 transcription
factors. Although this excludes Forkhead target
genes as direct mediators of the transforming
capacity of the oncogenic MLL-AFX and PAX3-
FKHR fusion products, those genes might still
be indirectly regulated by the fusions. Cells that
contain PAX3-FKHR, for example, have
increased levels of the RTKs PDGF receptor and
MET, although the gene for neither of these
proteins is a target for FKHR or PAX3 separately
(52, 53). Both of these RTKs are very potent
activators of PI(3)K, which in turn is able to
inactivate FKHR. This process would thereby
have effects on cellular survival and proliferation.
This might suggest that the t(2;13) translocation
that already results in the loss of one functional
allele of FKHR can inactivate the second
functional allele by upregulating PI(3)K-
activating RTKs. The transforming capability of
the PAX3-FKHR fusion product could therefore
at least in part be due to its ability to inactivate
FKHR or even any of the other two Forkheads
(figure 3). In a similar manner, the way that the
MLL-AFX fusion protein contributes to the onset
of leukemia can be viewed in a new light. The
AFX gene lies on the X chromosome, meaning
that males have only one allele (51). A
translocation of the AFX gene to chromosome
11 would therefore not only result in the potent
transcriptional activator MLL-AFX, but also in
the functional knockout of AFX itself in males.
This latter effect could then conceivably
contribute to the leukemia.
5' 3'
5' 3'
FKHR
PAX3
TADB
FKHR
PAX3 FKHR
PDGFR/MET
PI(3)K
PKB
G1 arrest 
Apoptosis
DB
5' 3'TADB
Chrom 13
Chrom 2
t(2;13)
Figure 3. Model for transforming
capacity of the oncogenic PAX3-FKHR
fusion. In some rhabdomyosarcomas,
3' sequences of one FKHR allele on
chromosome 13, containing sequences
encoding its transactivation domain
(TA), have fused with 5' chromosome
2 sequences. This creates a fusion
between PAX3, with its DNA-binding
domain (DB), and FKHR-TA. This
hybrid transcription factor increases
gene expression of the RTKs PDGF
receptor (PDGFR) and MET, that both
are potent activators of PI(3)K. In this
way, the fusion protein might activate
PKB which would lead to inhibition of
FKHR protein encoded by the re-
maining functional FKHR alelle,
ultimately affecting survival and cell-
cycle progression. This signalling
cascade might contribute to the
oncogenic properties of the t(2, 13)
translocation.
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In conclusion, we have identified the AFX
Forkhead transcription factor as a protein that is
regulated by pathways that are controlled by the
proto-oncogene Ras and the tumor suppressor
PTEN. AFX and its closest relatives FKHR and
FKHR-L1 can arrest the ongoing cell-cycle,
causing cycling cells to enter a state of quie-
scence. Importantly, these Forkheads, when
overexpressed, have the ability to inhibit
proliferation of a variety of tumor cell-lines. This
suggests that, in order to proliferate and survive,
tumor cells have somehow inactivated
endogenous AFX, FKHR and FKHR-L1. Indeed,
FKHR is cytoplasmic in PTEN-negative renal
and prostate tumor cells, and protein levels of
the gene targets of the Forkheads (p27kip1, p130
and MnSOD) are generally low in tumor
samples. Finding ways to re-activate the
Forkheads, possibly through relocalizing them
to the nucleus, might therefore provide a valuable
tool to inhibit the proliferation of such cells not
only in culture but also in a living organism.
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A large number of cells in the human body
is quiescent, but can be induced to enter the cell-
division cycle (cell-cycle) by small peptide
growth factors excreted by themselves or
surrounding cells. These growth factors bind to
a cell-surface receptor that subsequently
transduces the growth signal across the plasma
membrane to the cell’s interior. Upon receptor
activation many cascades of protein
modifications take place, which ultimately result
in the licencing of DNA duplication and
subsequent cell division. Human cancer cells
have, through genetic alterations, aquired the
ability to proliferate in the absence of extra-
cellular growth factor. This lead to the hypothesis
that constitutive activation of signalling pathways
normally controlled by growth factors may
contribute to the phenotype of uncontrolled
proliferaton often associated with human cancer
cells. One cascade that is activated by growth
factors, and dysregulated in certain types of
human tumors, is the PI(3)K pathway. PI(3)K is
a lipid-kinase that, under normal circumstances,
is recruited to and activated by ligand-bound
growth factor receptors. When activated, PI(3)K
produces 3' phosphorylated phosphoinositides
that act as second messengers to recruit a variety
of proteins to the plasma membrane, one of
which is PKB. Once properly localized, PKB is
activated by upstream kinases and released from
the plasma membrane to phosphorylate its
substrates that participate in a variety of cellular
processes including glycolysis, protein synthesis,
survival, transcription, and cellular proliferation.
Importantly, PI(3)K signalling and thus PKB
activity is negatively controlled by the PTEN
tumor suppressor, a protein often found mutated
in human tumors.
At the time of the start of the study
described in this thesis a number of PKB
substrates had been identified that could explain
at least certain aspects of the regulation of
glycolysis, protein synthesis and survival by
PKB, but no effectors had been found that could
mediate its control over transcription and
proliferation. We set out to identify transcription
factors regulated by PKB, and, inspired by a
study in the nematode C.elegans, we identified
AFX, a Forkhead transcription factor with two
close relatives named FKHR and FKHR-L1.
Chapter3 describes this identification, and
shows in detail that the PI(3)K/PKB pathway
participates in growth factor-induced inhibition
of AFX transcriptional activity. PKB does so by
direct phosphorylation of AFX on two serine
residues. In addition to and independent of the
PI(3)K/PKB pathway, the Ras/RalGEF/Ral route
is also involved in growth factor-induced
inhibition of AFX. In chapter 4 the research to
elucidate the mechanism by which PKB-
dependent phosphorylation of AFX inhibits its
activity is described. In this chapter, we show
that activation of PKB results in a relocalization
of AFX from the nucleus to the cytoplasm. In
quiescent, serum-starved cells, AFX is active and
nuclear at steady-state, although it constitutively
shuttles in and out of the nucleus. Once a cell
has been given a growth factor, PKB is activated
after which it translocates to the nucleus. There,
it phosphorylates AFX on the two serine residues,
one of which is located at the heart of a non-
classical NLS. Subsequently, since the
phosphorylation of the serine residue in the NLS
by PKB has inactivated that NLS, PKB-
phosphorylated AFX is no longer able to re-enter
the nucleus after it has been exported. Chapter
5 describes the functional consequence of the
inhibition of AFX, FKHR and FKHR-L1 by
PKB. We show that AFX can arrest the ongoing
cell-cycle at the G0/G1 phase. AFX, and
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presumably also its two family members, does
so by actively transcribing the gene encoding the
p27kip1 cdk-inhibitor. This leads to an increase in
the amount of p27kip1 protein to a level sufficient
to fully inhibit the activity of cyclin E/cdk2
complexes that are essential for proper G1/S
transition. Activation of PKB, in turn, inhibits
AFX and thereby stimulates cell-cycle
progression. In chapter 6, we refine the function
for the three Forkheads transcription factors as
described in chapter 5. We show that FKHR-L1
activation not only arrests cell proliferation, but
that it actually induces a state of cellular
quiescence, even in human tumor cells. For this
study, we created a conditionally active FKHR-
L1 protein that is specifically activated by a
synthetic ligand named 4OHT. Prolonged
addition of 4OHT to cells expressing this
conditionally active Forkhead resulted in
quiescent cells and allowed the identification of
genes specifically induced by Forkhead activity.
In this way, we were able to identify the p130
pocket protein, a regulator of quiescence, as a
candidate target gene. In chapter 7 we use the
same inducible system to investigate the
contribution of the Forkheads to the cellular
protection from oxidative damage, a function
described for the C. elegans othologue DAF-16.
We show that conditional activation of FKHR-
L1 indeed protects cells from the damaging
effects of reactive oxygen species. A mammalian
cell contains several anti-oxidant enzymes that
can scavenge such reactive oxygen species. We
show that activation of Forkheads results in the
upregulation of at least two of such enzymes,
MnSOD and catalase. For the Forkhead-induced
increase in MnSOD, we provide evidence that
FKHR-L1 directly regulates the activity of the
promoter for the MnSOD-encoding gene.
Interestingly, in C. elegans the DAF-16 pathway
regulates organismal longevity through similar
enzymes, presumably by affecting the lifespan
of longevity-regulating neurons. Since some of
the Forkheads are markedly expressed in brain
tissue of mice, this may indicate by analogy that
the Forkhead pathway in mammals can likewise
regulate organismal lifespan.
In conclusion, this thesis describes the
identification of a novel component of the
PI(3)K/PKB signalling cascade, the Forkhead
transription factor AFX, that is responsible for
some of the effects on cellular proliferation that
have been observed for this pathway. Moreover,
the data from chapter 6 imply that the PI(3)K/
PKB/Forkhead pathway is particularly important
in the regulation of cell-cycle exit and entry, a
feature that may be significant in the context of
a human cancer cell. From all the data described
in this thesis, we propose the following model:
In normal quiescent human cells, the Forkhead
transcription factor is active and contributes to
the maintenance of the quiescent state. When
cells are presented with a growth factor or when
certain oncogenic mutations take place (i.e. in
the gene for PTEN), the PI(3)K/PKB pathway is
activated, leading to inhibition of the Forkheads,
down-regulation of the genes for p27kip1, p130
and MnSOD, and subsequent entry into the
proliferative state (figure 1). Possibly, this series
of events might significantly contribute to the
emergence of certain types of human cancers.
Figure 1. Model for Forkhead-mediated control of
proliferation. In the absence of growth factor, Forkheads
are active and maintain the quiescent state via the
upregulation of p27
kip1
, p130 and possibly MnSOD (left).
Once PKB gets activated, either by growth factors or by
oncogenic mutations in upstream regulators such as
PTEN (PTEN
mut
), Forkhead activity is inhibited, leading
to cell-cycle entry and proliferation.
Forkhead
p27kip1
p130
MnSOD?
Quiescence
Forkhead
p27kip1
p130
MnSOD?
Proliferation
PKB
Growth factor
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Cell-cycle control by protein kinase B
118
Het menselijk lichaam bestaat uit allerlei
geïntegreerde onderdelen met ieder een
specifieke taak. Een voorbeeld van zo’n
onderdeel is een orgaan, zoals de longen, of een
systeem, zoals de bloedsomloop. Al deze
onderdelen zorgen ervoor dat het lichaam
optimaal blijft functioneren. Elk van de
onderdelen bestaat uit allerlei soorten weefsels.
Zo hebben de longen weefsels die de zuurstof-
opname verzorgen, maar ook weefsels die het
mogelijk maken dat een long kan uitzetten. Een
weefsel is op zijn beurt opgebouwd uit cellen.
Deze cellen zijn de eigenlijke werkpaarden van
het lichaam. Het zijn de cellen die zuurstof
opnemen, transporteren, verwerken en omzetten
tot energie, die zorgen dat een spier samentrekt,
enzovoorts.
In een cel spelen zich een groot aantal
processen af. Er moet bijvoorbeeld zuurstof
worden omgezet in energie, er moet contact
gehouden worden met naburige cellen, er moet
snel gereageerd kunnen worden op veranderende
omstandigheden, er moeten bouwstenen worden
aangemaakt en afgebroken, en ga zo maar door.
Al deze processen worden uitgevoerd door
eiwitten. In één cel zijn duizenden van deze
eiwitten werkzaam in honderden diverse
processen.
Zo nu en dan zijn er cellen die vervangen
moeten worden. Dit houdt in dat er een reeks
processen moet worden uitgevoerd die leidt tot
celdeling: het verdubbelen van één cel tot twee
cellen. Cellen in de maagwand, bijvoorbeeld, zijn
behoorlijk slijt-gevoelig en moeten eens in de
zoveel tijd vervangen worden, wat inhoudt dat
gezonde buurcellen gaan delen om het tekort aan
te vullen.
De regulatie van celdeling is een delicaat
proces. Als er te weinig celdeling plaatsvindt,
worden versleten cellen niet aangevuld, wat de
functie van een weefsel kan aantasten. Als er
echter te veel celdeling plaatsvindt, kan er een
tumor ontstaan. Daarom is het geheel van
processen die de celdeling verzorgt zeer goed
gecontroleerd, zowel door de cel zelf, door de
buurcellen, als door het lichaam. Naburige cellen
controleren de celdeling door het uitscheiden van
een groeifactor. Zo’n groeifactor is een klein
eiwit dat kan binden aan specifieke eiwitten op
de buitenkant van een cel (figuur 1 en 2).
Wanneer een groeifactor aan een cel bindt,
veranderen allerlei eiwitten in zo’n cel van
gedaante. Er wordt bijvoorbeeld ineens een
bepaald soort eiwitten aangemaakt, andere
worden ineens actief terwijl ze daarvoor nog in
een rusttoestand verkeerden. Uiteindelijk dragen
al deze veranderingen bij aan de celdeling (figuur
1).
Uit het hierboven beschrevene valt af te
leiden dat er een gevaarlijke situatie kan ontstaan
wanneer een cel in afwezigheid van zo’n
groeifactor gaat delen. Dit kan gebeuren wanneer
ineens een bepaald soort eiwit wordt aangemaakt,
of wanneer een bepaald eiwit, wat eigenlijk
behoort te slapen, actief wordt. Het gevolg is dat
een cel zou kunnen gaan delen terwijl er geen
versleten cellen vervangen hoeven te worden. Dit
Samenvatting (voor de normale mens)
Figuur 1. regulatie van celdeling door buurcellen. De
witte cel scheidt een groeifactor uit die bindt aan de grijze
cel. Hierdoor worden er in de grijze cel allerlei processen
(X, Y, Z) in gang gezet die uiteindelijk leiden tot celdeling.
groeifactor
groeifactor
groeifactor
X, Y, Z
Samenvatting
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kan leiden tot een overmaat aan cellen, en
wellicht uiteindelijk tot een tumor.
Hoe kan het dat een cel zoiets gaat doen?
Dit heeft alles te maken met genen. Genen zijn
stukken DNA, die een code zijn voor de aanmaak
van een bepaald eiwit. Je kan het vergelijken met
een handleiding. Stel dat je een computer wilt
maken en je koopt hiervoor een handleiding.
Zo’n handleiding is niets meer dan inkt op papier,
maar het is een code voor de handelingen die je
moet verrichten om de computer te bouwen. Zo
werkt ook een cel als hij eiwitten wil maken. Hij
leest hiervoor de juiste handleiding (gen) en hij
weet dan welke bouwstenen hij moet gebruiken
om het juiste eiwit te bouwen. De hele
verzameling van genen is dus een blauwdruk van
een cel. De codes voor de aanmaak van alle
eiwitten staan erin. Het is belangrijk dat alle
genen worden verdubbeld op het moment dat een
cel gaat delen, zodat beide cellen uiteindelijk
weer een volledige set van genen en dus een
volledige blauwdruk meekrijgen. Om terug te
komen op de vraag aan het begin van deze alinea:
hoe komt het dat een cel zonder toestemming
gaat delen? Dit komt doordat er wel eens een
foutje sluipt in bepaalde belangrijke genen. Deze
foutjes (ook wel mutaties genoemd) kunnen
allerlei oorzaken hebben: Ze kunnen ontstaan
door factoren van buitenaf, zoals sigarettenrook,
maar ook door fouten in het kopiëren en
verdubbelen van de genen wanneer een cel deelt.
Het foutje in het gen levert ook een foutief eiwit
op, wat geen effect hoeft te hebben op de werking
van het eiwit, maar wat soms wel het geval is.
Het foutje kan ervoor zorgen dat het eiwit nooit
meer actief wordt, dat het onmiddellijk wordt
afgebroken, dat het constant actief wordt,
etcetera. Mocht er een foutje zijn gemaakt in een
gen dat codeert voor een eiwit dat een rol speelt
in celdeling, dan bestaat de mogelijkheid dat het
foutje ervoor zorgt dat een eiwit wordt
aangemaakt dat continu het signaal blijft geven
dat de cel moet delen. Een voorbeeld is gegeven
in figuur 2. Stel dat er drie genen zijn die coderen
voor drie eiwitten, A, B en C. In een rustende cel
(figuur 2a) zijn A en B inactief, maar C actief,
en deze laatste remt de celdeling. Wanneer er
groeifactor bindt aan de cel wordt A geactiveerd.
A activeert vervolgens B, en B remt C. De
uitkomst van dit schema is dat er celdeling
optreedt wanneer er groeifactor bindt (figuur 2b).
Stel dat er een foutje optreedt in het gen voor
eiwit B, en dat dit foutje ervoor zorgt dat B altijd
actief is. B is dan niet meer afhankelijk van A
(en dus niet meer afhankelijk van de groeifactor)
om C uit te zetten (figuur 2c). Dit kan ertoe leiden
A
B
C
Normaal
A
Bmut
C
Abnormaal
-
-
Celdeling Celdeling
groeifactor
A
B
C
Normaal
+
+
-
Celdeling
Figuur 2. Schema’s van gereguleerde en niet-
gereguleerde celdeling. A. In een cel in
rusttoestand is eiwit C actief en remt (-)
celdeling. B. In aanwezigheid van groeifactor
wordt eiwit A geactiveerd (+), die op zijn beurt
eiwit B activeert, die op zijn beurt eiwit C remt.
De uitkomst van deze gebeurtenissen is
celdeling. C. In een tumorcel kan het volgende
zijn gebeurd: er is een mutatie geslopen in het
gen dat codeert voor eiwit B. Dit levert een
foutief eiwit B op (B
mut
), dat door het foutje per-
manent aan staat, zelfs zonder groeifactor of
activiteit van eiwit A. Zonder de juiste
toestemmingen remt eiwit B
mut
 eiwit C. De
uitkomst is wederom celdeling.
A B C
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dat een rustende cel zonder toestemming zomaar
gaat delen. De twee cellen die ontstaan uit deze
deling hebben nu allebei het foutje, gaan dus weer
zonder toestemming delen, enzovoorts, totdat er
zoveel cellen zijn gevormd dat er sprake kan zijn
van een tumor.
In dit proefschrift beschrijf ik onderzoek
naar zo’n A-B-C route. In dit geval heet eiwit A
PI(3)K, eiwit B heet PKB en eiwit C heet AFX.
In menig kankercel staat deze route permanent
aan doordat er een foutje is geslopen in een
bepaald gen dat codeert voor een eiwit dat deze
route normaal uitzet.
In normale cellen wordt PI(3)K (indirect)
geactiveerd door groeifactoren. PI(3)K activeert
PKB en PKB remt AFX (figuur 3), net zoals in
het A-B-C voorbeeld van figuur 2b. Hoofdstuk
drie gaat over de ontdekking dat AFX door PKB
wordt geremd. Voordat hoofdstuk drie werd
gepubliceerd, was bekend dat PKB geactiveerd
kon worden door PI(3)K en ook dat er
waarschijnlijk een eiwit C onder controle van
PKB zou staan. Wij zijn vervolgens op zoek
gegaan naar de identiteit van eiwit C en vonden
AFX.
Hoofdstuk vier beschrijft in detail de
wijze waarop PKB de activiteit van AFX remt.
Wij laten zien dat PKB ervoor zorgt dat de locatie
van AFX in de cel verandert. Zonder PKB
activiteit (en dus zonder groeifactor) zit AFX in
de kern van de cel, daar waar de genen liggen
opgeslagen. AFX zit daar omdat het bijdraagt aan
het vertalen van de codes van enkele van die
genen naar functionele eiwitten. Wanneer PKB
actief wordt, verandert AFX op zodanige wijze
dat hij niet meer in de kern aanwezig kan zijn.
Met andere woorden: PKB zorgt ervoor dat AFX
niet meer kan bijdragen aan het lezen van genen.
PKB inactiveert AFX.
Tot dusver hebben we aangetoond dat er
in de mens een bepaalde A-B-C-route bestaat en
hebben we vele details van deze route
opgehelderd. De belangrijke volgende vraag is:
we weten dat PI(3)K en PKB betrokken zijn bij
celdeling en tumorvorming, maar wat heeft AFX
hiermee te maken? Zou het kunnen zijn dat de
genen die door AFX worden aangestuurd en die
door PKB te activeren niet meer worden vertaald,
invloed uitoefenen op de celdeling? In hoofdstuk
vijf en zes beschrijven we twee genen die
mogelijk met behulp van AFX worden vertaald
naar eiwitten die de celdeling verhinderen. We
laten zien dat de celdeling geremd kan worden
door AFX te activeren in cellen. De celdeling
wordt niet alleen geremd door AFX, maar de cel
wordt zelfs in rusttoestand gebracht. Tevens laten
we zien dat activering van PKB dit op zijn beurt
kan verhinderen (figuur 3). Een belangrijke
observatie die we in deze hoofdstukken
beschrijven, is dat activering van AFX in
tumorcellen de celdeling van deze tumorcellen
remt. Dit betekent dat AFX in staat is om de
ongecontroleerde deling van tumorcellen (die
vaak geen groeifactor meer van naburige cellen
nodig hebben) te remmen. Dit biedt mogelijke
perspectieven op nieuwe behandelingen van
kanker; wellicht kan in de toekomst door AFX
te activeren, de groei van tumoren geremd
Figuur 3. Schema’s van de regulatie van celdeling door
de PI(3)K-PKB route. Net zoals in het voorbeeld in figuur
2 remt AFX in een rustende cel de celdeling (links).
Activatie van PI(3)K door groeifactoren leidt tot activatie
van PKB, wat leidt tot remming van AFX, wat uiteindelijk
leidt tot celdeling.
PI(3)K
PKB
AFX
-
+
+
Celdeling
PI(3)K
PKB
AFX
-
Celdeling
groeifactor
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worden.
Tenslotte bespreken we in hoofdstuk
zeven een derde gen dat door AFX wordt
gereguleerd en dat mogelijk ook betrokken is bij
de regulatie van celdeling. Dit gen is beroemd
geworden door zijn rol in de bescherming van
de cel tegen radicalen. Radicalen zijn moleculen
die schadelijk zijn voor de cel, aangezien ze
allerlei structuren, zoals eiwitten en genen,
kunnen beschadigen. Zodoende kunnen er foutjes
in genen sluipen, wat een oorzaak kan zijn van
kanker, maar ook van veroudering (van zowel
de cel als het organisme). Het eiwit waar het
derde gen voor codeert, is een eiwit dat zulke
schadelijke radicalen opruimt. Het is daarom
mogelijk dat AFX naast bescherming tegen
kanker ook bescherming tegen veroudering biedt.
Samenvattend hebben we in vier jaar
onderzoek het volgende gevonden: PKB remt
AFX en AFX remt celdeling. PKB activeert dus
celdeling door AFX te remmen (figuur 3).
Onderzoek naar tumorcellen laat zien dat PKB
daarin vaak geactiveerd is. Men denkt dat dit
bijdraagt aan de ongecontroleerde celdeling van
die tumorcellen. Ons onderzoek geeft een
mogelijke verklaring naar de werking hiervan:
wij denken dat ongecontroleerde celdeling van
sommige tumorcellen komt doordat PKB actief
is en AFX remt.
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Om te beginnen, het cliché: hèhè, eindelijk het allerlaatste stukje tekst en waarschijnlijk het
enige dat iedereen leest. Allereerst wil ik de twee mensen bedanken van wie ik het meest heb geleerd:
Boudewijn en Hans (op alfabetische volgorde). LB: vanaf het begin heb ik het gevoel gehad dat wij
samenwerkten in plaats van dat jij je gedroeg als een echte begeleider. Dat heeft ervoor gezorgd dat
wij altijd tegen elkaar hebben gezegd wat we op onze lever hadden, vooral wat proeven en modellen
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BramStijnBasMennoFrederikHarry…of toch een meisje? Tegen de tijd dat we dit in druk zien, weten
we het. Ennuh… laten we de jaarlijkse eet-date erin houden, voor zover mogelijk.
Hans: je runt een zeer behoorlijke keet. Niet alleen heb je indruk op me gemaakt door de
manier waarop je met de wetenschappelijke randzaken omgaat, maar ook door je niet aflatende
interesse in, en enthousiasme over, de proeven. Al met al ben jij een bewijs van de mogelijkheid dat
volledig weg zijn van de bench best aardig zou kunnen zijn (je ziet het: ik heb nog wat overreding
nodig). Bedankt voor de mogelijkheid om altijd bij je binnen te lopen en mijn (naïeve) vragen aan je
te stellen, en natuurlijk: bedankt voor een tweede Spetses! HAHAHAHA……….op naar praatjes in
‘s man’s zwembroek met nog wat stukjes olijf tussen de tanden!
Vervolgens de derde Bos-dinosaurus: René (mèt é). Jij en ik hebben een potje gave proeven
gedaan, al zeg ik het zelf. Ik verheug me erop om (hopelijk) over een jaar of drie weer met jou samen
te werken, maar dan aan (en ik citeer Robbie W) the Most Interesting Topic in Science Ever. Maar
om bij het hier en nu te blijven: hoe zit het ook weer met SOD en catalase en peroxide enzo? Veel
succes in de stad van AJAX (sorry Boudewijn). Dr. De Rooij, congres-kamergenoot: over het stinkbed
kan ik inmiddels niets meer zeggen, je was me helaas voor. Maar ‘just for the record’: we waren met
z’n tweeën en IK was het niet! Bedankt voor de toffe congressen, mijn introductie op de vakgroep
(jaja, ben ik niet vergeten), de squash-potjes (ben ik inmiddels de te kloppen man?…vast niet), en de
lessen over de GEFs. Maar Epac tekenen met al zijn domeinen lukt me nog steeds niet. Nancy
(spreek uit: nan-sie): hou vol hè? Je hebt het vast niet altijd makkelijk en zeker niet met dat
vermaledijde eiwit van ons (to SASA or not to SASA). Trouwens: zouden we eindelijk al ‘ge-dipt’
hebben? En oh ja, ik heet Kops, niet Koops! Jorrit: VLAM! Vreemd dat wij elkaar zo zijn misgelopen
tijdens onze studie, maar dat hebben we een beetje goedgemaakt, hoop ik. Wel wat vaker naar de
kapper gaan a.u.b. Goehoed dat je m’n paranimf wil zijn (als je die dag haalt tenminste, na je B-raf
verraad). Bereid je je wel goed voor op je rol als secondant? Pietâh: hoe’st? ik hoop dat je de naam
Pieterplakin nog jaren met trots mag dragen, maaruuuh... ben je al heer en meester van de FACS?
Bedankt voor de TMF-live belletjes, de mede-drang tot branden, de schrijf-tips (toch stiekem
localization en signalling), en het wel naar de kapper gaan. Jürgen: Nietzsche cool, Mulisch
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bedankt voor het assistent-vrij houden van mijn laatste jaar. Savi: finally no more hiphop to disturb
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wanneer je het (veel) te druk had. Roel, Marcel, Ina, Richard, Ton, Marjan, Piet, Gerrit, Felicia,
Agnes, Marianne, Beatrice: bedankt voor het regelen van een hoop zooi, zodat ik me kon concentreren
op het doen van proeven. VanderVlietjes, Sussenbachjes, Timmertjes en Holstegetjes: succes, de
mazzel, en bedankt voor de goeie sfeer. Arjan: hou je me op de hoogte van de laatste roddels (wie
doet het met wie!?! Neeee toch!?!)? Succes met vogelen en replicatie. Tobias: nooit zo efficiënt
geluld over wetenschap als met jou op een zomers Utrechts terras. Bedankt voor de perfecte
samenwerking, en ik hoop je veel te zien in sunny California (met zoveel mogelijk bier op zoveel
mogelijk terrasjes). Paul (the English patient): thanks for pointing me to the Bos-lab, for the (not
nearly) weekly exercise, and the Forkhead-chitchat. Will you visit me in your favourite city? Hope
we’ll stay in touch for a long long time.
Kaaaaaaaaaltjeeeeeeeeee! Dit is ‘m dan! Hoe vind je hem? Onze weekend-dates waren (en
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